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Our body is constantly challenged by invasion of pathogenic bacteria, viruses, 
fungi and parasites. The immune system is our armour against it. The cells of the 
immune system evolved to fight the invasion of the infectious intruders while being 
able to recognize the non-infectious self antigens that should be left in peace1. The 
immune system can be divided into innate and adaptive immune responses. Innate 
immunity serves as a first line of defence while the adaptive immune system protects 
us from re-infection2. Innate immune responses do not require prior exposure to 
certain pathogen and are often called unspecific ones. Nevertheless, activation of 
innate immune cells depend on recognition of specific pathogen associated molecular 
patterns (PAMPs) by a wide range of pattern recognition receptors (PRR). Mast cells, 
macrophages, dendritic cells, natural killer cells and granulocytes are the mediators 
of the innate immunity3-7. The innate immune responses create an essential 
foundation for the initiation of adaptive immunity. In the adaptive immune response, 
antigen-specific lymphocytes proliferate and differentiate into effector cells that 
eliminate pathogens. B cells and T cells are the key players in adaptive immunity. 
They circulate between blood and lymph until they come across their specific antigen. 
After encountering antigen, B cells become activated and differentiate into memory 
B cells or plasma cells that produce pathogen specific antibodies. Antibody mediated 
immunity is known as humoral immunity and provides the defence mechanism 
against the extracellular pathogens8,9. Each T cell express a unique receptor that 
recognizes peptide fragment presented in the context of a major histocompatibility 
complex (MHC) molecule10. There are two classes of MHC molecules that can present 
peptides to the two distinct T cell types. MHC class I molecules present peptide to CD8 
positive T cells known as the cytotoxic T cells11. The cytotoxic T cells are specialized 
in killing cells that present the MHC peptide specific for its T cell receptor. As peptides 
presented in the context of MHC class I come mostly from inside the cell the CD8+ T 
cells are an efficient defence mechanism against intracellular pathogens. MHC class 
II molecules are expressed uniquely by antigen presenting cells (APC) like dendritic 
cells, macrophages and B cells12. Peptides bound to MHC class II are predominantly 
delivered from exogenous proteins. CD4 positive T cells can recognize peptides that 
are presented in the context of MHC class II molecules. The peptide recognition with 
an appropriate second signal and cytokine stimulation will lead to a differentiation 
of the naïve T cell into T helper cell (Th). Activated Th cells can differentiate into 
different subsets - that is, Th1, Th2, and Th17 cells - that drive different classes of 
specific immune responses13 (Fig. 1). The Th1 subset secretes mainly IL-2 and IFN-γ 
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giving support to cytotoxic T cells and activating macrophages. Th2 cells simulate 
humoral responses by providing help to the B cells14,15. Recently, a new Th17 subset 
that produces high levels of IL-17 has been described16,17. This subset is implicated 
in regulation of inflammatory responses18. An additional subset of T cells that 
can suppress proliferation of all above-mentioned subsets and prevent excessive 
immune responses that may result in autoimmunity is known as regulatory T cells 
(Treg)19. Several types of Treg cells have been described on the basis of their origin, 
generation and mechanism of action. These cells can be broadly subdivided into 
two groups: endogenous, known also as naturally occurring Treg cells (nTreg cells), 
and inducible Treg cells (iTreg cells) also described as adaptive Treg cells20. The 
naturally occurring Treg cells originate from thymus and express the transcription 
factor Foxp321,22. The suppressive activity of these cells is known to be antigen 
non-specific and involves cell contact-dependent mechanisms23. Adaptive Treg cells 
that develop in the periphery can be divided into at least two types: interleukin 10 
(IL-10)-producing, Foxp3 negative Tr1 cells24 and  Foxp3 positive Th3 cells producing 
Figure 1. Schematic representation of the functional plasticity of DCs to polarize naïve T 
cells. According to the type of pathogen and the presence of a variety of surrounding tissue factors 
DCs via expression of particular cytokines profiles or cell surface molecules regulate the naïve T cell 
differentiation. Different Th-cell lineages are specialized in the eradication of specific pathogens (Th1, 



















































high amounts of TGF-β25,26. The precise mechanisms by which these cells function to 
maintain the balance between immunity and tolerance are not fully understood. It 
is presumed that crosstalk among these various Treg cell populations is required for 
the integrated control of the immune responses27.
Dendritic cells
Dendritic cells (DCs) are professional antigen presenting cells that play a key 
role in maintenance of the balance between immunity and tolerance in our body28. 
They link innate and adaptive immunity and are important in both initiation and 
modulation of the immune response29. DCs are widely distributed between different 
tissues at the contact sites with the external milieu, such as the skin, gut or lungs 
where they constantly scavenge the environment for the presence of invading 
pathogens. 
DC subsets
DCs represent a widely distributed population of bone marrow derived cells. 
Although they share many common features, multiple subtypes of DCs with distinct 
functions have been identified30. Two major intrinsically different subpopulations 
of DCs are the conventional DCs (cDCs), and the plasmocytoid DCs (pDCs). Both of 
them can arise from common myeloid and lymphoid precursor but theirs function, 
activating cytokines and markers are different31. Plasmacytoid DCs are the front line 
in anti-viral immunity as they rapidly produce high amounts of type I interferon 
in response to viruses32. On the other hand, conventional DC subsets have ability 
to respond to different microbial structures and to direct T cell differentiation. 
Conventional DCs can be subdivided into migratory DCs, which traffic from 
peripheral tissues to the lymph nodes, and lymphoid-organ-resident DCs, which 
develop from bone-marrow precursors within the lymphoid organs33. Migratory 
DCs can be further divided into three major groups: interstitial DCs (dermal DCs), 
CD103+ DCs and Langerhans cells. Lymphoid-organ-resident DCs can be categorized 
into three subsets in the spleen on the basis of their expression of CD4 and CD8α: 
CD4+ DCs, CD8+ DCs and CD4–CD8– (double negative) DCs. Additionally, a subset of 
monocyte-derived DCs, commonly used in human and mouse studies of DC biology is 
considered as a precursor of migratory or so called emergency DCs. Different subset 
of DCs differ in theirs ability to capture and process antigens. Migratory DC types are 
more specialized in antigen transport from peripheral tissues to secondary lymphoid 
tissues, whereas lymphoid-organ-residing DCs are specialized at generation and 
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display of peptide/MHC complexes to naive T cells that reside within lymph nodes. 
All dendritic cells (DCs) have functional MHC class I and MHC class II presentation 
pathways. It was suggested that the migratory DC subsets CD103+ DCs are mainly 
responsible for MHC class I restricted presentation, whereas dermal DCs control MHC 
class II restricted presentation34. Ability to deliver exogenous antigens to the MHC 
class I pathway, known as a cross-presentation is restricted to some DC types. The 
role of the different subsets of DCs in antigen cross-presentation has been studied 
extensively in mice.  Murine CD8+ DCs are more efficient in cross-presentation than 
CD8– DCs35,36. In general CD8+ DCs are better in presenting the antigens in the context 
of MHC class I than CD8– DCs superior in MHC class II restricted presentation33. 
Human equivalent of CD8+ DCs was recently identified as a CD141+ DC subset37-41.
DC life cycle
Migratory DCs residing in non-lymphoid peripheral tissues in the immune 
steady state are considered as immature. These cells have unique ability to 
recognize and take up antigens. Antigen uptake in the presence of danger signal 
and inflammation leads to maturation of dendritic cell. Mature DC migrates to 
secondary lymphoid organs to stimulate T cells. Lymphoid-organ-resident DCs do 
not conform to the described above Langerhans cell paradigm; they develop from 
bone-marrow precursors within the lymphoid organs without previously trafficking 
through peripheral tissues. In the absence of infection, the resident DCs maintain 
an immature phenotype throughout their entire lifespan42. As resident DCs do not 
migrate out of lymphoid organs antigen has to be deliver to them by other cells of the 
immune system or lymph itself. 
Expression of Pattern Recognition Receptors (PRRs) by DCs
Immature DCs express large array of PRRs including Toll-like receptors (TLRs), 
C-type lectins, NOD-like receptors and RIG-like helicases. TLRs are transmembrane 
receptors present on the plasma membrane or within the endosomal compartment 
that recognize a variety of PAMPs, like specific structures of microbial lipoproteins, 
glycolipins, CpG DNA, RNA and lipopolisacharydes43-45. Another class of PRRs present 
on the surface of immature DCs are C-type lectins, which recognize carbohydrate 
structures on pathogens46. RIG-like helicases and NOD-like receptors are present 
in the cytosol and are involved in sensing the intracellular pathogens. RIG-like 
helicases bind mainly viral RNA47. NOD-like receptors beside binding diverse PAMPs 
also bind endogenous danger associated molecular patterns (DAMPs)48. DAMPs are 
the molecules that can be released from the cell or cell compartment upon tissue or 




ATP as well as heat-shock proteins (HSP) and high-mobility group box 1 (HMGB1) 
can act as these danger signals49-51. Some of the NOD-like receptors are crucial 
components of an inflammasome52. The inflammasome represents a high molecular 
weight complex that activates inflammatory caspases and activates cytokines of the 
IL-1 family.
Multiple PRRs are differentially expressed between different DC subtypes. 
Differential expression of these receptors can provide each DC subset with distinct 
capacities to capture and initiate responses against specific pathogens.
Binding of the PAMPs and DAMPs to PRRs induce various intracellular signaling 
pathways including NFκβ, AKT/PI3K, and MAPK pathways leading to inflammatory 
responses53. As cross talk between different PRRs exist, combined activation of 
different receptors results in distinct intensities and the nature of the response54. 
This cross talk adds another dimension to already great competence of DCs to sense 
the environment and establish the specific immune response directed at clearing 
the pathogen.
Antigen uptake and presentation by DCs
Equipped with this very efficient sensing mechanism immature DCs patrol the 
body tissues in search for non-self antigens. Once in contact with such, they use 
different phagocytic pathways to engulf it. Uptake of the antigens can occur via specific 
receptor–mediated endocytosis or unspecific phagocytosis and macropinocytosis55. 
Taken up antigens must be processed before can be presented to T cells. In the 
endosomal compartment variety of exogenous antigens may be degraded and 
resulting peptides are loaded on MHC class II molecules accumulated in the same 
compartment. In general, MHC class I molecules are loaded with peptides derived 
from cytosolic proteins in the endoplasmic reticulum (ER). However, exogenous 
antigens may be also loaded on MHC class I molecules in the process known as cross 
presentation56. 
Maturation of DC can be triggered by binding of different PAMPs and DAMPs to 
the PRRs, inflammatory cytokines (e.g. TNFα and IL-1β) or the ligation of surface 
expressed activating receptors like CD4057-59. In the process of maturation DCs 
transform from highly phagocytic stationary cell into migratory ones. They lose 
ability to efficiently take up and process antigens. Instead, they start to express 
CCR7, which enables them to migrate towards lymphatic tissues to T cell-rich areas60. 
Additionally, DCs upregulate whole set of genes involved in antigen presentation and 
costimulation including MHC class II, CD40, CD80, CD86 as well as cytokines that 
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promote and modulate inflammation and effector cells function29. These changes are 
necessary for DCs to initiate T cell responses. 
Three simultaneous signals are necessary for the activation of T cells. Beside 
antigen presented in the context of MHC second signal must be derived from 
binding the costimulatory molecules61. One of the best-characterized costimulatory 
receptors expressed by T cells is CD28, which interacts with CD80 (B7-1) and CD86 
(B7-2) on the membrane of APCs. Another molecular pair found to be essential for 
costimulation is CD40/CD154. CD40 is continuously expressed on the APC, and the 
expression of CD154 can be induced on the T cell upon activation via CD28 receptor62. 
Third signal is provided by cytokines produced by DCs or other microenvironmental 
sources. Next to T cell activation, DCs regulate also a differentiation of T cells into the 
appropriate subset of T helper cells. Sensing the environment via PRRs and cytokine 
receptors incite DCs to switch into a suitable program. These pre-programmed DCs 
will produce the set of cytokines and express the correct array of costimulatory 
molecules to instruct the effector T cell development (Fig. 1). For instance, IL-12 
producing DCs will induce differentiation of naïve CD4+ cells into Th1 subset63. pDCs 
delivered from solid tumours were shown to secrete IL-4 directing development 
of Th2 lineage14,15,64. There is also cytokine independent, differential Notch ligation 
dependent stimulation of subset differentiation of naïve T cells into Th1 and Th2 
effector cells by DCs65. Notch 1-4 receptors are present on naïve T cells. If DCs will 
be stimulated by type 1 pathogen (viruses, bacteria) they will upregulate Delta-like 
ligand (DLL) on their surface that will bind to Notch 3 on naïve T cell and induce 
differentiation into Th1. Activation of DCs by type 2 pathogens like parasites or 
allergens will lead to upregulation of another Notch ligand called Jagged. Ligation 
of Jagged by Notch 1 and 2 on naïve T cell will lead to differentiation into Th2 
subset. Binding of Jagged to Notch will induce Th2 differentiation. Notch directs Th2 
differentiation by inducing GATA3 and by directly regulating il4 gene transcription66. 
Th17 subset development is supported by IL-6 and TGF-β67. Tolerogenic DCs 
that produce TGF-β and IL-10 will stimulate expansion of Tregs. The sentinels 
qualifications of the DCs are so high that even the same pathogen in the different life 
stage will evoke a different program in DCs, e.g., stimulation of DCs with the yeast 
form of C. albicans leads to IL-12 production and Th1 responses, while its hyphae 





Recognition of non-self molecules by DCs drives inflammation and adaptive 
immunity responses to pathogens. However, DCs also play a very important role in 
maintaining tolerance to self-antigens. They contribute to the deletion of autoreactive 
lymphocytes during maturation in the central lymphoid organs, as well as suppress 
the autoreactive lymphocytes, which have escaped elimination in the periphery69. 
These two processes are referred to as central and peripheral tolerance. In the 
thymus, DCs presenting tissue specific antigens (TSA) to autoreactive T cells supply 
the negative selection signal or directed them to the Treg lineage70-73. Generation 
of tolerance in the periphery is mediated mostly by so-called tolerogenic DCs. 
Tolerogenic DCs can induce or enhance the suppressive function of existing Tregs 
and convert activated T cells into Tregs. Immature DCs are typically tolerogenic. 
Presentation of the antigen to the T cells in the periphery by immature DCs without 
delivery of costimulatory signals will result in T cell apoptosis or anergy, or might 
give rise to immunosuppressive Tregs74-76. DCs can also acquire the tolerogenic 
phenotype by phagocytosis of apoptotic cells in a steady state or in presence of IL-10 
or TGF-β cytokines in the microenvironment77-80. 
Defects in the cross-tolerance via DCs may result in accumulation of autoreactive 
T cells and lead to autoimmune diseases. Signals that tolerogenic DCs use to 
broadcast their suppressive message to T cells are still incompletely understood. 
A better understanding of these issues may offer new opportunities for the 
treatment of autoimmunity, allograft rejection, allergy, asthma and various forms of 
hypersensitivity.
DC-associated molecules
The central role of DC in the initiation of the immune responses and in the 
maintenance of the balance between the immunity and tolerance is currently 
exploited to treat cancer, autoimmune diseases and to prevent the transplant 
rejection81-85. Fundamental knowledge on factors that determine DC function 
is necessary for further development of DC-based therapies. Identification and 
characterisation of novel DC-associated molecules like DC-SIGN86, DC-CK187, DCIR88, 
Dectin-1 and -289,90, DEC20591 and DC-SCRIPT92,93 have already provided new insight 
in DC immunobiology. In this thesis we make effort to unravel the role of Dendritic 
Cells Specific TrAnsMembrane Protein (DC-STAMP) in DCs.
DC-STAMP was first identified in dendritic cells94 and IL-4 stimulated 
macrophages95. Further research demonstrated expression of DC-STAMP also in 
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osteoclasts96. DC-STAMP is highly conserved between different species. Human 
DC-STAMP has 81% of homology on mRNA level and 95% homology on protein 
level with murine DC-STAMP97. Protein contains 479 amino acids and has from 4 
to 7 putative transmembrane domains and three N-linked glycosylation sites94, and 
localizes to the endoplasmic reticulum (ER) in DCs97 (Fig. 2). Human DC-STAMP 
gene localizes to chromosome 8q23 and consists of four exons98. Mouse DC-STAMP 
gene localizes to chromosome 15 and its organisation is conserved with the human 
one97. DC-STAMP was shown to be necessary for fusion of osteoclasts and foreign 
body giant cells99 but its function in DCs is only recently emerging. In the following 
chapters of this thesis we characterised two binding partners of DC-STAMP: LUMAN 
and OS9. LUMAN is a type II transmembrane protein that belongs to the bZIP family 
of transcription factors and resides in ER. OS9 is also an ER associated protein 
implicated in ER-to-Golgi transport and ER-associated degradation.
Figure 2. Model of DC-STAMP structure. DC-STAMP localizes to the ER membranes in immature DCs. 
Putative 7-transmembrane domain model is based on hydrophobicity analysis of the sequence. C-terminal 








Signalling from the ER and its cross-talk with immune response 
pathways
The ER responds to and regulates many aspects of cellular metabolism and 
homeostasis. It is the main site for calcium storage and signalling, lipid biosynthesis, 
and protein synthesis and folding. Almost all secretory and membrane proteins 
are folded and assembled in the lumen of ER. Newly synthesised polypeptides 
translocate to the lumen of the ER and attain a three-dimensional conformation after 
undergoing of protein folding and posttranslational modifications. Improper protein 
folding can lead to the accumulation of misfolded proteins resulting in ER-stress. To 
dampen this ER stress, eukaryotic cells make use of an unfolded protein response 
(UPR). 
UPR was first described in yeast cells, which possess a single UPR signalling 
pathway100. In eukaryotic organism this mechanism evolved to the three-arm UPR 
signal-transduction pathway mediated by three distinct transmembrane proteins: 
inositol-requiring transmembrane kinase/endonuclease 1 (IRE1), pancreatic ER 
kinase (PERK) and activating transcription factor 6 (ATF6)101-105. In the absence of ER 
stress, IRE1, PERK and ATF6 are sequestered in inactive complexes with GRP78/BIP 
chaperone. ER stress results in dissociation of BIP from these complexes allowing 
activation of the all three UPR signalling pathways. 
The ER associated degradation (ERAD) and regulated intramembrane proteolysis 
(RIP) are also components of UPR. ERAD is a secretory protein quality control process 
that results in the removal of aberrant proteins from the ER106. ERAD substrates are 
recognized by molecular chaperones in the lumen of ER and after retro-translocation 
to the cytoplasm degraded by ubiquitin-proteasome machinery107. 
RIP is the process regulating the activity of the membrane–associated 
transcription factors in the ER and ATF6 is one of them108. The key components 
of RIP comprise a distinct class of membrane associated transcription factors, 
anchoring partners that localize the factors to the ER, and proteases that are 
located in the Golgi compartment. The transcription factors are inserted in the ER 
membranes with DNA-binding and transcriptional–activation domains oriented 
towards cytosolic face of the membrane. The main step in the controlling the activity 
of these factors in specific pathways appears to reside in their regulated release 
from the ER in response to the specific stimuli. They are then transported to the 
Golgi where they are cleaved in a site-specific manner by resident proteases. This 
results in the release of the cytosolic domain, which is transported to the nucleus 
to effect transcription of specific target gene and orchestrate an adaptive response 
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to the stress or imbalance encountered107,109,110. RIP was first described for sterol 
regulatory element binding proteins, SREBP 1 and 2111,112. SREBPs control genes 
involved in cholesterol and fatty acids metabolism113,114. They are retained in the ER 
in a complex with multimembrane spanning protein SCAP115,116. SCAP senses lower 
cholesterol levels in ER membranes and in response escorts SREBPs to the Golgi, 
where they are cleaved by Golgi proteases, S1P and S2P, thus liberating the SREBP 
N-terminal transactivation domain of the protein.
Recently, the concept of the cross-talk between UPR and immune response 
pathways started to emerge indicating the importance of the UPR in the immune 
system117.
Initially, intact UPR was described as necessary for plasma cell differentiation118,119 
and dendritic cells survival and function120. Recently, research by Martinon et 
al. showed that TLR ligands (LPS, Pam3CK4) can selectively activate one of the 
branches of UPR pathways in macrophages, namely IRE/XBP1121. As a result of 
this activation, alternatively spliced XBP1 influences the NF-κβ driven cytokine 
Figure 3. Activation of UPR sensors after TLR stimulation. Stimulation of macrophages with TLR 
ligands results in activation of IRE1 and production of the spliced form of the XBP1 transcription factor. 
XBP1 can enhance the transcription of inflammatory cytokines. In contrast to IRE1, the PERK and ATF6 
sensors are negatively regulated by TLR ligation. Figure adapted from117,126.
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production, enhancing the effect of TLR ligation (Fig. 3). A different group described 
that proinflammatory cytokines could induce UPR in the liver tissue122, pointing at 
another intersection of UPR with the innate immune responses. In addition, ER-stress 
was also reported to impair the MHC class I presentation, thus, influencing the 
adaptive immune responses123. Finally, malfunctions in UPR system can negatively 
influence immune responses, which potentially contribute to the development of the 
autoimmunity117,121,124,125. The growing knowledge about importance of the cross-talk 
between UPR and immune system directs current attention of the immunologists 
towards processes taking place in the ER.
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Scope of this thesis
DCs are important players of the immune system. The aim of this thesis is to better 
understand DCs at the molecular level by investigating the role of DC-STAMP and its 
interacting partners LUMAN and OS9 in DC immunobiology. The knowledge about 
interacting proteins can shed a light on theirs function. Yeast-2-hybrid analysis was 
performed to identify binding partners of DC-STAMP. Two proteins which interact 
with cytoplasmic tail of DC-STAMP were identified: OS9 and LUMAN. 
 In Chapter 2 we describe the interaction of DC-STAMP with OS9 in dendritic 
cells. OS9 is the ER-resident protein previously implicated in ER-to-Golgi transport 
and unfolding protein responses (UPR). We show that DC-STAMP colocalizes with 
OS9 in immature DCs. Upon maturation DC-STAMP translocates towards Golgi 
compartment while OS9 stays in ER. We demonstrate that OS9 play a crucial role in 
facilitating this translocation, suggesting a novel role of OS9 in DCs.
In Chapter 3 interaction of DC-STAMP with transcription factor LUMAN is 
described. LUMAN is an ER-resident transcription factor, which for its activation 
needs to be translocated to Golgi compartment.  Golgi residing proteases can cleave 
the LUMAN and liberated active N-terminal part of LUMAN will translocate to the 
nucleus to activate its target genes. This study for the first time shows expression 
of LUMAN protein in DCs and demonstrate its activation in mature DCs. Our data 
suggest DC-STAMP being an important factor in this activation.
In Chapter 4 we use a gene silencing approach to identify the role of DC-STAMP 
in dendritic cells. We show that knock-down of DC-STAMP in murine bone 
marrow-derived DCs (mBMDCs) leads to deregulation of cytokine and chemokine 
production upon LPS stimulation. As DC-STAMP knock-down mBMDC have 
impaired ability to stimulate Th1 lineage development we postulate an importance 
of DC-STAMP in immune responses to LPS. 
In Chapter 5 we performed microarray experiment to identify target genes of 
LUMAN in DCs. By lentiviral overexpression of active form of LUMAN in DCs we 
identify ApolipoproteinA4 (ApoA4) as a novel target gene of LUMAN. As ApoA4 is 
described as an anti-inflamatory protein we suggest the role of LUMAN in DCs may 
involve quenching the inflammation. 
In Chapter 6 we summarized our finding, discuss their implication in 
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Abstract
Dendritic cell-specific transmembrane protein (DC-STAMP) has been first 
identified as an EST in a cDNA library of human monocyte-derived dendritic cells 
(DCs). DC-STAMP is a multimembrane spanning protein that has been implicated in 
skewing haematopoietic differentiation of bone marrow cells towards the myeloid 
lineage, and in cell fusion during osteoclastogenesis and giant cell formation. To 
gain molecular insight in how DC-STAMP exerts its function, DC-STAMP interacting 
proteins were identified in a yeast-2-hybrid analysis. Herein, we report that amplified 
in osteosarcoma 9 (OS9) physically interacts with DC-STAMP, and that both proteins 
co-localize in the endoplasmic reticulum in various cell lines, including immature 
DC. OS9 has previously been implicated in ER-to-Golgi transport and transcription 
factor turnover. Interestingly, we now demonstrate that toll-like receptor (TLR)-
induced maturation of DC leads to the translocation of DC-STAMP from the ER to 
the Golgi while OS9 localization is unaffected. Applying TLR-expressing CHO cells 
we could confirm ER-to-Golgi translocation of DC-STAMP following TLR stimulation 
and demonstrated that the DC-STAMP/OS9 interaction is involved in this process. 
Collectively, the data indicate that OS9 is critically involved in the modulation of ER-
to-Golgi transport of DC-STAMP in response to TLR triggering, suggesting a novel 




Dendritic cells play a pivotal role in the initiation of innate and adaptive immune 
responses. Immature DCs capture foreign antigens in peripheral tissues and migrate 
to the T-cell areas of secondary lymphoid organs where they present these antigens 
to T- and B-cells. The capture of antigens in the steady state allows DCs to control 
immunotolerance towards self1,2. Antigen uptake in the context of inflammation or 
infection results in DC maturation. In the presence of inflammatory cytokines and 
through binding of so-called pathogen-associated molecular pattern (PAMP) to 
one or more paralogues of the toll-like receptor family, DC mature and acquire the 
capacity to induce potent immunity.  They initiate both innate and adaptive immune 
responses3,4. As a consequence, DC have gained considerable interest as vaccine 
adjuvants and are currently exploited in the treatment of cancer after loading DC 
with tumor-cell derived antigens5,6.
Although much is now known about the cellular nature of DC, molecular insight in 
its function, although mounting, is fragmentary at best. In order to gain more insight 
into this aspect of DCs, we and others have analyzed DC at the molecular level. One 
of the genes identified was DC-STAMP, which appears to be preferentially expressed 
by myeloid DC7-10. Others have reported the induction of DC-STAMP expression in 
macrophages stimulated with interleukin 4 (IL-4)11, as well as its expression in 
osteoclasts12. DC-STAMP has 4 to 7 transmembrane regions, and its gene localizes 
to chromosome 8q239. In monocyte-derived DC and HEK293 cells, DC-STAMP 
localizes to the endoplasmic reticulum8. Biological roles for DC-STAMP are only 
recently emerging. We previously reported that DC-STAMP inhibits granulopoiesis, 
but promotes myeloid differentiation in murine bone marrow cells transduced with 
a retroviral construct expressing DC-STAMP fused to GFP7. Also, there is evidence 
for a role of DC-STAMP in osteoclastogenesis, as DC-STAMP expression appears 
to facilitate osteoclast differentiation in a murine macrophage RAW cell line that 
is otherwise incapable of differentiating into osteoclasts13. These findings were 
further corroborated in homozygous DC-STAMP knock-out mice, as these mice have 
mild osteopetrosis and display debilitating defects in the formation of multinuclear 
osteoclasts and giant multinucleated cells in response to foreign bodies, showing 
that DC-STAMP is required for cell fusion. However, the molecular mechanism by 
which DC-STAMP exerts its effect in osteoclasts and DC remains unknown14.
In order to identify interacting partners of DC-STAMP, we have constructed a 
prey cDNA library of mature and immature DCs, and used the cytoplasmic tail of 
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DC-STAMP interacts with OS9
DC-STAMP as a bait in a yeast-2-hybrid screening. Here we report the identification 
of amplified in osteosarcoma 9 (OS9) as an interacting partner of  DC-STAMP. The 
interaction of the two proteins is confirmed biochemically and by their colocalization 
in various cell types, including DC. Previous studies have implicated a role for OS9 in 
ER-to-Golgi transport15,16. Interestingly, we now demonstrate that DC-STAMP enters 
the secretory pathway upon TLR stimulation in DC transduced with an adenovirus 
expressing DC-STAMP and CHO cells stably expressing TLR. The localization of OS9 
in CHO cells and DC is not affected by maturation stimuli. Mutational analysis of 
DC-STAMP and OS9  suggest a critical role of the OS9/DC-STAMP interaction in the 
ER-to-Golgi transport of DC-STAMP.
Materials and methods
Plasmids, adenoviral vectors and cloning
Plasmids pGADGH and pGBT9 were used for yeast-2-hybrid analysis, and pER-DsRed, which 
contains the ER-targeting sequence of calreticulin fused to DsRed, was used for co-localiza-
tion studies (all from Clontech, Mountain View, CA). The plasmids and adenoviral plasmids 
encoding DC-STAMP fused to the GFP protein have been described elsewhere8. The plasmid 
encoding DC-STAMP fused to a heamagglutinin (HA) tag was created by replacing the EGFP 
moiety of the pEGFP-N3 backbone with an HA tag. Human OS9 and its splice variant were 
amplified with specific primers (Sigma Genosystems, St. Louis, MO) from cDNA derived from 
human immature DC. Their coding sequences were cloned in frame into the pECFP-N1 vector 
(Clontech, Mountain View, CA). Carboxy-terminally HA-tagged constructs were generated by 
replacing the ECFP moiety an HA tag. Primer sequences and sequences of the oligonucleotide 
encoding the HA tag are available upon request. All generated constructs were verified for in-
tegrity and correct insertion by means of sequencing at the sequencing facility at the Depart-
ment of Human Genetics, Radboud University Nijmegen Medical Centre. For the generation 
of OS9-GST fusion proteins in bacteria for the immunization of rabbits, the cDNA sequence 
corresponding to the C-terminal 80 amino acids of OS9 were inserted in frame with the C-
terminus of GST in pGEX-1, and transformed and propagated in Escherichia coli DH5a cells. 
For the production of GST-OS9 fusion proteins, the pGEX-1-OS9 construct was transformed 
in E. coli BL21. Generally, plasmid DNA was isolated from E. coli DH5a or DH10b bacteria 
using either the Endofree Plasmid Maxi Kit (Qiagen, Venlo, the Netherlands), or the HiSpeed 
Plasmid Maxi Kit (Qiagen, Venlo, the Netherlands). The cDNA library used in the yeast-2-hy-
brid analysis was purified by means of cesium chloride equilibrium centrifugation, essentially 
as described elsewhere17.
Yeast-2-hybrid analysis
Total RNA for the construction of a prey library was isolated from both immature and mature 
DC using TriZOL (Invitrogen, Carlsbad, CA), treated with DNase I, and mRNA was  isolated 
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with the Oligotex mRNA midi kit (Qiagen, Venlo, the Netherlands). Messenger RNA was con-
verted to cDNA with the Superscript kit (Invitrogen, Carlsbad, CA) and used to generate a 
prey library in pGADGH.  The bait, corresponding to amino acids 403–470 of the cytoplasmic 
tail of DC-STAMP, was cloned into pGBT9. The library was amplified in E. coli (strain DH10b, 
Invitrogen, Carlsbad, CA).
The yeast strain YGH118 was used in order to screen the library for interactants with the car-
boxyterminal tail of DC-STAMP. The bait was transformed in to competent yeast as desrcibed 
elsewhere19. The cDNA library was then transformed into a clone containing the bait using a 
high-efficiency transformation protocol20. Yeast culture and the analysis of interactions was 
carried out as described elsewhere21, 22.
Cell lines, cell culture, transfection and adenoviral transduction
Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco`s modified Eagle 
medium (DMEM) containing 4500 mg/l D-glucose, sodium pyruvate and GlutaMAX (Invi-
trogen, Carlsbad, CA), supplemented with 10% heat-inactivated fetal calf serum (FCS), 0.1 
mM MEM non-essential amino acids and 100 units/ml Antibiotic-Antimycotic (Invitrogen, 
Carlsbad, CA) at 37°C under 5% CO2. For transfections, cells were plated at a density of 5*106 
cells/75 cm2, and incubated overnight to allow the cells to adhere. The next day, cells were 
transfected with a total of 10 mg of DNA using Lipofectamine (Invitrogen, Carlsbad, CA), ac-
cording to the manufacturer's directions.
Chinese hamster ovary cell stably expressing human TLR2 or TLR4  were cultured as de-
scribed before23. Both CD25 reporter expression after TLR stimulation as well as CD14 and 
TLR expression were assessed by means of fluorescence-activated cell-sorting (FACS) analy-
sis as described before23. The following TLR ligands were used in the indicated concentration: 
LPS (Sigma–Aldrich, St. Louis, MO), 100 ng/ml; Pam3Cys (Sigma–Aldrich, St. Louis, MO), 10 
mg/ml; PGN, 10  mg/ml; and zymosan (kind gifts of dr. Mihai Netea, Department of Internal 
Medicine, Radboud University Nijmegen Medical Centre), 10 particles/cell.
Human monocyte-derived DC were generated using GM-CSF and IL-4, and their purity and 
maturation were assessed by means of FACS analysis as described previously24. Adenovirus 
transduction of DC was carried out as described before8.
RNA isolation and reverse-transcriptase polymerase reaction
Total RNA for reverse-transcription polymerase reaction (RT-PCR) was isolated from cells 
using TriZOL (Invitrogen, Carlsbad, CA). RNA concentration was determined spectrophoto-
metrically, and quality was assessed by means of conventional agarose gel electrophoresis. 
Reverse transcription using random hexamers was essentially done as described elsewhere25. 
Approximately 5 ng of cDNA was used as input in subsequent RT-PCRs. In order to identify the 
2 isoforms of OS9, the following primers were used: 5'-TGGAGGAAAAACAGAGTCCAGAGC-3' 
(forward) and 5'-CCTCATCAGTCAGCCAACGTGC-3' (reverse). Reactions were set up with 
Amplitaq Taq DNA polymerase kit (Applied Biosystems, Foster City, CA). The following PCR 
program was used: 5 min 95°C, and then 30 sec 95°C, 45 sec 57.5°C and 30 sec 72°C for 35 
cycles, and thereafter 5 min 72°C. PCR products were assessed by conventional agarose gel 
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electrophoresis.
Co-immunoprecipitation of OS9 and DC-STAMP
The monoclonal antibody used for immunoprecipitation experiments (anti-HA, clone 12CA5, 
mouse IgG2b) as well as normal rabbit serum, were covalently coupled to Protein G sepharose 
Fast Flow beads (GE Healthsciences Bio-Sciences, Uppsala, Sweden) using dimethyl pimel-
imidate dihydrochloride (Sigma–Aldrich, St. Louis, MO) in 0.2 M triethanolamine (pH 8.3) as 
a protein cross-linker. Right before use, the antibody-protein G sepharose complexes were 
washed extensively with lysis buffer. Bare protein G beads and beads coupled to rabbit IgGs 
were subsequently used to preclear lysates in order to diminish unspecific binding of proteins 
to 12CA5 in the following steps.
For co-immunoprecipitations, HEK293 cells were co-transfected with constructs encoding 
GFP, DC-STAMP-GFP and OS9-HA or their mutants as described above, and after 48 h lysed 
in 1.5 ml modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris/HCl pH 7.5, 1% 
(w/v) Triton X-100, 5 mM EDTA, 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
sodium dodecyl sulfate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mg/ml aprotinin and 
2 mg/ml leupeptin). Insoluble material was removed by centrifugation. After preclear with 
bare beads and beads coupled to rabbit IgG, the immunoprecipitation was performed with 
beads coupled to 12CA5. All steps were performed at 4°C. Supernatant was saved and stored 
at –80°C and beads were washed 4 times with RIPA buffer before being transferred to a clean 
1.5 ml tube for a final wash. Beads were stored at –80°C until further processing.
Polyacrylamide gel electroforesis and Western blotting
Lysates of DC were prepared in SDS lysis buffer as described elsewhere25. For polyacrylamide 
gel electroforesis (PAGE), reducing sample buffer (62.5 mM Tris/HCl pH 6.8, 25% (v/v) glyc-
erol, 2% (w/v) sodium dodecyl sulfate, 0.01% (w/v) bromophenol blue, 5% (v/v) b-mercap-
toethanol) was added 1:1 to a lysate equivalent to ~50,000 cells. As DC-STAMP-GFP tends 
to aggregate during heating, samples were not boiled before being loaded onto gel. Samples 
were subjected to polyacrylamide gel electrophoresis using the MiniProtean system (BioRad, 
Hercules, CA) and further processed for Western blot analysis. After blocking, membranes 
were incubated with a mixture of two primary antibodies against either GFP (clones 7.1 and 
13.1, Roche Applied Science, Almere, the Netherlands), the HA tag (rat monoclonal 3F10; 
Sigma–Aldrich, St. Louis, MO) or purified rabbit polyclonal IgGs against OS9. After washing, 
membranes were incubated with a matching horseradish peroxidase-conjugated second-
ary antibody (DAKO, Glostrup, Denmark). Immunoreactive bands were visualized using the 
ECL kit (GE Healthsciences Bio-Sciences, Uppsala, Sweden). Afterwards, membranes were 
stripped in 0.2 M glycine/1% (w/v) sodium dodecyl sulfate, pH 2.5, blocked and reprobed 
with a mouse monoclonal against b-Actin (1:20,000; Sigma–Aldrich, St. Louis, MO), and pro-
cessed as described above.
Production of anti-OS9 antibodies
GST-OS9 fusion protein was produced in BL21 E. coli bacteria and purified using glutathion 
sepharose beads essentially using standard protocols25. The immunization of rabbits was ap-
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proved by the institutional Ethics Committee for Animal Experimentation and in accordance 
with local and national guidelines. Rabbits were immunized 8 times with purified GST-OS9. 
The first intracutaneous immunization was performed with complete Freund's adjuvant, and 
subsequent subcutaneous immunizations were performed with incomplete Freund's adju-
vant. When sera could detect transiently expressed OS9 in HEK293 lysates in a Western blot 
assay, rabbits were sacrificed and their whole blood collected. Polyclonal rabbit IgG were 
isolated from serum by depleting antibacterial and anti-GST IgG with CNBr-activated sep-
harose beads (GE Healthsciences Bio-Sciences, Uppsala, Sweden) coated with bacterial GST 
lysate, essentially as described by the manufacturer. Polyclonal anti-OS9 IgG were then iso-
lated using Fast Flow Protein G beads, eluted with 900 ml 200 mM glycine pH 2.5, 150 mM 
NaCl, 1 mM EDTA and neutralized in 100 ml 1M Tris pH 8.0. The antibody concentration was 
measured using the BCA kit (Pierce, Rockford, IL), and positive fractions were stored at 4°C.
Immunofluorescence staining and microscopy
Dendritic cells or HEK293 cells were seeded onto slides coated with 25 mg/ml fibronectin, 
and cells were fixed with 1% paraformaldehyde in PBS, permeabilized with ice-cold metha-
nol, washed with PBS, blocked and stained with antibodies either against protein disulfide 
isomerase, an ER marker (PDI; Affinity Bioreagents, Golden, CO), ER-Golgi intermediate com-
partment 53 (ERGIC53; kind gift of dr. J. Fransen, Department of Cell Biology, Nijmegen Centre 
for Molecular Life Sciences,), or polyclonal anti-OS9 antibodies. Antibodies were used as rec-
ommended by the various manufacturers. Fluorescently labeled secondary antibodies were 
obtained from Molecular Probes (Eugene, OR), and cells were mounted in Vectashield (Vector 
Labs, Burlingame, CA). Transfected CHO/TLR cells were seeded onto glass cover slips coated 
with fibronectin, fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% Triton, 
blocked and stained with antibodies against HA (rat monoclonal 3F10) to detect HA-tagged 
OS9 or OS9DC, a rabbit anti-Sec23 polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA) a 
marker for the ER exit sites, or a mouse monoclonal against GM130 (BD Biosciences, San Jose, 
CA), a marker for the cis-Golgi. The ER was visualized using a construct encoding ER-DsRed 
(Clontech, Mountain View, CA). Alexa647-labeled secondary antibodies against either rat or 
mouse IgG were used to visualize OS9 variants or GM130, respectively, whereas Sec23 was 
visualized with secondary anti-rabbit antibodies labeled with Alexa568 (Molecular Probes, 
Eugene, OR). Cells were mounted using Mowiol (Calbiochem, San Diego, CA) and further pro-
cessed as descibed above. Confocal laser scanning microscopy (CLSM) was carried out with 
a BioRad MRC1024 confocal laser microscope at the Microscopic Imaging Facility of the De-
partment of Cell Biology, Nijmegen Centre for Molecular Life Sciences, Radboud University 
Nijmegen Medical Centre, Nijmegen, the Netherlands.
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To confirm the interaction of DC-STAMP with OS9, co-immunoprecipitation 
experiments were performed in HEK293 cells following transient transfection with 
OS9 and DC-STAMP. As no suitable antibodies are available for DC-STAMP, GFP-tagged 
DC-STAMP and HA-tagged OS9 were used instead. We note that the presence of a GFP 
moiety at the carboxy terminus of the DC-STAMP bait protein did not influence the 
OS9 interaction  in the yeast-2-hybrid analysis (data not shown). As shown in Fig. 
1A (middle pictures), both OS9-HA and DC-STAMP-GFP were readily detected in the 
total lysates following transfection. In addition, OS9-HA was efficiently precipitated 
at stringent conditions (RIPA buffer containing 1% Triton X-100, 0.1% SDS and 
0.5% sodium deoxycholate; see Fig. 1A, upper left picture). Western blot analysis 
demonstrated that DC-STAMP-GFP, but not control GFP, co-precipitated with OS9-HA 
(Fig. 1A; lane 6, upper right picture). We note that also in the reciprocal experiment 
OS9-HA co-immunoprecipitated with DC-STAMP-GFP but not GFP (data not shown). 
These results corroborate our findings in the yeast-2-hybrid assay and indicate that 
DC-STAMP can indeed interact with OS9 at stringent conditions. 
Results
OS9 interacts with the cytoplasmic tail of DC-STAMP
To identify DC-STAMP binding partners, a yeast-2-hybrid analysis was performed. 
The predicted cytoplasmic carboxy-terminal tail of DC-STAMP, corresponding 
to amino acids 403–470, was used to screen a prey cDNA library derived from 
a mixture of immature and mature DC26. As shown in Table 1, of the 58 positive 
colonies identified, 8 colonies (14 %) contained a sequence derived from human 
OS9. Further sequence analysis revealed that both OS9 isoform 1 (6 clones) and 
an alternative splice variant of OS9 (2 clones)  were present amongst the positive 
clones. 
Table 1. Overview of the Y-2-H results with the cytoplasmic tail of DC-STAMP
* Includes 1 clone of an OS-9 splice variant
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Figure 1. DC-STAMP and OS9 interact with each other. A) Co-immunoprecipitation of DC-STAMP 
and OS9 in HEK293 cells. DC-STAMP and OS9 were co-expressed as fusion proteins to GFP and HA, 
respectively, and immunoprecipitated with mouse monoclonal 12CA5 (against the HA tag). Total lysates 
and immunoprecipitations were subjected to Western blotting, and proteins were detected using 
antibodies specific for their tags (see Materials and methods for details). As controls, cells transfected 
with pEGFP-N3 were taken along, as well as single transfections with plasmids encoding either DC-
STAMP-GFP or OS9-HA. Arrows indicate the products of expected size. b-Actin was stained and visualized 
as a normalization control. The data are representative of three experiments. B) Various bait constructs 
(prepared in a pGBT9 backbone), containing deletion mutants of the carboxyterminal tail of DC-STAMP, 
were prepared and screened in a yeast-2-hybrid assay with the carboxyterminal 370 amino acids of OS9 
(upper block). Also, various deletion mutants of OS9 (prepared in a pGADGH backbone) were screened 
in a yeast-2-hybrid assay against the full-length carboxyterminal tail of DC-STAMP (lower block). 
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Next, we set out to define the OS9/DC-STAMP interacting domains in further detail 
by Y-2-H analysis. All OS9 clones that were found to interact with the cytoplasmic 
tail of DC-STAMP match the carboxy-terminal half of OS9 (amino acids 298–667) 
(Fig. 1B, upper box, grey bars). Analysis of additional OS9 deletion mutants (Fig. 1B, 
upper part) did not yield a smaller OS9 domain able to interact with the cytoplasmic 
tail of DC-STAMP, suggesting that the complete C-terminal half is required for 
proper binding. As OS9 isoform 2 (amino acids 290–612) does interact with the 
cytoplasmic tail of DC-STAMP in the Y-2-H assays (Fig. 1B, upper part) as well as in 
IP experiments (data not shown)  the amino acids 534–588 that are absent in OS9 
isoform 2 are not essential for interaction with DC-STAMP (Fig. 1B, upper part). To 
further define the parts in the cytoplasmic tail of DC-STAMP that are responsible 
for the interaction with OS9, we created a series of deletion mutants in the carboxy-
terminal tail of DC-STAMP. Subsequent Y-2-H studies revealed that the smallest part 
in the carboxyterminal part of DC-STAMP that is still able interact with OS9 contained 
amino acids 403–434 (Fig. 1B, lower part). Thus, the cytoplasmic tail of DC-STAMP 
is able to bind to amino acids 298–667 of OS9 through a strech of 31 amino acids in 
its carboxy-terminal tail, just proximal to the C-terminal transmembrane domain. It 
should be noted, however, that additional IP experiments with a DC-STAMP carboxy-
terminal deletion mutant revealed that this deletion mutant is still able to interact 
with OS9, suggesting that OS9 interacts through multiple interfaces with other parts 
of DC-STAMP that are exposed to the cytosol (see below and supplementary Fig. S1).
OS9 is expressed in immature and mature DC
To assess the expression of OS9 and the OS9 splice variants  at the mRNA and 
protein levels in DC, immature and LPS-matured monocyte-derived DC were 
generated and analyzed by RT-PCR and Western blotting. As a positive control, various 
clones identified in the yeast-2-hybrid screening were included for comparison. RT-
PCR on cDNA derived from immature and mature DC shows that full-length OS9 and 
isoform 2 are indeed expressed (Fig. 2A). We were unable to detect OS9 isoform 3 
(data not shown). 
To investigate OS9 expression at the protein level, a polyclonal rabbit antiserum 
was raised against the carboxy-terminal 80 amino acids which are present in all 
known isoforms of OS9. Immature DC were generated with IL-4 and GM-CSF, and 
further matured with the TLR ligand LPS for 4, 8, 12 and 48 h, and protein samples 
were prepared for each time point. Succesful maturation of DC was confirmed by the 
upregulation of the co-stimulatory molecules CD80 and CD83, which are considered 
a hallmark of DC maturation (see Supplementary data, Fig. S2). As shown in Fig. 2B, 
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both full-length OS9 and isoform 2 were readily detected on Western blots in 
immature DC. LPS-induced DC maturation results in a transient increase in both 
OS9 isoforms at 4 and 8 h after which OS9 protein levels drop in fully mature DC to 
a slightly lower level as observed in immature DC. The predicted OS9 isoform 2 is 
expressed at higher levels than full-length OS9 throughout DC maturation.
OS9 localizes to the endoplasmic reticulum in immature and 
mature DC
Previously, we reported that DC-STAMP localizes to the ER in immature DC. 
Interestingly, mammalian OS9 is a cytosolic protein that has also been shown  to 
strongly associate with the cytosolic side of the ER in different cell lines15. In order 
to analyze the subcellular localization of OS9 in DC, immature and  mature DC 
were stained with polyclonal rabbit IgG directed against human OS9 and either a 
monoclonal against the ER marker PDI (protein disulfide isomerase) or the ER-Golgi 
intermediate compartment protein ERGIC53. HEK293 cells transfected with OS9 
protein fused to CFP were included for comparison. As shown in Fig. 3A, endogenous 
OS9 in immature DC predominantly colocalizes with the ER marker PDI, but not 
with ERGIC53 (second and third rows of pictures). The ER localization of OS9 is not 
affected by maturation of DC by LPS (Fig. 3A, fourth row of pictures). We note that 
Figure 2. OS9 is expressed in dendritic cells. A) Both full-length OS9 and its isoform 2 are expressed in 
immature (iDC) and mature DC (mDC) at the mRNA level. Positive controls: 26B, a yeast-2-hybrid clone 
picked up in the screen containing full-length OS9; 62C and 206A, yeast-2-hybrid clones containing OS9 
isoform 2. B) Western blot analysis of OS9 expression in immature and maturing DC. A polyclonal rabbit 
serum, raised against the carboxyterminal 80 amino acids of human full-length OS9, was used to detect 










some cytoplasmic staining is also seen with the anti-OS9 serum, which is in line with 
previous biochemical data15. Furthermore, the staining observed in DC essentially 
mimicked the distribution in OS9-CFP-transfected 293 cells (Fig. 3A, outermost 
right column). 
Since co-localization studies of OS9 and endogenous DC-STAMP in DC are 
hampered by the absence of suitable antibodies against DC-STAMP, DC were 
transduced with an adenoviral construct encoding DC-STAMP-GFP8 and stained 
with the polyclonal anti-OS9 serum. As shown in Fig. 3A (upper row of pictures), 
DC-STAMP-GFP shows a distribution reminiscent of the ER, and clearly co-localizes 
with endogenous OS9 in the ER of immature DC. Interestingly, while DC-STAMP-
GFP almost exclusively colocalized with OS9 and the ER marker PDI in immature 
DC (Fig. 3B, upper row of pictures), DC-STAMP-GFP localization appears to shift to 
the intermediate compartment in mature DC. After DC maturation the localization 
of DC-STAMP-GFP appeared much more heterogeneous. In approximately 20–35% 
of the mature DC, DC-STAMP-GFP was present in small speckles that showed a 
clear colocalization with ERGIC53 near the nucleus (Fig. 3B, lower row of pictures 
indicated by an arrow). The observed diversity in DC-STAMP staining may reflect 
the transient nature of the relocalization, the heterogeneity in the cell population, 
or both. Little or no colocalization of DC-STAMP-GFP with the intermediate 
compartment marker ERGIC53 is observed in immature DC (Fig. 3B, middle row 
Figure 3. OS9 resides in the ER in DC, regardless of DC maturation status, whereas DC-STAMP 
translocates to the intermediate compartment. A) Immature monocyte-derived DC were fixed and 
stained with the rabbit polyclonal serum against OS9 (pseudocolored red), as well as a mouse monoclonal 
against either ER marker PDI (three left pictures, second row; in green), or the intermediate compartment 
marker ERGIC53 (three left pictures, third row; in green) and mounted and analyzed by means of CLSM. 
Also, immature DC were transduced with adenovirus expressing DC-STAMP-GFP (in green), fixed and 
stained to detect endogenous OS9 (in red; upper row of pictures). As a control, HEK293 cells were 
transiently transfected with a construct encoding OS9-CFP and stained with an anti-GFP antibody 
(pseudocolored red) and colocalization was assessed with the ER marker PDI and the intermediate 
compartment marker ERGIC53 (both in green: outermost right column). OS9 does not translocate to 
the intermediate compartment upon maturation of DC. Immature DC were matured for 48 h with LPS 
and stained with the polyclonal serum against OS9 (pseudocolored red) and the monoclonal antibody 
for ERGIC53 (in green; fourth row of pictures) B) DC-STAMP-GFP translocates to the intermediate 
compartment between ER and Golgi in DC. Immature DC were transduced with adenovirus encoding 
DC-STAMP-GFP, matured for 48 h and processed for CLSM, and colocalization of DC-STAMP (in green) 
was assessed in immature DC with ER marker PDI (upper row of pictures; in red) and in both immature 
(middle row of pictures) and mature DC (lower row of pictures) with intermediate compartment marker 
ERGIC53 (in red). The arrow indicates typical co-localization of DC-STAMP with ERGIC only seen in 
mature DC. Scale bars: 20 mm.
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of pictures). Thus, while OS9 localization is largely unaffected by TLR stimulation 
of DC, DC-STAMP relocalizes to the intermediate compartment out of the ER in a 
significant proportion of the mature DC.
DC-STAMP is redistributed in a CHO/TLR model system upon 
TLR stimulation
Co-localization studies in primary DC are difficult and are further hampered 
by the dynamic nature of the components in the secretory pathway (i.e. the ER, ER 
exit sites and Golgi) during maturation. Therefore, we set up a model system using 
CHO cells co-expressing either TLR2 or TLR4 and CD14 to analyze DC-STAMP re-
localization in further detail23. These CHO cells also express human CD25 under 
control of an NFκβ promoter, allowing to monitor successful TLR stimulation by 
CD25 upregulation (Fig. S3). CHO/TLR cells transfected with DC-STAMP-GFP were 
stimulated or left unstimulated and stained with antibodies against Sec23, a marker 
for ER exit sites.  CLSM analysis revealed that DC-STAMP-GFP rapidly (within 1 h) 
translocated to the ER exit sites after TLR stimulation, as evidenced by the occurence 
of a punctate DC-STAMP-GFP pattern that exclusively colocalized with Sec23 (Fig. 
4A, upper two rows). Moreover, when cells were stimulated for 6 h, DC-STAMP-
GFP appeared in a clear bright spot adjacent to the nucleus, where it completely 
colocalized with the cis-Golgi marker GM130 (Fig. 4A, two lower rows). Identical 
co-localization data (Fig. 4B) were obtained after LPS exposure when full length 
human OS9 was co-transfected in CHO/TLR/DC-STAMP-GFP cells, suggesting that 
the endogenous Chinese hamster OS9 homologue is sufficient to drive human DC-
STAMP transport. It should be noted that, when co-expressed with the human OS9 
splice variant as identified in the yeast-2-hybrid analysis, DC-STAMP-GFP was still 
able to translocate to the secretory pathway (data not shown). Collectively, these 
data demonstrate that after TLR stimulation DC-STAMP relocalizes from the ER via 
Figure 4. DC-STAMP translocates to the secretory pathway in the CHO/TLR model, irrespective of 
human OS9. A) Upon TLR stimulation, DC-STAMP-GFP colocalizes with Sec23 and GM130. DC-STAMP-
GFP was expressed in CHO/TLR cells, plated onto glass cover slips, and not stimulated (first and third 
row of pictures) or stimulated for 1 h (second row of pictures) or 6 h (fourth row of pictures). Cells 
were fixed and stained with polyclonal rabbit IgG against Sec23, a marker for ER exit sites (upper two 
rows of pictures) or with a mouse monoclonal against GM130, a marker for the cis-Golgi (lower two 
rows of pictures) and cells were mounted and analyzed by means of CLSM. B) DC-STAMP and OS9 do not 
colocalize after TLR stimulation. CHO/TLR cells were transfected with constructs encoding DC-STAMP-
GFP (green) and OS9-HA, and either not stimulated (upper row of pictures) or stimulated for 6 h (lower 
row of pictures). OS9 was visualized using rat monoclonal 3F10 against the HA tag (in red) and cells were 
mounted and analyzed by means of CLSM. Scale bars: 20 mm.
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the intermediate compartment to the Golgi in the CHO model system, similar to the 
findings in TLR-stimulated human DC.
The OS9/DC-STAMP interaction affects DC-STAMP redistribution
To investigate the importance of the DC-STAMP/OS9 interaction in  DC-STAMP 
relocalization, a GFP-tagged DC-STAMP deletion mutant was constructed in which 
amino acids 403–434 in the cytoplasmic carboxyterminus that are known to interact 
with OS9 are lacking (supplementary Fig. S4). As noted before, DC-STAMP interacts 
with OS9 through multiple interfaces outside its cytoplasmic tail. Both wild-type and 
mutant GFP-tagged DC-STAMP were transfected into CHO/TLR cells, together with a 
construct encoding the ER-targeting signal of calreticulin to the fluorescent protein 
DsRed in order to visualize the ER. Interestingly, whereas full-length DC-STAMP-GFP 
showed complete co-localization with ER-DsRed in steady-state conditions, it moves 
out of the ER upon TLR ligation (compare upper and third row of pictures, Fig. 
5A). The DC-STAMP-GFP mutant lacking the minimal carboxyterminal OS9 binding 
domain failed to show this redistribution after stimulation in CHO/TLR cells, but 
instead displayed an ER-like distribution  as evidenced by the overlap of expression 
with ER-resident ER-DsRed (compare second and last row of pictures, Fig. 5A). 
These data imply that OS9 is required for the relocalization of DC-STAMP. 
To further confirm that OS9 is indeed required for the relocalization of DC-
STAMP, we constructed a human OS9-HA deletion mutant lacking the complete 
C-terminal domain (OS9DC, supplementary Fig. S4), which is known to interact with 
the cytoplasmic tail of DC-STAMP and thus may affect TLR-dependent DC-STAMP 
relocalization. We note, however, that also this OS9DC mutant is still able to interact 
with full length DC-STAMP (data not shown), strengthening the finding that OS9 
and DC-STAMP interact through multiple domains.  Furthermore, this mutant still 
localizes to the ER15. Consistent with earlier experiments, DC-STAMP readily displays 
the typical punctate pattern in response to the TLR stimulus in CHO/TLR cells in 
the presence of full-length OS9 (Fig. 5B, compare first and third row of pictures). 
In contrast, in the presence of OS9DC DC-STAMP stays in the ER (compare second 
and last row of pictures, Fig. 5B). These data indicate that OS9DC effectively acts 
as a dominant-negative mutant for the redistribution of DC-STAMP following TLR 
triggering. Moreover, these data collectively provide evidence for a role for OS9 in 




This study was carried out to gain insight in the molecular environment of DC-
STAMP, a protein involved in myeloid differentiation and giant cell formation. By 
means of yeast-2-hybrid analysis and co-immunoprecipitation assays, we identified 
OS9 as a bona fide DC-STAMP-interacting protein (Figs. 1 and 2). Furthermore, 
endogenous OS9 co-localizes with DC-STAMP in the ER of immature DC and in OS9 
transfected HEK293 cells (Fig. 3). Intriguingly, upon TLR stimulation DC-STAMP, but 
not OS9 relocalized from the ER to the intermediate/Golgi compartment in OS9-
dependent manner in DC and TLR expressing CHO cells (Figs. 4 and 5).  
OS9 is a broadly expressed protein consisting of 3 different isoforms. Here we 
show that DC express OS9 isoforms 1 and 2 and that the expression levels of both 
isoforms are modulated upon TLR induced DC maturation. Within immature DC, 
OS9 predominantly co-localized with the the ER resident protein PDI, and upon 
maturation displayed similar intracellular distribution, as its expression did not 
overlap with the intermediate compartment marker ERGIC53. Functionally, OS9 has 
been implicated in ER-to-Golgi transport of the membrane protease meprin A beta 
(MEP1B).  Our data now demonstrate the involvement of OS9 in the transport of 
DC-STAMP out of the ER upon DC maturation. Using CHO cells expressing TLR2 or -4 
it was confirmed that DC-STAMP relocalizes to the cis-Golgi in the presence of full-
length OS9 (Fig. 5) and OS9 isoform 2 (data not shown), and this process is inhibited 
by OS9DC. Interestingly, the region in cytoplasmic tail of DC-STAMP that binds to OS9 
also appears to be required for its transport (Fig. 5). Studies by Litovchick et al.15 
showed that MEP1B transport requires full-length OS9 isoform 1 but that, in contrast 
to DC-STAMP transport, this process is inhibited by OS9 isoform 2. Furthermore, 
MEP1B transport depends on the motif (Y/F)C(X/XX)(R/K)(R/K)(R/K) in its 
cytoplasmic tail. Mutant MEP1B, lacking this motif, cannot be transported from the 
ER to the Golgi27, and does not bind OS9. Although a DC-STAMP mutant lacking the 
cytoplasmic OS9-interacting domain is also unable to translocate, it does not contain 
a motif resembling the one present in MEP1B. Contrary to MEP1B, which is a type I 
transmembrane protein, DC-STAMP has at least 4 transmembrane domains and our 
data show that DC-STAMP interacts with OS9 through multiple interfaces. Another 
important difference between MEP1B and DC-STAMP is that the latter does not go 
to the plasma membrane, whereas MEP1B does, which may reflect differences in 
(required) binding motifs. Collectively, these data suggests that OS9 binds to more 
transmembrane proteins than the 25 predicted so far15 and serves as a multitarget 
adapter for transport of  proteins from the ER-to-Golgi. How exactly OS9 regulates ER-
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Figure 5. The OS9/DC-STAMP interaction affects DC-STAMP redistribution. A) CHO/TLR cells were 
transfected with constructs encoding DC-STAMP-GFP and ER-DsRed (first and third row of pictures), or a 
construct encoding deletion mutant DC-STAMPD403–434-GFP, which lacks the minimal carboxyterminal 
OS9-interacting domain (second and fourth row of pictures). Cells were either not stimulated (upper two 
rows of pictures) or stimulated with a TLR ligand for 6 h (lower two rows of pictures), fixed, mounted 
and the DC-STAMP redistribution (in green) was assessed by means of CLSM. B) Co-transfections in CHO/





































row of pictures) or OS9DC-HA (second and fourth row of pictures), which lacks the DC-STAMP-interacting 
domain as determined by yeast-2-hybrid analysis. Cells were either not stimulated (upper two rows of 
pictures) or stimulated with a TLR ligand for 6 h (lower two rows of pictures), fixed, mounted and the DC-
STAMP redistribution (in green) was assessed by means of CLSM. In all pictures, the red color represents 
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to-Golgi transport of DC-STAMP or MEP1B remains unclear. In the case of MEP1B, OS9 
has been suggested to reside at the interface of ER and the secretoty pathway based 
on Western blot analysis15. We were unable, however, to show that OS9 colocalizes 
with the transitional ER/COPII sites (data not shown), where cargo is concentrated 
for transport to the Golgi. Instead, DC-STAMP colocalization with Sec23-positive ER 
exit sites was readily observed following TLR activation. It is tempting to speculate 
that the OS9/DC-STAMP pathway fulfills a role in ER-to-Golgi transport during DC 
maturation. During DC maturation, many different transmembrane proteins, such as 
cytokines, cytokine receptors, chemokines and MHCI-antigen complexes need to be 
transported to the surface of the cell. Whether or not the DC-STAMP/OS9 pathway 
is directly involved in the increased transport during DC maturation remains to be 
determined.
Besides its role in ER-to-Golgi transport, OS9 has been reported to play role in the 
regulation of proteasome-mediated degradation of the transcription factor hypoxia-
inducible factor 1 alpha (HIF1a) and the vanilloid transient receptor potential protein 
4 (TRPV4). HIF1a  is involved in the genetic response to hypoxia28. Interestingly, 
immune cells are often exposed to low oxygen tensions, which markedly affect their 
cellular metabolism29. OS9 is an essential component of a multiprotein complex that 
regulates HIF-1alpha levels through proteasomal degradation in an O2-dependent 
manner. Recent studies have also implicated OS9 in the clearance of misfolded 
protein conformers30 and of mutated a1-antitrypsin from the ER31. Moreover, OS9 is 
involved in the maturation of TRPV4 by preventing the polyubiquitination of TRPV4 
monomers and, importantly, impedes TRPV4 transport to the plasma membrane32. 
It should be noted that the levels of DC-STAMP, based on immunofluorescence data, 
go down dramatically after TLR stimulation (see Figs. 3, 4 and 5). Although we have 
not in detail explored the degradation of DC-STAMP in the presence of OS9 upon 
TLR stimulation, preliminary biochemical data suggest that, besides promoting DC-
STAMP relocalization, OS9 may also be involved in the degradation of DC-STAMP 
(data not shown). In steady-state conditions, OS9 interacts with DC-STAMP in the 
ER and may act as a chaperone there, possibly regulating the expression of DC-
STAMP proteins and/or the disposal of their misfolded derivates, whereas upon 
TLR stimulation their interaction may lead to rapid overall clearance of excess DC-
STAMP in the ER. However, further experiments are needed to uncover the precise 
mechanism behind this process. 
Since DC-STAMP has been implicated in both osteoclastogenesis, where it appears 
to be required for cell fusion, as well as the development of myeloid cells from bone 
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marrow-derived hematopoietic stem cells, it is tempting to speculate that the OS9/
DC-STAMP pathway plays a role in both processes. Still little is known regarding the 
role of DC-STAMP in DC activation and function. The finding that the DC-STAMP/OS9 
pathway is responsive to TLR-triggering implies a role for inflammatory stimuli in 
its activation. Further research is needed to clarify the role of this novel pathway in 
immune signaling and inflammatory protein transport in DC.
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Supplementary figures
Figure S1. The DC-STAMPD403–434 mutant also co-immunoprecipitates with OS9. DC-STAMP 
D403–434 and OS9 were co-expressed in HEK293 cells as fusion proteins to GFP and HA, respectively, 
and immunoprecipitated with mouse monoclonal 12CA5 (against the HA tag). Total lysates and 
immunoprecipitations were subjected to Western blotting, and proteins were detected using antibodies 
specific for their tags (see Materials and methods for details). The arrows indicate expected products. The 
arrow with asteriks indicates DC-STAMP protein which is post-translationally modified.
Figure S2. Example of successfully matured DC. Surface expression of the maturation markers CD80 
and CD83 was assessed by means of FACS before and after stimulation of DC with LPS. Legend: thin line, 
isotype control; thick line, immature DC; dotted line, DC matured for 48 h with LPS.
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Figure S3. CHO cells stably expressing a TLR were stimulated with TLR ligand and NFκβ-driven 
surface expression of reporter CD25 was assessed by means of FACS. Legend: thin line, isotype 
control; thick line, unstimulated cells; dotted line, cells stimulated with ligand for 7 h.
Figure S4. Maps of the mutants used in this study. A) A schematic representation of the carboxyterminus 
of a DC-STAMP mutant lacking the minimal OS9 binding domain as determined by yeast-2-hybrid analysis, 
corresponding to amino acids 403–434. The mutant is fused to GFP. B) Schematic overview of the OS9 
variants used in this study. OS9fl: OS9 isoform 1; OS9DC: OS9 deletion mutant lacking the part identified 
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Abstract
Dendritic cells (DC) are the professional antigen-presenting cells (APC) which 
efficiently prime the immune response or induce tolerance. We recently identified 
Dendritic Cell Specific TrAnsMembrane Protein (DC-STAMP), a novel 470 amino acid 
protein preferentially expressed by dendritic cells. Previously we demonstrated that 
DC-STAMP re-localizes towards the Golgi upon DC maturation.  To identify proteins 
that interact with DC-STAMP, a yeast-2-hybrid analysis was performed.  Here, we 
report a physically interacting partner of DC-STAMP in the endoplasmic reticulum 
(ER), called LUMAN (also known as CREB3 or LZIP). LUMAN was previously 
described as an ER-resident transcription factor with unknown function.  It is 
activated in a process called regulated intramembrane proteolysis (RIP), which 
involves translocation to the Golgi and subsequent proteolytic cleavage. The 
proteolytically activated form of the protein then translocates to the nucleus. Our 
data indicate that DC-STAMP plays an important role in the modulation of LUMAN 
activation. Moreover, we demonstrate that LUMAN is endogenously expressed by 
DC and becomes activated by RIP upon DC maturation induced by various different 




Dendritic cells (DC) are the professional antigen-presenting cells of the immune 
system. They instruct and control B and T lymphocytes, but also activate natural 
killer (NK) cells and can produce large amounts of interferon, thus providing a link 
between the adaptive and innate immune system. Inflammatory mediators and 
Toll-like-receptors (TLR) promote DC activation/maturation resulting in DC, well-
equipped to initiate adaptive immunity1,2. In the presence of immune inhibitory 
signals, however, immature or semi-mature DCs induce immune tolerance via the 
induction of suppressive regulatory T cells (Treg)3,4. How these external signals 
translate into the genetic programming of the DC is largely unknown. This genetic 
reprogramming process takes place in a relative short time frame (from several 
minutes to 24 h) and does not require cell division. Multiple transcription factors, 
notably NFκβ, are already present in an inactive state in immature DC5. The external 
signals that DC receive determine the activation of pathways to these “ready to go” 
transcription factors ensuring a rapid, well-controlled response by the DC. 
 To fully exploit DC in a clinical setting, a molecular understanding of DC 
immunobiology is essential. Several novel molecules preferentially expressed by 
DC have been isolated and functionally characterized. We have identified a novel 
DC-specific transmembrane protein DC-STAMP that is tightly regulated during DC 
activation6,7.  DC-STAMP is a multimembrane spanning protein localizing to the 
endoplasmic reticulum (ER)8. It was implicated in myeloid lineage differentiation9, 
in osteoclast fusion10 and very recently in the maintenance of immune tolerance 
through DC11. The function of DC-STAMP at the molecular level is unknown. A yeast-
2-hybrid analysis was performed to discover its interacting proteins. Previously, we 
identified and characterized OS9 as a bona fide DC-STAMP binding partner associated 
with the ER12. We showed that upon DC maturation DC-STAMP translocates to the 
Golgi apparatus and this re-localization is influenced by OS9. A second interacting 
partner of DC-STAMP identified by yeast-2-hybrid screening was LUMAN.  
 LUMAN (Gene Symbol: CREB3; also known as LZIP) is a basic leucine 
zipper transcription factor of the CREB/ATF gene family. It was first identified as 
a counterpart of the herpes simplex virus transcriptional activator VP16 that binds 
to the host cell factor (HCF) binding protein13.  Although LUMAN is ubiquitously 
expressed at the mRNA level, endogenous LUMAN protein has been found only in 
the trigeminal ganglional neurons and recently also in monocytes14,15.  In ganglional 
neurons, and in transfected cell lines, LUMAN is found primarily associated with the 
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ER14. Raggo et al. (2002) showed that LUMAN undergoes a proteolytic processing 
event known as regulated intramembrane proteolysis (RIP)16, a process of rapid 
protein activation without a need for cell division. Regulated intramembrane 
proteolysis (RIP) was first described for sterol regulatory element-binding proteins 
(SREBP) and later for activating transcription factor 6 (ATF6), two well-characterized 
ER-associated bZIP transcription factors17,18. In the steady state, transcription factors 
reside in ER, but upon the stimulation (depletion of sterols for SREBP, ER stress 
for ATF6), these transcription factors leave the ER and proceed to the Golgi where 
they are subsequently cleaved by two specific proteases releasing the cytoplasmic 
aminoterminal part of the transcription factor. This active form of the transcription 
factor translocates to the nucleus to drive transcription of target genes17,18. LUMAN 
is a type II transmembrane protein and like ATF6, all known functional domains 
involved in transcription are located in the aminoterminal region and hence, on the 
cytoplasmic side of the ER membrane16.  The relocalization to different compartments 
can be mimicked using Brefeldin A (BfA), a chemical agent able to fuse the ER and 
Golgi and thereby making Golgi-resident proteases accessible without an additional 
stimulus16,19.
In this study we characterized LUMAN as a binding partner of DC-STAMP in 
dendritic cells. We demonstrate that LUMAN is expressed at the protein level in DCs. 
Furthermore, for the first time we show LUMAN activation upon DC maturation, as 
it is proteolytically activated and translocates to the nucleus. Moreover, we show 
that the physical interaction between DC-STAMP and LUMAN influences proteolysis 
of LUMAN upon BfA treatment. Our data strongly suggest that activation of LUMAN 





Plasmids, adenoviral vectors and cloning
The adenoviral constructs encoding DC-STAMP fused to a GFP tag and plasmids encoding DC-
STAMP fused to an HA tag were described elsewhere8. The plasmid encoding DC-STAMP fused 
to the RFP protein was created by replacing the EGFP moiety of the pEGFP-N3 backbone with 
RFP.  Human cDNA of LUMAN was amplified with specific primers and cloned in frame into the 
pEYFP-C1 vector (Clontech, Mountain View, CA) and FLAG-pcDNA3 vector (kind gift of R.A.J. 
Janssen, Galadeno, Leiden, the Netherlands). To create the LUMAN-IRES-GFP plasmid, the 
IRES consensus sequence was inserted upstream of the GFP moiety of pEGFP-N3 (Clontech, 
Mountain View, CA), whereas the coding sequence of LUMAN, including the stop codon, was 
cloned upstream of IRES-GFP. The coding sequences of LUMAN dp (aa 1–144) and LUMAN 
dn (aa145–372) were cloned in frame into the pECFP-N1 vector (Clontech, Mountain View, 
CA). The OS9-HA construct was described previously12. All constructs were verified for in-
tegrity and correct insertion by means of sequencing at the sequencing facility at the Depart-
ment of Human Genetics, Radboud University Nijmegen Medical Centre. For the generation of 
LUMAN-GST fusion proteins in bacteria for the immunization of rabbits, the cDNA sequence 
corresponding to the aminoterminal 151 amino acids of LUMAN was inserted in frame with 
the carboxyterminus of GST in pRP265 (derivative vector from pGEX-2T; kind gift of F. N. van 
Leeuwen, UMCN Nijmegen) Generally, plasmid DNA was isolated from E. coli DH5a or DH10b 
bacteria using the Endofree Plasmid Maxi Kit (Qiagen, Venlo, the Netherlands).
Yeast-2-hybrid analysis
Plasmids pGADGH and pGBT9 were used for yeast-2-hybrid analysis (Clontech, Mountain 
View, CA). The cDNA library used in the yeast-2-hybrid analysis was constructed as described 
previously12. The bait, corresponding to amino acids 403–470 of the cytoplasmic tail of DC-
STAMP, was cloned into pGBT9. The library was amplified in E. coli (strain DH10b, Invitrogen, 
Carlsbad, CA) and analysis was performed as described previously12.
Cell culture, transfections, transductions and generation of human DC
Human embryonic kidney HEK293 cells were cultured in DMEM (GibcoBRL Life Technolo-
gies), supplemented with 10% heat-inactivated FCS (GibcoBRL Life Technologies); 10 nM 
HEPES pH7.7 (Boehringer Mannheim GmbH, Germany); 0.1 mM MEM non essential amino 
acids and 100 units/ml Antibiotic-Antimycotic (both GibcoBRL Life Technologies) at 37oC in 
5% CO2. HEK293 cells were transfected with LipofectAMINE (GibcoBRL Life Technologies) as 
described elsewhere8.
HL60 and THP1cell lines were cultured in RPMI1640 (GibcoBRL Life Technologies), supple-
mented with 10% heat-inactivated FCS (GibcoBRL Life Technologies) and 100 units/ml An-
tibiotic-Antimycotic (both GibcoBRL Life Technologies) at 37oC in 5% CO2. Hep3B cells were 
maintained in DMEM (GibcoBRL Life Technologies), supplemented with 10% heat-inactivated 
FCS (GibcoBRL Life Technologies) and 100 units/ml Antibiotic-Antimycotic (both GibcoBRL 
Life Technologies) at 37oC in 5% CO2.
Chinese hamster ovary cells (CHO) and CHO cells stably transfected with the TLR2 or TLR4 
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(CHO/TLR) were cultured as described before20. This clonal line has been co-transfected with 
CD14 and an NFκβ-dependent reporter plasmid that drives the expression of surface CD25 Ag 
in response to TLR activation. CHO cells were transfected with LipofectAMINE (GibcoBRL Life 
Technologies) as described elsewhere12.
Human monocyte-derived DC were generated using GM-CSF and IL-4, and their purity and 
maturation were assessed by means of FACS analysis as described previously21-24. Adenotrans-
duction of DC was perfomed as described elsewhere8.
RNA isolation and quantitative PCR
Total RNA for RT-PCR was isolated from cells using TriZOL (Invitrogen, Carlsbad, CA). RNA 
concentration was determined spectrophotometrically, and quality was assessed by means of 
conventional agarose gel electrophoresis. Reverse transcription using random hexamers was 
essentially done as described elsewhere25. 
Relative mRNA levels were determined using the ABI PRISM 7000 Sequence Detection System 
and SYBR Green Reagent (Applied Biosystems). Copy DNA was synthesized from 2.0 µg of 
total RNA using Moloney murine leukemia virus reverse transcriptase (MMLV-RT; Invitro-
gen Corp.). A quantitative PCR reaction mix contained 1 x SYBR Green Master Mix, 300 nM 
of each forward and reverse primer, and 25 ng cDNA in a total volume of 25 µl. The following 
primers were used: hLUMAN forward (5’-ACCCAGATGACTCCACAGCAT-3’), hLUMAN reverse 
(5’-GAATAAGCCCCTCCTTCTCCAA-3’), hDC-STAMP forward (5’TTCAGTGGATTTATGGCCTT-
GC–3’), hDC-STAMP reverse (5’-GCTGTCATTTAGCTGTGCCTC–3’), hPBGD (porphobilinogen 
deaminase) forward (5’-GGCAATGCGGCTGCAA-3’), hPBGD reverse (5’-GGGTACCCACGCGAAT-
CAC-3’) (all from Sigma-Aldrich St. Louis, MO). Mean relative mRNA expression from 3 repli-
cate measurements was calculated using ABI PRISM 7000 SDS software (version 1.0; Applied 
Biosystems). Expression per sample was normalized to the Ct value of PBGD, and then nor-
malized to the expression in monocytes, which was set to 1. 
Production of anti-LUMAN antibodies
GST-LUMAN fusion protein was produced in BL21 E. coli bacteria and purified using glutathion 
sepharose beads essentially using standard protocols25. The institutional Ethics Committee 
approved the immunization of rabbits for Animal Experimentation and in accordance with 
local and national guidelines. Rabbits were immunized 4 times with purified GST-LUMAN. The 
first intracutaneous immunization was performed with complete Freund’s adjuvant, and sub-
sequent subcutaneous immunizations were performed with incomplete Freund’s adjuvant. 
When sera could detect transiently expressed LUMAN in HEK293 lysates in a Western blot 
assay, rabbits were sacrificed and all their blood collected. Polyclonal rabbit IgG was isolated 
from serum by depleting antibacterial and anti-GST IgG with CNBr-activated sepharose beads 
(GE Healthsciences Bio-Sciences, Uppsala, Sweden) coated with bacterial GST lysate, essen-
tially as described by the manufacturer. Polyclonal anti-LUMAN IgG was then isolated using 
Fast Flow Protein G beads, eluted with 900 µl 200 mM glycine pH 2,5; 150 mM NaCl, 1 mM 
EDTA and neutralized in 100 µl 1M Tris pH 8.0. The antibody concentration was measured 
using the BCA kit (Pierce, Rockford, IL), and positive fractions were stored at 4°C.
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Protein analysis and immunoprecipitation
Lysates were prepared in SDS lysis buffer as described elsewhere25. For PAGE gel electro-
phoresis, reducing sample buffer (62.5 mM Tris/HCl pH 6.8, 25% (v/v) glycerol, 2% (w/v) 
sodium dodecyl sulfate, 0,01% (w/v) bromophenol blue, 5% (v/v) b-mercaptoethanol) was 
added 1:1 to a lysate equivalent to ~200 000 cells. Samples were subjected to polyacryla-
mide gel electrophoresis using the MiniProtean system (BioRad, Hercules, CA) and further 
processed for Western blot analysis.  After blocking, membranes were incubated with one 
of the following antibodies: mouse anti-GFP (0.04 µg/ml; a mixture of mouse monoclonals, 
7.1 and 13.1; Roche Applied Science, Almere, the Netherlands), mouse anti-FLAG (5 µg/
ml; Sigma-Aldrich; St. Louis, MO), rat anti-HA (3F10; Roche Applied Science BV, Almere, the 
Netherlands), rabbit anti-LUMAN (1:100), or mouse anti β-actin (1:10 000; Sigma-Aldrich, St. 
Louis, MO). The membranes were washed and incubated with a secondary HPR conjugated 
goat anti-mouse IgG (H+L) Ab (0.4 µg/ml, DAKO, Glostrup, Denmark) or swine anti-rabbit 
Ab (0.4 µg/ml, Dako, Glostrup, Denmark). Immunoreactive bands were visualized using 
the ECL kit (GE Healthsciences Bio-Sciences, Uppsala, Sweden) on Kodak Scientific Imaging 
Films. If necessary, membranes were stripped in 0.2 M glycine/1% (w/v) sodium dodecyl 
sulfate, pH 2.5, blocked, re-probed and processed as described above. When indicated, the 
goat anti-rabbit AlexaFluor 680 (0.1 mg/ml; Molecular Probes, Eugene, OR) and goat anti-
mouse IRDye800CW (0.1 µg/ml; LI-COR Biosciences, Lincoln, NE) were used as a secondary 
antibody followed by analysis with the LI-COR Odyssey (LI-COR Biosciences, Lincoln, NE; 169 
μm resolution, 3–7 sensitivity). Integrated intensities were analyzed using Excel (Microsoft 
Corp., Redmond, WA).
In the case of immunoprecipitations, HEK293 cells were transiently transfected GFP, DC-
STAMP-GFP and FLAG-LUMAN as described above, and after 48 h lysed for ~1 h in 1.5 ml lysis 
buffer containing 50 mM HEPES pH 8.0, 5 mM, MgCl2, 150 mM NaCl, 1 mM PMSF, 20 mg/ml 
aprotinin, 10 mg/ml leupeptin and 1% Brij-97. Insoluble material was removed by centrifu-
gation. After preclear with bare beads and beads coupled to rabbit IgG, the immunoprecipita-
tion was performed with beads coupled to GFP (rabbit polyclonal; a kind gift of dr FJM Kup-
peveld, UMCN Nijmegen). All steps were performed at 4°C. Supernatant was saved and stored 
at –80°C and beads were washed 4 times with lysis buffer before being transferred to a clean 
1.5 ml tube for a final wash. Beads were stored at –80°C until further processing. 
IF staining and Confocal laser scanning microscopy
For immunofluorescent staining, HEK293 cells were seeded on 8-chamber slides (NUNC) 
coated with fibronectin (20 µg/ml, Roche Applied Science BV, Almere, the Netherlands). Im-
mature and mature DC were seeded on glass coverslips coated with poly-L-lysine (100 µg/
ml Sigma–Aldrich; St. Louis, MO). Where indicated, cells were treated with BFA (10 mg/ml, 
Sigma–Aldrich; St. Louis, MO) for a maximum of 6 h. Furthermore, cells were fixed with 1% 
PFA for 15 minutes, permeabilized by methanol (–20oC; 1 min), and blocked with 3% BSA 
(Calbiochem, San Diego, CA) in PBS. The following antibodies were used: mouse anti-PDI 
(Protein Disulfide Isomerase, 1:100; MA3-019, ABR); rabbit anti-LUMAN (1:100). As isotype 
controls purified IgG2a (Becton Dickinson) or pre-bleed non immune serum of the immu-
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nized rabbit were used. As secondary antibodies, Texas Red-conjugated goat anti-mouse IgG, 
(5 μg/ml; H+L, Molecular Probes; Eugene, OR), Alexa488-, Alexa568- or Alexa 647-conjugated 
goat anti-mouse IgG and goat anti-rabbit IgG (Invitrogen Corp.) were used where appropiate. 
Slides were mounted with Vectashield or Vectiashield–PI (Vector Laboratories, Burlingame, 
CA) and analysed by CLSM using Biorad MRC1024 or Olympus FV100 at the Microscopic 
Imaging Facility of the Department of Cell Biology, Nijmegen Centre for Molecular Life Sci-
ences, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. The data 
were analyzed using Olympus FV1000 and ImageJ software.
Results 
LUMAN is a binding partner of DC-STAMP
To gain insight in the molecular pathway involving DC-STAMP, a yeast-2-hybrid 
screening was performed to identify DC-STAMP-interacting proteins. As DC-STAMP 
is preferentially expressed in DC, we first constructed a yeast-2-hybrid library 
of a mixture of cDNAs isolated from immature and mature DC with a complexity 
of 106 independent clones. This library was screened using the 74 amino-acid 
carboxyterminal cytoplasmic tail of DC-STAMP as bait. Ten out of 58 clones 
represented one single gene, LUMAN (CREB3, LZIP)26. LUMAN is a 372 amino acids 
long protein that belongs to the CREB/ATF family of transcription factors. As shown 
in Fig. 1A (and schematically in Fig. 3A), two independent clones of different lengths 
specifically interacted with the DC-STAMP bait. No interaction was observed with 
the empty bait vector. 
To confirm the specific binding of LUMAN to DC-STAMP, HEK293 cells were 
transfected with cDNAs encoding DC-STAMP-GFP and FLAG-LUMAN fusion proteins. 
Cells co-transfected with FLAG-LUMAN and GFP served as a control. Western blot 
analysis of total lysates showed that DC-STAMP-GFP, GFP and FLAG- LUMAN are 
expressed in single and double transfectants (Fig. 1B). DC-STAMP-GFP and GFP 
were both efficiently immunoprecipitated from total lysates using a mixture of 2 
monoclonal GFP antibodies. Subsequent Western blot analysis revealed that Flag-
LUMAN is specifically present in the DC-STAMP-GFP immunoprecipitated fraction. 
No LUMAN was co-immunoprecipitated with GFP alone (Fig. 1B). Moreover, the 
observation that LUMAN is not only co-immunoprecipitated with DC-STAMP, but 
also with the previously identified DC-STAMP-interacting protein OS9, further 
substantiates these findings (Fig. S1). They also suggest that DC-STAMP, LUMAN and 
OS9 are part of the same complex.
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Previously we described that DC-STAMP localizes to the endoplasmic reticulum8. 
Raggo et al. reported ER-localization of LUMAN in transfected COS cells16. To confirm 
and extend these findings, HEK293 cells were transfected with DC-STAMP-RFP and 
YFP-LUMAN constructs and stained for the ER-resident protein PDI. As shown in 
Supplementary Fig. S2A, both DC-STAMP-RFP and YFP-LUMAN show clear co-
localization with PDI. In addition, a clear co-localization of DC-STAMP-RFP and 
YFP-LUMAN is observed upon their co-expression in cell lines of different origin 
(HEK293 and CHO; Fig. 2). Since co-localization studies of LUMAN and endogenous 
Figure 1. LUMAN is a DC-STAMP-interacting protein. A) Two LUMAN clones of different length interact 
with the DC-STAMP bait in a Y-2-H analysis. A cDNA library of immature and mature DC was screened with 
the cytoplasmic tail of DC-STAMP as bait.  B) LUMAN co-immunoprecipitates with DC-STAMP in HEK293 
cells. HEK293 cells were transfected with constructs encoding DC-STAMP-GFP or GFP and FLAG-LUMAN, 
where GFP served as a control. The immunoprecipitation was performed using the polyclonal rabbit 
αGFP antibody, whereas GFP was visualized with a mixture of mouse monoclonal antibodies. To visualize 
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DC-STAMP in DC are hampered by the absence of suitable antibodies against DC-
STAMP, DC were transduced with an adenoviral construct encoding DC-STAMP-GFP8 
and stained with the polyclonal anti-LUMAN serum. As shown in Fig. 2 (lower row 
of pictures), in immature DC DC-STAMP-GFP shows a distribution reminiscent of the 
ER, as does endogenous LUMAN. Collectively, these observations fully support the 
yeast-2-hybrid data and provide evidence that DC-STAMP and LUMAN are binding 
partners that are present in the ER compartment of the cell. 
Mapping of the binding regions
To identify the minimal part of LUMAN that is able to bind to DC-STAMP, a 
series of LUMAN deletion mutants was made and tested in the yeast-2-hybrid 
assay. The longest LUMAN clone interacting with DC-STAMP identified in the initial 
screen spans amino acids 62–372 (Fig. 3A). The minimal amino-acid sequence of 
Figure 2. Co-localization of DC-STAMP and LUMAN. Two different cell lines (HEK293 and CHO) 
were co-transfected with DC-STAMP-RFP and YFP-LUMAN and co-localization was analyzed by CLSM. 
Immature DC were transduced with an adenoviral construct encoding DC-STAMP-GFP and stained with 
the polyclonal anti-LUMAN serum. Scale bar: 10μm.  
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LUMAN needed for binding to the cytoplasmic tail of DC-STAMP is located between 
amino acid 98 and 276. This region of LUMAN contains the DNA binding domain, 
the leucine zipper motif and extends approximately 30 amino acids beyond the 
Figure 3. Mapping of the interaction domains of DC-STAMP and LUMAN by means of yeast-2-hybrid 
analysis. A) Mapping of the binding site in LUMAN using different deletion mutants cloned in the prey 
vector. The minimal region in LUMAN needed for the interaction with the DC-STAMP cytoplasmic tail 
spans amino acids 98–276. Both originally identified clones (9c and 67c) contain this region. B) Mapping 
of the binding site in DC-STAMP by means of yeast-2-hybrid analysis. The minimal region of DC-STAMP 
which interacts with LUMAN spans amino acids 430–456 of the cytoplasmic tail of DC-STAMP. Note that a 
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transmembrane domain14. Based on this we conclude that cytosolic part of LUMAN 
interacts physically with the cytosolic carboxyterminus of DC-STAMP. Intriguingly, 
the lumenal part of LUMAN is also necessary, possibly establishing conformational 
requirements for this interaction.
To map the DC-STAMP binding site, a series of DC-STAMP cytoplasmic-tail deletion 
mutants was generated and tested in the yeast-2-hybrid system as well. The minimal 
sequence that is required for LUMAN binding comprises amino acids 430–456 of the 
DC-STAMP cytoplasmic tail (Fig. 3B). We note that fusion of GFP to the C-terminus of 
the cytoplasmic-tail did not affect the interaction in the yeast-2-hybrid experiments 
(Fig. 3B). The observed binding to amino acids 430–456 was as efficient as the 
entire DC-STAMP cytoplasmic bait. Interestingly, the membrane proximal amino 
acids 403–434 in the cytoplasmic tail of DC-STAMP do not appear to contribute to 
LUMAN binding. These are exactly the 30 amino acids that have previously been 
identified as the binding site for the DC-STAMP interacting protein OS9 (Fig. 3B and 
12). Collectively, these data show that LUMAN binds to the carboxyterminal part of 
DC-STAMP proximal to but not overlapping with the OS9 binding site in DC-STAMP. 
Furthermore, our data indicate that the amino acid sequence of LUMAN required 
for binding to DC-STAMP involves the central part of the sequence including its 
transmembrane region. 
Elevated LUMAN protein expression in DC
Next, we determined LUMAN mRNA levels during DC differentiation and maturation 
by quantitative RT-PCR. A panel of cell lines and freshly isolated leukocyte subsets 
were included as controls and DC-STAMP mRNA levels were analyzed in parallel. 
As shown in Fig. 4A LUMAN mRNA is expressed at approximately the same level in 
all cell lines, freshly isolated leukocytes, and different stages of DC differentiation/
maturation. These data are in line with previous studies demonstrating that 
LUMAN mRNA is ubiquitously expressed in a wide variety of different cell types26. 
In contrast, DC-STAMP mRNA is essentially absent in the cell lines, monocytes and 
lymphocytes (Fig. 4B). Upon differentiation of monocytes towards immature DC 
DC-STAMP mRNA levels are increased 500-fold and are strongly down-regulated 
upon DC maturation (Figure 4B and 6). These data demonstrate that LUMAN mRNA 
is ubiquitously expressed in DC as well as other cell lines examined. Immature DC 
are unique in that they express high levels of the DC-STAMP mRNA as well as its 
binding partners LUMAN (Fig. 4) and OS912. 
Although LUMAN mRNA is ubiquitously expressed, endogenous LUMAN protein 
has so far only been found in trigeminal ganglional neurons and monocytes using 
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immunohistochemistry14,15. To assess LUMAN protein expression in DC, a rabbit 
polyclonal antibody was raised against the aminoterminal 220 amino acids of 
LUMAN. The anti-LUMAN antibodies specifically detected a doublet of 65 kDa and 
60 kDa in HEK293 cells transfected with a LUMAN-IRES-GFP construct. The size of 
Figure 4. Expression of LUMAN at the mRNA and protein level. Messenger RNA levels of LUMAN A) 
and DC-STAMP B) in different human cell lines, freshly isolated leukocytes and DC during differentiation. 
The expression in monocytes is set to 1. C) Protein expression of LUMAN during DC differentiation 
analyzed by Western blot analysis using a rabbit polyclonal antibody against the aminoterminal part of 
LUMAN. HEK293 cells transfected with a LUMAN-IRES-GFP construct were included as a control. Due to 
overexpression of the transfected protein a shorter exposure of the last lane of the Western blot is shown. 
D) Quantitative analysis of LUMAN expression in various cell types. Integrated intensity of full length 
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these protein bands nicely fit previously published data on size of LUMAN protein 
in transfected COS cell line, with the lower band representing the non-glycosylated 
form of LUMAN16. Next, total cell lysates from PBMC, PBL, monocytes, and days 3 
and 6 immature monocyte-derived DC were subjected to Western blot analysis and 
data were quantified relative to β-actin. As shown in Fig. 4C, LUMAN is expressed 
in freshly isolated PBMC, PBL and monocytes at low levels. Day 3 monocyte-
derived DC express 8-fold higher levels of LUMAN relative to monocytes and this 
increased expression is sustained in day 6 immature DC (Fig. 4C and D). The larger 
product of the endogenous LUMAN doublet has the same molecular weight as 
observed in LUMAN-transfected 293 cells and likely represents glycosylated LUMAN 
protein. The electrophoretic mobility of the smaller protein is somewhat higher 
in the transfected cells than in DC, which may be a reflection of cell type-specific 
glycosylation differences. We conclude that although LUMAN mRNA is expressed to 
similar extend in different immune as well as non-immune cells, LUMAN protein 
expression is increased up to 8-fold in immature DC relative to monocytes. 
LUMAN undergoes RIP and nuclear translocation upon DC 
maturation
The transcription factor LUMAN is a type II transmembrane protein that 
localizes to the ER. LUMAN has been shown to translocate from the ER to the 
Golgi where it undergoes a proteolytic processing event known as Regulated 
Intramembrane Proteolysis (RIP)16. As a result, the aminoterminal part of LUMAN 
carrying the transcription factor moiety is released from the carboxyterminal 
part and translocates to the nucleus. The physiological signals that activate RIP 
of LUMAN are not known. RIP can be mimicked by Brefeldin A (BfA), an agent 
inducing fusion of the ER and Golgi compartments19. To study the localization of 
endogenously expressed LUMAN in DC, immature DC were cultured in the presence 
or absence of BfA, stained with the polyclonal anti-LUMAN antibody, and analyzed 
by CLSM. HEK293 cells transfected with FLAG-LUMAN were included as a control. 
As shown in Fig. 5A, staining of immature DC with the polyclonal LUMAN serum 
resulted in a cytoplasmic staining pattern, similar to the ER staining pattern in the 
FLAG-LUMAN expressing control cells. Double staining of immature DC for LUMAN 
and the ER marker PDI confirmed the ER localization of LUMAN in immature DC 
(Fig. S2A; upper row). LUMAN staining of BfA treated immature DC or FLAG-LUMAN 
transfected control cells resulted in a clear shift in the localization of LUMAN from 
the cytoplasm to the nucleus. The nuclear localization of LUMAN was confirmed by 
co-staining of the BfA-treated immature DC with the nuclear marker PI. These data 
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strongly suggest that the machinery responsible for RIP of LUMAN is present and 
can be activated in DC.
Previously, we showed that in DC-STAMP-GFP-transduced immature DC, 
DC-STAMP localizes to the ER8 and translocates towards the Golgi compartment 
upon DC maturation using the TLR4 ligand LPS12. Unfortunately, co-localization 
studies of LUMAN and DC-STAMP in DC are hampered by the absence of antibodies 
against DC-STAMP. To study the localization of LUMAN in DC at different conditions, 
immature DC and LPS induced mature DC were stained for LUMAN. Strikingly, 
while in immature DC LUMAN is predominantly present in the ER, in mature DC 
the endogenous LUMAN protein is mainly localized in the nucleus (Fig. 5B and Fig. 
S2B, lower row). RIP has been shown to release a 37–40 kDa protein consisting of 
the aminoterminal part of LUMAN that is able to enter the nucleus16. To determine 
whether the nuclear localization observed for LUMAN in mature DC is accompanied 
by RIP, Western blot analysis was performed on immature and mature DC. As shown 
in Fig. 5B, a protein of 37–40 kDa reactive with the anti-LUMAN serum is present in 
mature but not immature DC and coincides with its nuclear localization. These data 
indicate that LPS induced DC maturation results in RIP of LUMAN, resulting in the 
accumulation of the aminoterminal part of LUMAN in the nucleus of mature DC.
To assess the kinetics of LUMAN activation a time course experiment was 
performed using BfA and LPS stimulations of DC. As a control HEK293 cells were 
transfected with LUMAN-IRES-GFP construct and stimulated with BfA for 6 h, which 
resulted in a 37 kDa product reactive with anti-LUMAN serum. Interestingly, in DCs 
the cleaved aminoterminal part of LUMAN protein with a size of 40 kDa appears from 
16 h on after LPS stimulation (Fig. 5C). Additionally, the weak product of 37 kDa is 
visible as a result of BfA treatment of DC after 8 hours (Fig. 5C, indicated by asterisk). 
We conclude that RIP of LUMAN is a late event upon the LPS-induced DC maturation 
and is more efficient than BfA treatment. Moreover, activation of LUMAN can be 
a general event since the 40 kDa product of LUMAN was observed upon different 
types of stimulation usually leading only to immune activation (Fig. 5D and Fig. S3).
The presence of DC-STAMP inhibits proteolysis of LUMAN
The data so far show that DC are unique among LUMAN expressing cells in that 
they co-express its interacting partner DC-STAMP. To elucidate the role of DC-STAMP 
in this complex process, we determined whether the presence or absence of 
DC-STAMP affects BfA induced RIP of LUMAN in a CHO cell line model described 
previously12. Cells were transfected with YFP-LUMAN and either DC-STAMP-HA 
or a control construct encoding Dectin1-HA. Twenty-four hours after transfection 
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Figure 5. RIP activation of LUMAN. A) Analysis of LUMAN expression in untreated (left column) and 
BfA-treated (right column, 6 h) immature DC and HEK293 cells transfected with FLAG-LUMAN.  LUMAN is 
visualized using the polyclonal antibody against its aminoterminal part, followed by a secondary antibody 
coupled to Alexa488 (green). Nuclei are stained with PI (red). Scale bar: 10 μm. B) Endogenous expression 
of LUMAN in immature and mature DC analyzed by CLSM (upper row) and Western blot (lower picture). 
In both cases the staining was performed using the polyclonal antibody against the aminoterminal part of 
LUMAN followed by secondary antibody coupled to Alexa488 (green) for CLSM or to HRP and visualized 
by ECL for Western blot. Nuclei are stained with PI (red). Scale bar: 10 μm. C) Kinetics of LUMAN activation 






transfected cells were stimulated for 6 h with BfA or left untreated, lysed and 
subjected to Western blotting and quantitative protein analysis (Fig. 6A and B). It 
appeared hat DC-STAMP-HA, Dectin1-HA and YFP-LUMAN were expressed in the 
transfected cells (Fig. 6A and unpublished results). As expected, addition of BfA 
specifically induced the proteolytic activation of LUMAN (approximately 70 kDa, 
including YFP, Fig. 6A). Strikingly, the ratio between cleaved and uncleaved LUMAN 
following BfA treatment in the presence of DC-STAMP was significantly impaired as 
compared to Dectin-1 (Fig. 6B). The inhibitory effect of DC-STAMP on BfA-dependent 
LUMAN activation was confirmed in multiple independent experiments and shown 
to be independent of the type of tags on either DC-STAMP or LUMAN (unpublished 
results). Collectively, these data indicate that, in the absence of additional stimuli, 
BfA induced RIP of LUMAN is downregulated by DC-STAMP. 
Discussion
This study was carried out to gain insight in the molecular function of DC-STAMP, 
a protein involved in myeloid differentiation and giant cell formation. By means 
of yeast-2-hybrid analysis and co-immunoprecipitation assays, we identified 
LUMAN as a bona fide DC-STAMP-interacting protein (Figs. 1 and 2). The LUMAN-
interacting domain in DC-STAMP does not overlap with that of OS9, another binding 
partner of DC-STAMP. Furthermore, LUMAN co-localizes with DC-STAMP in the ER 
of transfected HEK293 and CHO cells (Fig. 3).  We also demonstrate endogenous 
expression of LUMAN protein in dendritic cells (Fig. 4 and 5). LUMAN is localized in 
the ER in immature DC, like DC-STAMP. Intriguingly, upon DC maturation, LUMAN 
re-localizes to the nucleus, presumably to activate or repress transcription of target 
genes. Moreover, by co-transfecting DC-STAMP and LUMAN into a model cell line 
ml) and subjected to Western blot analysis. LUMAN was visualized using a secondary antibody coupled 
to Alexa680 and analyzed with Odyssey software.  HEK293/ LUMAN-IRES-GFP transfected cells treated 
with BFA for 6 h were included as a control. β-actin was used as a loading control. Due to lower expression 
of the cleaved product of LUMAN in BfA-treated samples the corresponding part of the Western blot is 
shown after longer exposure. D) LUMAN activation in differently matured DC. DC were mature by LPS (1 
μg/ml), mix of TLR7/8 and TLR3 ligands (R848 0.4 μg/ml, Poly I:C 20 μg/ml), cytokine mix (IL1β, IL6, 
TNFα and PGE2; all 1 μg/ml), and mix of IL10 and Dexamethasone (100 U/ml; and 10-6 M, respectively) 
and subjected to Western blot analysis. Western blot analysis after 24 h of stimulation is shown. LUMAN 
was visualized as described above.  HEK293/LUMAN-IRES-GFP transfected cells treated with BfA for 6 h 
were taken along as a control. β-actin was used as a loading control. 3
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modulation of BfA-mediated activation of LUMAN by DC-STAMP is demonstrated 
(Fig. 6).
The yeast-2-hybrid approach demonstrated that the newly discovered interactors 
LUMAN and OS9 each bind to different regions within the cytoplasmic tail of 
DC-STAMP (Fig. 3). When mapping of the binding sites of LUMAN we observed an 
interesting phenomenon: the interaction with DC-STAMP requires both cytoplasmic 
and lumenal sequences. As the cytoplasmic tail of DC-STAMP was used as bait, we 
hypothesize that the interaction takes place at the cytoplasmic side of the ER, and 
that the lumenal domain of LUMAN is needed to ensure a proper conformation at 
the cytoplasmic side of the ER. We cannot exclude the possibility that LUMAN and 
DC-STAMP also interact through their lumenal domains inside the ER, and further 
research is needed to address that possibility.
LUMAN is ubiquitously expressed at the mRNA level but at the protein level it 
was observed only in the trigeminal ganglional neurons and monocytes14,15. Our 
result confirms the ubiquitous mRNA levels of LUMAN (Fig. 4).  Additionally, we 
clearly show its protein expression in DC, which was almost 10 times higher than 
in monocytes. In some of the experiments we observed two (iso)forms of LUMAN, 
where the larger protein likely represents a glycosylated form of full-length LUMAN, 
as reported by Raggo et al.16. Strikingly, for the first time we were able to detect 
the transcriptionally active aminoterminal part of endogenous LUMAN in mature 
DC (Fig. 5). Based on the kinetics of LUMAN activation it is reasonable to assume 
Figure 6. DC-STAMP modulates the ability of BFA to cause RIP of LUMAN. A) CHO/TLR cells 
were transfected with YFP-LUMAN together with DC-STAMP-HA or Dectin-HA as a control. 24 h after 
transfection, cells were or were not stimulated with BfA for 6 h and subjected to Western blot analysis. 
LUMAN was visualized by staining with a mixture of two monoclonal αGFP antibodies. B) Quantitative 
analysis of LUMAN cleavage was performed using Odyssey software. The graph represents the ratio 




that LUMAN serves in a feedback control mechanism, as the activation of LUMAN is 
a late event during DC maturation (Fig. 5C). This notion is further supported by the 
reported role of its interacting partner DC-STAMP in DC activation and function, as 
a recent study by Sawatani indicates its possible role in the maintenance of immune 
self-tolerance11. 
Most of our experiments were conducted using LPS, a TLR4 ligand, as a maturation 
stimulus. It is, however, interesting to note that two different “maturation cocktails” 
currently used to mature DC in clinical vaccination studies21,22 resulted in the same 
proteolytically cleaved LUMAN protein (Fig. 5D). Strikingly, stimulation leading 
towards a tolerogenic phenotype did not result in LUMAN activation (Fig. 5D) 
suggesting a specific pathway in DC primed towards immunity.  An additional 50 
kDa product in mature DC was observed, which seemed to be more pronounced at 
later time points than the 40 kDa product. An interesting possibility is that LUMAN 
may undergo SUMOylation, which would add approximately 10 kDa to the protein, 
in line with the observed size. This is further supported by bioinformatics analysis 
(unpublished results), which revealed three possible SUMOylation sites in the 
nuclear, aminoterminal part of LUMAN. 
There is some controversy regarding the localization of endogenous LUMAN. It 
has been reported that LUMAN is primarily associated with the ER in the trigeminal 
ganglional neurons and in transfected cell lines14, whereas other studies show that 
LUMAN is expressed in the cytoplasm with partial cell membrane localization in 
monocytes15. Our data support ER localization of LUMAN protein in different cell 
lines and endogenously in immature DC (Figs. 2 and 5 and S2). Brefeldin A treatment, 
known to facilitate re-localization of activated LUMAN to the nucleus, indeed resulted 
in nuclear localization of LUMAN in a transfected cell line as well as in immature 
DC. Interestingly, upon DC maturation the endogenous, aminoterminal part of 
LUMAN clearly localizes to the nucleus, confirming the presence of the machinery 
in DC needed to proteolytically activate LUMAN (Fig. 5). These observations fully 
corroborate the data obtained by Western blot analysis. 
Since DC are primary cells, manipulation of these cells using molecular techniques 
is often difficult. Most notably, DC-manipulation often has an impact on DC function 
and induces maturation which is one of the processes we now show are important in 
relation to DC-STAMP/LUMAN. We therefore used a cell line model in which DC-STAMP 
is not endogenously expressed and which allows easy modulation of its expression 
by standard transfection technologies. CHO cells were used to investigate whether 
DC-STAMP plays a role in the activation of LUMAN. The quantification of Western 
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blot analysis clearly shows that co-transfecion of DC-STAMP negatively influences 
the BfA-induced cleavage of LUMAN in CHO cells (Fig. 6). The overexpression of 
DC-STAMP in DCs had the same effect on BfA-induced LUMAN activation as in the 
transfected cell line, but to a lesser extent (unpublished results). The negative effect 
of DC-STAMP on BfA-induced cleavage of LUMAN observed in Fig. 6 may explain the 
data presented in Fig. 5C, where a time course analysis of BfA stimulation resulted in 
a very weak proteolytic product of 37 kDa in comparison to a larger cleaved product 
of LUMAN (40 kDa) upon LPS stimulation. The differences in size of cleaved Luman 
observed may be the result of a phosphorylation event and suggests that in DC the 
natural route of LUMAN activation via LPS is not identical to BfA-treatment that 
has so far been used to induce LUMAN translocation. Additionally, since DC-STAMP 
is preferentially expressed by DC, there may be a specific role for the LUMAN/
DC-STAMP pathway in the context of DC, since we were not able to clearly show LPS-
mediated activation of LUMAN in the CHO/TLR model.
Our data indicate a physical interaction of DC-STAMP and LUMAN (Figs.   1–3). 
Moreover, in or at the ER membrane DC-STAMP significantly influenced the BfA-
mediated cleavage of LUMAN. Interestingly, less full-length LUMAN protein was 
present in co-transfections with DC-STAMP, which suggests an additional effect of 
DC-STAMP on stability of LUMAN (Figs. 1B and 6). In this respect it is important to 
note that another DC-STAMP-interacting partner, OS9, is known to play a role in the 
regulation of proteasome-mediated degradation of the transcription factor hypoxia-
inducible factor 1 alpha (HIF1a) and the vanilloid transient receptor potential 
protein 4 (TRPV4)27,28. Our immunoprecipitation data (Fig. S1) show also physical 
interaction between OS9 and LUMAN, and OS9 may be important in the regulation 
of the stability or turnover of this transcription factor, however this needs further 
analysis.
As has been reported before, LUMAN can undergo RIP16, a process of rapid 
activation of ER-resident transcription factors by means of transport to and 
proteolytic cleavage in the Golgi. To reach the Golgi, an accessory protein is needed 
which serves as a sensor of the environmental changes of initiating the RIP or a 
transporter. For LUMAN, no natural triggers were known so far. Also, no ER-resident, 
interacting proteins have been reported. Here, we demonstrate for the first time 
the activation of endogenous LUMAN upon DC maturation. Based on similarities 
between the SREBP/SCAP model29 and LUMAN/DC-STAMP, a following model is 
proposed: in immature DC, DC-STAMP interacts with LUMAN and OS9 in the ER 
(Fig. 7A). Upon DC maturation, the DC-STAMP/LUMAN complex is released from 
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the ER (Fig. 7B; step 1) and the complex translocates to Golgi. LUMAN is activated 
by proteolytic cleavage and its aminoterminal part re-locates to the nucleus (Fig. 
7B; step 2). This model implies that DC-STAMP fulfills a role as a transport protein, 
much akin to the role of SCAP in SREBP activation, however we have not established 
a role as a sensor. Although not clear at this stage, OS9 may serve at the same time 
as a regulator of turnover as well as transport of the DC-STAMP/LUMAN complex 
transport in the ER12. It is likely that both OS9 and DC-STAMP play an important role 
Figure 7. Model of DC-STAMP/LUMAN/OS-9 pathway. A) Schematic representation of DC-STAMP, 
LUMAN and OS9 complex in the ER. DC-STAMP, LUMAN and OS9 interact with each other at the cytosolic 
site of the ER. B) In steady-state conditions in immature DC the DC-STAMP/LUMAN/OS9 complex reside in 
the ER (left). Upon DC maturation, OS9 does not alter its localization, but the DC-STAMP/LUMAN complex 
translocates to the Golgi (right; step 1), where LUMAN is subsequently cleaved and its aminoterminal 
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in LUMAN function as both DC-STAMP and OS9 physically interact with LUMAN (Fig. 
S1). 
As LUMAN plays a role in an ER stress response pathway30 a survey of public 
microarray data in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) has been performed and did not reveal differential expression of known 
LUMAN targets in activated DC, strongly suggesting that is involved in a different, 
novel pathway in DC.
Intriguingly, DC-STAMP has been also implicated in osteoclastogenesis, where it 
was suggested to localize to the cell membrane in osteoclasts10. It is very well possible 
that DC-STAMP localization is cell-type dependent. It is tempting to speculate 
that the LUMAN/DC-STAMP/OS9 pathway plays a role in both DC maturation and 
osteoclastogenesis. Here, we have provided evidence for a new pathway involving 
DC-STAMP, LUMAN and OS9 in response to innate immune signaling in DC. Ongoing 
and future research will clarify the role of this complex in DC immunobiology, and 
lead to a better understanding of the molecular wiring of these cells, hopefully to the 
benefit of their clinical use.
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Figure S1. LUMAN co-immunoprecipitates with OS9 in HEK293 cells. HEK293 cells were transfected 
with OS9-HA and LUMAN and different deletion mutants: LUMAN full-length (fl), dominant-postive 
(dp; amino acids 1–220), and dominant negative (dn amino acids 145–372) fused to YFP or CFP in a 
double transfection. The immunoprecipitation was performed using the mouse αHA (12CA5) monoclonal 
antibody. Only the fl and dn mutant of LUMAN are able to interact with OS9. To visualize LUMAN, Western 
blots were stained with a mixtured of two αGFP monoclonal antibodies. OS9-HA was visualized using the 
rat αHA monoclonal 3F10. 
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Figure S2. Localization of LUMAN  and DC-STAMP in tranfectants and in DC. A) ER localization of DC-
STAMP-RFP and YFP-LUMAN in HEK293 transfectants. HEK293 cells were transfected with constructs 
encoding DC-STAMP-RFP or YFP-LUMAN, and stained with αPDI antibody to visualize ER and analyzed 
by CLSM. IgG2a was used as a negative control. Scale bar: 10 μm. B) Endogenous expression of LUMAN 
in immature (upper row) and mature DC (lower row) co-stained with an ER marker PDI, followed by 
a secondary antibody conjugated to Alexa568 (red). LUMAN is visualized by the polyclonal antibody 
against the aminoterminal part of LUMAN, followed by secondary antibody coupled to Alexa488 (green). 





Figure S3. Expression of DC markers after different stimulation. Surface expression of the maturation 
markers CD80, CD83 and CD86 was assessed by means of FACS before and after different stimulation as 
used in the Fig. 5D.
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Abstract 
Dendritic cells (DCs) are the highly specialized antigen presenting cells of the 
immune system that play a key role in regulating immune responses. DCs can 
efficiently initiate immune responses or induce tolerance. Due to this dual function, 
DCs are studied in the context of immunotherapy for both cancer and autoimmune 
diseases. Characterization of DC-specific genes, leading to better understanding of 
DC immunobiology, will help to guide their use in clinical settings. We previously 
identified DC-STAMP, a multi-membrane spanning protein preferentially expressed 
by DCs. DC-STAMP resides in the endoplasmic reticulum (ER) of immature DCs 
and translocates towards the Golgi compartment upon maturation. In this study 
we knocked down DC-STAMP in mouse bone marrow-derived DCs (mBMDCs) to 
determine its function. We demonstrate that DC-STAMP knock-down mBMDCs 
secrete less IL-6, IL-12, TNF-α and IL-10 while IL-1 production is enhanced. 
Moreover, LPS-matured DC-STAMP knock-down mBMDCs show impaired T cell 
activation potential and induction of Th1 responses in an alloreaction. We show that 
DC-STAMP plays an important role in cytokine production by mBMDCs following 





Dendritic cells (DCs) are professional antigen presenting cells (APC) that play 
a central role in innate and adaptive immunity. DCs, armed with a wide range of 
receptors that sense danger signals and scavenge antigens in the surrounding 
environment, constantly scan our body. Antigen uptake in the presence of 
inflammation and danger signals results in DC maturation. In this active state 
DCs are able to efficiently induce immune responses1. On the other hand, in the 
absence of danger signals DCs regulate tolerance to self-antigens in order to prevent 
autoimmunity. 
During maturation DCs upregulate costimulatory molecules such as CD40, CD80 
and CD86 as well as MHC class II, which allows for effective antigen presentation 
to naïve T cells. Furthermore, mature DCs produce and secrete proinflammatory 
cytokines and chemokines to attract and activate innate effector cells as well as 
to direct the development of specific T helper (Th) subsets2. High levels of IL-12 
will induce differentiation of naïve CD4+ T cells into Th1 cells while blocking the 
development of the Th2 lineage3. To prime Th2 responses IL-4 produced by Th2 
cells themselves, NKT cells, eosinophils or basophils is needed4,5. Additionally, IL-1 
has a positive influence on expansion of the murine Th2 cells6. The murine Th17 
T-cell subset efficiently develops in the presence of the proinflammatory cytokines 
IL-6 and TGF-β7. 
Due to their immunoregulatory capacities DCs are a promising tool for 
immunotherapy. Indeed, DC-based therapies are currently being used for treatment 
of cancer, autoimmune diseases and the prevention of transplant rejection8-12. 
Detailed understanding of molecular aspects of DC immunobiology is crucial 
for optimal application of DCs in immunotherapy. Characterization of genes like 
DC-SIGN13, DC-CK114 and DC-SCRIPT15-17 has already resulted in many novel findings 
regarding the molecular basis of DC function. 
Recently, we reported on the isolation and characterization of a novel molecule 
named DC-STAMP, both in human and mouse DCs18,19. DC-STAMP was shown to be 
a multi-membrane spanning protein preferentially expressed by myeloid DCs18, 
macrophages20 and osteoclasts21. In immature DCs, DC-STAMP localizes to the 
endoplasmic reticulum22 and upon DC maturation translocates towards the Golgi 
compartment, which is most likely facilitated by its interacting partner OS923, a 
protein that has previously been implicated in ER-to-Golgi transport24,25. Interestingly, 
DC-STAMP also interacts with the ER-resident transcription factor LUMAN26. 
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LUMAN is activated in a process called regulated intramembrane proteolysis 
(RIP), which involves its translocation to the Golgi compartment, proteolytic 
cleavage and subsequent nuclear localization27. The immunological and biological 
processes DC-STAMP is involved in are only recently emerging. Functional studies 
in DC-STAMP knock-out mice have shown that DC-STAMP is essential for fusion of 
osteoclasts and foreign body giant cells21,28. Much less is known regarding the role 
of DC-STAMP in myeloid immune cells. DC-STAMP was shown to inhibit granulocyte 
development from hematopoietic progenitors cells29, however its expression is not 
required for proliferation and differentiation of DCs30. Initial data using immature 
DCs from DC-STAMP knock-out mice have suggested involvement of DC-STAMP in 
phagocytosis and antigen presentation. As aged DC-STAMP knock-out mice show 
symptoms of autoimmune diseases, a role of DC-STAMP in maintaining the balance 
between immunity and tolerance has been proposed30. 
In the current study we examined the role of DC-STAMP in immature and TLR-
matured DCs. For this purpose, we generated lentiviruses encoding DC-STAMP-
specific shRNAs to knock-down DC-STAMP in BMDCs. We found that DC-STAMP 
knock-down in mature but not immature DCs affects cytokine production, induction 
of T cell proliferation and Th1 cell activation. 
Materials and methods
Cell lines and cell culture
The human embryonic kidney cell line HEK293 was cultured in DMEM (Invitrogen) supple-
mented with 10% heat-inactivated FCS (Greiner Bio-One), 1% of non-essential amino acids 
(NEAA) (Invitrogen) and 0.5% antibiotic-antimycotic (Invitrogen). The mouse embryonic 
fibroblast cell line NIH3T3 was cultured in DMEM supplemented with 5% heat-inactivated 
FCS, and 0.5% antibiotic-antimycotic. HEK293FT cells (Invitrogen) were cultured in DMEM 
supplemented with 10% heat-inactivated FCS, 1% NEAA, 0.5% antibiotic-antimycotic, 1% 
ultra-glutamine (Lonza), and 1 mM sodium pyruvate (Invitrogen). Cells were kept under se-
lection with 500 μg/ml of Geneticin (G418) (Invitrogen).
Generation of bone marrow-derived DCs
Mouse BMDCs were generated from bone marrow progenitor cells, according to the modified 
protocol of Lutz31. Bone marrow cells were flushed from the femurs and tibias of 6- to 8-week-
old female C57BL/6 mice (Charles River WIGA Gmbh), washed and counted. Cells were plated 
at a concentration of 4 x 106 cells per 10 cm Petri dish in 13 ml of RPMI-1640 medium (In-
vitrogen) supplemented with 10% FCS, 1% ultra-glutamine, 28 μM of β-mercaptoethanol 
(Sigma–Aldrich), 0.5% antibiotic-antimycotic and 20 ng/ml of murine recombinant GM-CSF 
(PeproTech). After 3 days, 4 ml of fresh medium was added containing fresh GM-CSF to final 
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concentration of 8.75 ng/ml. At day 6 non-adherent and loosely adherent cells were harvest-
ed and used for transduction. 
Vectors and validation of RNAi
The construction of murine DC-STAMP-GFP vector was described previously22. Four SureSi-
lencing shRNA plasmids encoding the shRNA sequence targeting murine DC-STAMP: shST1 
(5’-gctggaagttcacttgaaact-3’), shST2 (5’-ttgtggctggaagtatgagaatgt-3’), shST3 (5’-tctggatgat-
cacctgtgttt-3’), shST4 (5’-ggttcctctcagtattattct-3’) and negative control scrambled shRNA 
(shScr) (5’-ggaatctcattcgatgcatac-3’) plasmid were obtained from SuperArray Bioscience. 
In order to validate the silencing of mDC-STAMP, HEK293 cells were co-transfected with a 
plasmid expressing mDC-STAMP-GFP plasmid and a SureSilencing shRNA plasmid encoding 
either a control shRNA or mDC-STAMP-targeting shRNA using Lipofectamine (Invitrogen) 
according to the manufacturer’s protocol. Forty-eight hours following transfection, mDC-
STAMP-GFP protein levels were determined by Western blot. 
Western blotting
Cells were lysed in 1% SDS buffer and subjected to Western blot analysis as described previ-
ously22. GFP-tagged mDC-STAMP was detected using mouse anti-GFP antibody (Roche). Actin 
was detected with a mouse anti-β-actin Ab (Sigma–Aldrich). Rabbit anti-mouse-HRP (Dako-
Cytomation) was used as a secondary antibody. For detection an ECL Western Blotting Detec-
tion Reagents kit (Amersham Bioscience) and BioMAx XAR Film (Kodak) were used. 
Generation of the lentiviral vector stocks
Using Gateway technology, DNA encoding sequences for short-hairpin RNAs in the BLOCK-iT-
U6-RNAi Entry vector were introduced into the pLenti6/BLOCK-iT-DEST vector (Invitrogen), 
following the manufacturer’s protocol. The individual vectors were co-transfected with pack-
aging vectors into the HEK293FT cells according to the manufacturer’s instructions. Virus 
was produced in HEK293FT culture medium supplemented with 82.5 μg/ml of water-soluble 
cholesterol (Sigma–Aldrich) and collected from tissue culture supernatant 24 and 48 h after 
transfection. Cell debris was removed by centrifugation and supernatant containing virus 
particles was filtered through a 0.45 μm filter. Aliquots were stored at –80°C until use.
Viral titers were determined by transduction of NIH3T3 cells with serial dilutions of the virus 
stock in the presence of 10 μg/ml of polybrane (Sigma–Aldrich). Two days after transduction 
the cells were cultured under selection with 2 μg/ml of Blasticidin (Invitrogen) for 12 days. 
Medium was refreshed every third day. To determine the titer, the number of colonies was 
determined after crystal violet staining. The titer ranged between 2 x 105 to 13 x 105 transfec-
tion units (TU)/ml
Lentiviral knockdown of mDC-STAMP in mBMDCs 
Mouse BMDCs were harvested after 6 days of culture and 1.2 x 106 cells were resuspended in 
700 μl of virus supernatant containing 10 μg/ml of DEAE-dextran (Pharmacia Biotech AB) to 
facilitate viral infection. Cell-virus suspensions were plated on 12-well tissue culture plates 
(700 μl/well) and centrifuged for 90 min at 2200 rpm and 37°C.  After centrifugation, virus 
supernatant was replaced by mBMDC culture medium. The infection procedure was repeated 
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the following day. As a negative control, mBMDC culture medium with DEAE-dextran was 
used. The multiplicity of infection (MOI) for silencing of DC-STAMP was matched with the MOI 
of the scrambled shRNA control in each experiment.
RNA isolation and quantitative real-time PCR (qPCR)
Total RNA was isolated from at least 6 x 105 cells using a Quick-RNA MiniPrep kit (Zymo Re-
search). RNA quantity and purity were determined using a NanoDrop spectrophotometer. Two 
micrograms of total RNA were treated with DNase-I (Invitrogen) and cDNA was synthesized 
using random primers and SuperScript Moloney murine leukemia virus reverse transcrip-
tase (II-MMLV) (Invitrogen).  Messenger RNA levels for the genes of interest were determined 
with a Bio-rad CFX96  (Bio-rad) using Fast Start SYBR Green kit (Roche) and primers for 
one of the following genes: porphobilinogen deaminase (PBGD) (forward: 5’-CCTACCATAC-
TACCTCCTGGCTTTAC-3’; reverse: 5’-TTTGGGTGAAAGACAACAGCAT-3’), DC-STAMP (forward: 
5’-TTGCCGCTGTGGACTATCTG-3’; reverse: 5’-GAATGCAGCTCGGTTCAAAC-3’), IL-6 (forward: 
5’-TGGGAAATCGTGGAAATGAG-3’; reverse: 5’-CAAGTGCATCATCGTTGTTC-3’), IL-1α (forward: 
5’-CGAAGACTACAGTTCTGCCATT-3’; reverse: 5’-GACGTTTCAGAGGTTCTCAGAG-3’), IL-1β 
(forward 5’-GTGATGAGAATGACCTGTTCTTTG-3’; reverse: 5’-GATTTGAAGCTGGATGCTCTC-3’), 
IL-12p40 (forward 5’-GACACGCCTGAAGAAGATGAC-3’; reverse: 5’-TAGTCCCTTTGGTCCAGT-
GTG-3’). Data were analyzed with Bio-rad CFX manager version 1.6 (Bio-rad) and checked 
for correct amplification and dissociation of the products. PBGD served as a reference gene. 
DC-STAMP and IL-6 levels relative to PBGD were calculated as: 2-(ΔCt).
Cytokine measurements
For cytokine assays, 1 x 105 day 11 mBMDCs were plated per well on 96-well plate in 200 μl of 
culture medium. Cells were stimulated with 1 μg/ml of LPS (E. coli, 0111:B4, Sigma–Aldrich). 
Supernatants were harvested at the indicated time points and stored at –80°C. Concentra-
tions of IL-12p70 and IL-6 in cell culture supernatants were measured by ELISA (BD Biosci-
ences), according to manufacturer’s protocol. 
The cytokines and chemokines IL-10, IFN-γ, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-7, 
IL-9, IP-10 (CXCL10), KC (CXCL1), MCP-1 (CCL2), MIP-1α (CCL3), MIP-2 (CXCL2), RANTES 
(CCL5), TNF-α and VEGF in cell culture supernatants were measured using the mouse cyto-
kine multiplex (Milliplex, Millipore) following the manufacturer’s protocol. Data analysis was 
performed using Bio-Plex Manager software (Bio-Rad Laboratories). 
Immunofluorescent staining and Confocal Laser Scanning Microscopy
Immature mBMDCs (day 11) were seeded onto cover slides coated with poly-L-lysine (Sigma–
Aldrich) (5 x 105 cells/slide), adhered for 2 hours and fixed with 1% PFA for 15 minutes. Cells 
were permeabilized with methanol (–20°C; 1 min) and blocked with 3% BSA (Calbiochem) in 
1 x PBS supplemented with 0.1% saponin (Sigma–Aldrich). Rabbit anti-calreticulin (Calbio-
chem) antibody was used to visualize ER. As an isotype control, purified rabbit IgG (Sigma–
Aldrich) was used. As a secondary antibody, goat anti-rabbit-Alexa488 (BD Biosciences) was 
used. The nucleus was stained with DAPI. Slides were mounted in Mowiol (Calbiochem) and 




Mixed lymphocyte reactions (MLRs) were performed using day 12 C57BL/6 mBMDCs as stim-
ulators. Splenocytes from Balb/c mice (Harlan) depleted for B220-positive cells were used 
as responders. Negative selection for B220-positive cells was performed to increase T cell 
numbers in the splenocyte pool. Briefly, splenocytes were stained with an anti-B220-FITC 
antibody (BioLegend) then incubated with magnetic beads coupled to anti-FITC antibodies 
and purified with a magnetic bead-based kit (MACS; Miltenyi–Biotec). Cells were labeled with 
1 μM CFSE (Invitrogen) at a concentration of 50 x 106 B220-negative cells/ml for 7 min at 
37°C in PBS with 1% FCS. MLR assays were carried out in 96-well round-bottom plates (200 
μl/well) at a ratio of 1:2 or 1:3 (responders to stimulators), for 4 to 5 days in T cell medium 
(IMDM (Invitrogen) containing 10% FCS, 1% antibiotic-antimycotic, 0.5% ultra-glutamine, 
28 μM of β-mercaptoethanol and 60 IU of human IL-2 (Proleukin; Chiron BV, Amsterdam, the 
Netherlands). The proliferation rate was assessed by FACS analysis of CFSE dilution. 
Flow cytometry
For cell surface labeling, the following anti-mouse antibodies were used (from BD Biosciences, 
unless stated differently): PE-conjugated anti-CD86 (GL1), anti-CD80 (16-10A1), anti-CD40 
(3/23), anti-CD8α (53-6.7), anti-MHC class II (M5/114.15.2, eBioscience); PerCP-conjugated 
anti-CD62L (Mel-14, BioLegend); APC-conjugated anti-CD11c (N418, BioLegend); APCCy7-
conjugated anti-CD4 (L3T4). Flow cytometry was performed using a CyAn flow cytometer 
(Beckman Coulter) and analyzed with FlowJo software (TreeStar). 
Statistical analysis
Statistical significance was calculated using a two-tailed Student t test (GraphPad Prism 
version 4.00 software). Data obtained from ELISA and Milliplex experiments were log2-trans-
formed before statistical analysis. Significance of difference was determined by the p value 
(*p< 0.05; **p< 0.01; ***p< 0.001).
Results 
DC-STAMP silencing in mouse bone marrow-derived DCs
To investigate the role of DC-STAMP in DCs, we performed DC-STAMP knock-
down studies in mBMDCs. Hereto, four different DC-STAMP shRNA sequences and 
a control scrambled shRNA sequence (shScr) were tested for their ability to silence 
murine DC-STAMP-GFP following co-transfection in HEK293 cells. Silencing was 
assessed by western blot analysis using antibodies directed against the GFP-moiety 
of the DC-STAMP-GFP fusion protein (Fig. 1A). The results show that the shRNA 
sequences shST1 and shST4 were most effective in DC-STAMP silencing whilst the 
scrambled shRNA had no effect. Therefore, these two DC-STAMP shRNA sequences 
were chosen for further use in mBMDCs. As mBMDCs are difficult to transfect, we 
4
91
Effect of DC-STAMP silencing in DCs
DC-STAMP-GFP 
shRNA                          -          shST1  shST2   shST3  shST4  shScr 

































used lentiviral shRNA delivery to stably produce shRNA from an integrated RNAi 
cassette and avoid as much as possible the host’s defense mechanisms. Assessment 
of  the effect of lentiviral transduction on maturation marker expression and 
cytokine production at the time of DC stimulation, revealed comparable levels of 
CD86 and MHC class II expression between non-transduced and mock transduced 
(shScr) mBMDCs . Additionally, proinflammatory and anti-inflammatory cytokines 
were not detectable in the supernatants of both non-infected and infected cells (data 
not shown). Taken together, these results indicate that infected cells did not mature 
spontaneously.
Bone marrow-derived DCs were infected with lentivirus expressing shST1, shST4 
or shScr at day 6 and day 7 of culture. As specific antibodies against mDC-STAMP are 
not available, silencing of mDC-STAMP in mBMDCs was determined at the mRNA 
level by quantitative real-time PCR (qPCR). Effective silencing of DC-STAMP mRNA 
was observed at both day 9 and day 11 of culture (40 and 90 hours after second 
transduction) (Fig. 1B and data not shown). DCs at day 11 of culture were used for 
further experiments. In accordance with the results in HEK293 cells, shST1 was more 
effective in silencing DC-STAMP (70% silencing) as compared to shST4 Collectively, 
these data show that we are able to effectively silence DC-STAMP mRNA in mBMDCs 
with two independent shRNAs. 
Figure 1. Efficiency of DC-STAMP silencing. A) HEK293 cells were co-transfected with mDC-STAMP-
GFP plasmid and one of four plasmids expressing different shRNA sequences, designed to silence 
DC-STAMP, or with plasmid expressing scrambled shRNA. Cells were lysed 48 hours post-transfection and 
lysates were subjected to Western blot analysis. Blots were stained for GFP and re-probed for β-actin as 
an internal reference. Data shown are representative of two independent experiments. B) Murine BMDCs 
were transduced with lentivirus expressing shST1 or shST4 to silence DC-STAMP, or shScr as a negative 
control. Messenger RNA expression of DC-STAMP was assessed by qPCR. Levels of normalized DC-STAMP 
mRNA expression in cells infected with shST1 and shST4 lentiviruses were related to normalized 
DC-STAMP mRNA expression in shScr lentivirus infected cells. Data are depicted as mean percentage of 




DC-STAMP silencing does not induce phenotypic changes in mBMDCs
First, the effect of DC-STAMP silencing on DC morphology and appearance was 
determined. Observation of the cells in culture after infection (day 6 and 7) until day 
11 of culture did not reveal significant differences in DC morphology of both the non-
adherent and loosely adherent cells between DC-STAMP knock-down and control 
cells (Fig. 2A). As DC-STAMP is a molecule residing in the endoplasmic reticulum, 
we investigated the ER in DC-STAMP knock-down and control cells in more detail 
by staining for the ER-residing protein calreticulin. Confocal microscopy analysis of 
the ER did not show any substantial differences in ER abundance or morphology 
in the DC-STAMP knock-down cells (Fig. 2B). This confirms results from DC-STAMP 
deficient mice indicating that DC-STAMP does not affect the appearance of the ER in 
DCs30.
To evaluate the effects of DC-STAMP silencing on the expression of DC surface 
molecules flow cytometry analysis was performed. Expression of MHC class I and 
class II, and the costimulatory molecules, CD80, CD86 and CD40 was analyzed on 
immature and LPS-matured DC-STAMP knock-down (shST1 and shST4) and control 
(shScr) mBMDCs. To monitor the effect of viral infection, non-infected cells (no 
virus) were taken along in this analysis. No significant differences between control 
(shScr) and DC-STAMP knock-down immature mBMDCs were observed for any of 
the surface markers analyzed (Fig. 2C and data not shown). Upon LPS stimulation 
for 24 h, CD80, CD86, and MHC class II expression levels were elevated in both 
control and DC-STAMP-silenced DCs (Fig. 2C and data not shown). Non-infected 
and control shRNA (shScr) infected mBMDC did not significantly differ in their 
response to LPS stimulation, although the upregulation of costimulatory molecules 
in lentivirus infected cells was somewhat less. Furthermore, no differences in overall 
morphology or cell death were observed between the DC-STAMP knock-down 
and control cells following LPS-induced DC maturation. These data show that the 
phenotype of DC-STAMP knock-down cells does not differ from the control cells and 
correlates with results obtained from DC-STAMP knock-out mice30. Additionally, our 
data show that the upregulation of costimulatory molecules following maturation is 
not affected in DC-STAMP silenced DCs relative to control cells. 
LPS-induced cytokine secretion is altered in DC-STAMP knock-down 
mBMDCs
Upon DC maturation, along with changes in cell surface molecule expression, 
DCs also begin secreting cytokines and chemokines that play an important role in 
regulating immune responses. To determine the capacity of DC-STAMP knock-down 
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Figure 2. DC-STAMP silencing does not induce phenotypic changes in mBMDCs. Murine BMDCs were 
infected with shScr and shST1 lentivirus at day 6 and day 7 of culture. A) Light field microscopy image 
of mBMDCs in culture 4 days post-infection. B) Lentiviraly transduced mBMDCs stained with antibody 
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mBMDCs to produce cytokines, cells were either left unstimulated or stimulated 
with LPS for 6, 16 and 24 h and the production of IL-6 was measured by ELISA. No 
difference in the cytokine production by the mBMDCs was observed without LPS 
stimulation, indicating that knock-down of DC-STAMP does not induce spontaneous 
IL-6 production. In contrast, the amount of IL-6 in supernatants of the DC-STAMP 
knock-down DCs after LPS stimulation was significantly decreased relative to 
control mBMDCs at all time points (Fig. 3A). Moreover, this effect was proportional 
to the level of DC-STAMP silencing. Cells transduced with shST1 produced 50% less 
of IL-6 than control mBMDCs whilst cells transduced with shST4 produced only 
20-30% less. Next, IL-12p70 levels were measured in supernatants of DC-STAMP 
knock-down and control DCs. No IL-12 was spontaneously induced in immature 
DC-STAMP knock-down DCs (Fig. 3B). Interestingly, IL-12p70 was readily detected 
at 16 and 24 h of LPS stimulation, but the levels were significantly lower in DC-
STAMP knock-down mBMDCs (shST1) (Fig. 3B). The finding that the level of DC-
STAMP down-regulation with the two independent shST1 and shST4 DC-STAMP 
shRNAs is proportional to the decrease in IL-12 production further demonstrates 
the relevance of this observation.
To further define the effect of DC-STAMP on cytokine and chemokine production, 
supernatants of immature and 24 hours LPS-matured mBMDCs transduced 
with shST1 and shScr were analyzed by Milliplex bead assay. As expected, the 
predominantly T cell derived cytokines IFN-γ, IL-2, IL-4, IL-5, IL-9, IL-17, as well 
as IL-7 and IL-15 were not present at detectable levels in the supernatants of 
mBMDCs irrespective of DC-STAMP silencing and LPS stimulation (data not 
shown). Expression of the chemokines RANTES, IP-10, KC, MCP-1, MIP-2 as well as 
growth factor VEGF was readily detected upon LPS stimulation but no significant 
differences between shST1 and shScr control cells were observed (Fig. 3C and data 
not shown). In contrast, the proinflammatory chemokine MIP-1α was expressed by 
both immature and mature DC and was clearly decreased in the supernatants of 
both immature and LPS-matured DC-STAMP knock-down DCs (Fig. 3C). Secretion 
of TNF-α and the anti-inflammatory cytokine IL-10 was also significantly decreased 
in supernatants of the LPS-matured DC-STAMP knock-down mBMDCs. On the 
other hand, LPS induction of the proinflammatory cytokine IL-1α was significantly 
against calreticulin (green) to visualize ER and DAPI staining of nucleus (blue) analyzed by CLSM. C) Flow 
cytometric analysis of CD80, CD86 and MHC class II surface expression in CD11c+ immature (-LPS) and 
LPS-matured (+LPS) non-infected (no virus), shScr and shST1 mBMDCs. Isotype controls are indicated by 
shaded area. Data shown are representative of two or three independent experiments. 
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increased in DC-STAMP knock-down mBMDCs relative to control DCs at the 24 hour 
time point. IL-1β levels were also increased in supernatants of mature DC-STAMP 
knock-down mBMDCs although the difference did not reach statistical significance 
(Fig. 3C). Further analysis revealed that the increase in IL-1α production in LPS-
matured DC-STAMP silenced DCs is not present at earlier time points (6 and 16 h) 
(data not shown).
To address whether the observed deregulation in cytokine production can be 
explained by an effect of DC-STAMP silencing on cytokine transcription, the levels 
of the IL-6, IL-12p40, IL-1α and IL-1β mRNA were assessed (Fig. 3D). Detected 
differences in mRNA levels fluctuated between experiments, however the same 
tendency was observed. IL-6 and IL-12p40 mRNA levels were decreased in DC-STAMP 
knock-down cells (shST1) (20-75% for IL-6, 20-65% for IL-12p40), while mRNA of 
IL-1α and IL-1β levels were increased (25-48% for IL-1α and 27-35% for IL-1β).
Taken together, these results demonstrate that DC-STAMP deficiency results in 
the deregulation of cytokine production by mBMDCs and suggest the involvement of 
transcriptional regulation of cytokine genes in this phenomenon.  
DC-STAMP deficiency leads to decreased T-cell proliferation
Next, we investigated the capacity of immature and LPS-matured DC-STAMP 
knock-down and control DCs to stimulate proliferation of CFSE-labeled allogeneic 
splenocytes depleted for B220 positive cells. The proliferation rate of total CD3+ 
T cells co-cultured with immature mBMDCs did not differ between DC-STAMP 
knock-down and control cells (Fig. 4A and 4B). In contrast, when the LPS-matured 
DC-STAMP knock-down mBMDCs were used as stimulators a significantly decreased 
proliferation rate of total CD3+ T cells was observed (Fig. 4A and 4B). In line with 
this finding, a significantly higher expression of CD62L was still present on CD4+ 
as well as CD8+ T cells in the cultures stimulated with the matured DC-STAMP 
knock-down mBMDCs compared to those stimulated with control DCs (Fig. 4C and 
4D). No difference in CD62L expression was observed on the T cells activated by 
the immature mBMDCs. These data confirm that DC-STAMP knock-down mature 
mBMDCs have an impaired ability to activate T cells in an allogeneic MLR.
T cells stimulated by activated DCs can differentiate into different directions 
to promote Th1, Th2 or Th17 type responses. As we observed differences in 
proliferation rate and activation of T cells of co-cultures stimulated with mature 
mBMDCs, we analyzed supernatants from these co-cultures for the presence of 
a number of cytokines and chemokines (Fig. 4E). Strikingly, the levels of IFN-γ, a 
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Figure 3. LPS-induced cytokine secretion is altered in DC-STAMP knock-down mBMDCs. Murine 
BMDCs transduced with shST1, shST4 or shScr were stimulated with 1 μg/ml of LPS for 6, 16 and 24 
hours. A) Levels of secreted IL-6 were measured by ELISA. Data are expressed as a percentage of control 
(shScr). Mean ± SEM calculated of four independent experiments. Values in all experiments ranged from 
5 to 500 ng/ml. B) Levels of secreted IL-12 p70 were measured by ELISA. Data shown are representative 
of three independent experiments and are expressed as a percentage of control (shScr). Mean ± SEM 
calculated from triplicates. Values in all experiments ranged from 0.4 to 5 ng/ml. C) Levels of secreted 
cytokines were determined in supernatants 0 and 24 hours after LPS stimulation using Milliplex bead 
assay. Mean ± SEM calculated from at least three independent experiments. Two-tailed Student t test was 
performed in A, B and C (ND-not detectable, *p< 0.05; **p< 0.01; ***p< 0.001). D) Total RNA was isolated 
from shScr and shST1 mBMDCs stimulated with LPS. Messenger RNA expression levels of IL-6, IL-12p40, 
IL-1α and IL-1β were determined by quantitative RT-PCR where PBGD served as an internal reference. 
Results shown are representative of at least three independent experiments. The differences in mRNA 
levels between shScr and shST1 in all experiments ranged from 20% to 75% for IL-6, 20-65% for IL-
12p40, 25-48% for IL-1α and 27-35% for IL-1β.
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Figure 4. Decreased ability of DC-STAMP knock-down mBMDCs to stimulate T cell proliferation 
in allogeneic MLR. Splenocytes depleted for B220+ cells from Balb/c mice were stained with CFSE and 
co-cultured with immature (-LPS) or LPS-matured (+LPS) DC-STAMP knock-down (shST1) or control 
(shScr) mBMDCs from C57BL/6 mice. A) FACS data of CFSE dilution in CD3+ T cells. B) Quantified T-cell 
proliferation as a mean fluorescent intensity (MFI) of CFSE dilution in CD3+ T cells. Mean ± SEM of four 
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T cells (Balb/c) from co-cultures with DC-STAMP knock-down (shST1) or with control (shScr) mBMDCs 
(C57BL/6) (black line) compared to isotype control (grey shaded area). Data shown are representative 
of three independent experiments. D) Quantification of CD62L MFI on CD3+CD4+ and CD3+CD8+ T cells 
(Balb/c) from co-cultures with DC-STAMP knock-down mBMDCs (shST1) and shScr mBMDCs (C57BL/6). 
Data are expressed as mean ± SEM of three independent experiments. E) Supernatants from allogeneic 
MLR co-cultures with mature mBMDCs were analyzed for indicated cytokines and chemokines by 
Milliplex bead assay. Data shown are mean ± SEM from triplicates and are representative of at least three 
experiments. Two-tailed Student t test was performed in B, D and E (ND-not detectable, *p< 0.05; **p< 
0.01; ***p< 0.001).
cytokine produced mainly by CD4+ cells of the Th1 phenotype, were significantly 
reduced in supernatants from co-cultures with DC-STAMP knock-down mature 
mBMDCs. Cytokines produced by Th2 type cells, IL-4 and IL-5, were present in 
somewhat higher amount in supernatants of co-cultures with DC-STAMP knock-
down mBMDCs although these differences were not statistically significant. No 
difference in IL-17 levels was observed in the co-cultures with DC-STAMP knock-
down and control mBMDCs while IL-10 was decreased without reaching statistical 
significance. Corresponding to our results obtained from supernatants of mBMDCs 
cultures, IL-6 expression was decreased and IL-1α expression was increased in 
co-cultures with mature DC-STAMP knock-down mBMDCs. The proinflammatory 
chemokines MCP-1 and VEGF were present in significantly higher quantities in 
supernatants of co-cultures with DC-STAMP knock-down mBMDCs (Fig. 4E) relative 
to control DC. Together, these results show that LPS-matured DC-STAMP knock-
down mBMDCs are less efficient in stimulating T cell proliferation and initiating 
IFN-γ producing Th1 cells.
Discussion 
DCs are professional antigen-presenting cells that are critically involved in the 
initiation of the primary immune response1. Maturation of the DC is important for 
priming naïve T cells and the generation of appropriate T cell responses. Here we 
show that silencing of the DC-expressed molecule DC-STAMP results in a distorted 
cytokine production both on mRNA and protein level in mBMDCs following LPS 
exposure. The importance of DC-STAMP in mBMDC maturation is further emphasized 
by the decreased ability of mature but not immature DC-STAMP knock-down DCs to 
stimulate naïve T cells and to prime Th1 responses. 
Studies of DC-STAMP overexpression in murine bone marrow progenitor cells 
have suggested that DC-STAMP affects granulocyte development from hematopoietic 
progenitor cells29. On the other hand, analysis of DC-STAMP knock-out mice mBMDCs 
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shows that DC-STAMP is not necessary for DC proliferation and differentiation30. 
Little is known about the role of DC-STAMP in the maturation of DCs. DC maturation 
is a key checkpoint in the initiation of immunity and has important consequences on 
the quality of the immune response. Our previous studies have shown translocation 
of DC-STAMP from ER towards the Golgi compartment upon maturation of DCs23. 
This differential localization of DC-STAMP in immature and mature DCs may suggest 
that DC-STAMP exerts an important role during the complex process of maturation. 
No significant differences in the morphology and the expression of DC-maturation 
markers between DC-STAMP knock-down and control immature and mature 
mBMDCs was observed. These data indicate that DC-STAMP silencing does not affect 
the phenotype of mBMDCs.
Upon TLR ligation, besides co-stimulatory molecule expression, DCs also start 
to produce a wide range of cytokines and chemokines to attract and stimulate 
other cells of the immune system1. Our data show that despite the mature cell 
surface phenotype, DC-STAMP knock-down mBMDCs exhibit distorted cytokine 
production upon LPS stimulation (Fig. 3). Further analysis indicated that observed 
differences in secretion of IL-6, IL-12, IL-1α and IL-1β proteins are accompanied 
by the corresponding changes in mRNA levels (Fig. 3D), suggesting regulation at 
the transcriptional level. Interestingly, one of the DC-STAMP interacting partners, 
LUMAN, is a transcription factor that resides in the ER. For its activation LUMAN is 
translocated towards the Golgi compartment, cleaved and subsequently accumulates 
in the nucleus27. Previously, we have shown that LUMAN protein in human myeloid 
DCs becomes translocated to the nucleus following TLR4 ligation in mature DCs26. 
Others have shown that LUMAN can bind to cAMP response element (CRE) and 
unfolded protein response element (UPRE) transcription factor binding sites in 
promoters of target genes32-34. CRE sites are present in promoters of many cytokines, 
including, IL-2, IL-6, IL-10 and TNF-α35. It is therefore tempting to speculate that 
LUMAN is responsible at least in part for the deregulation of cytokine production 
observed in TLR-matured DC-STAMP knock-down DCs. LUMAN knock-down studies 
are required to confirm this hypothesis.
We further observed that levels of IL-1α and IL-1β were increased in DC-STAMP 
knock-down mBMDCs. This upregulation of IL-1 family cytokines seems to be 
contradictory to the observed decrease in IL-6 production as it is well established 
that IL-1 is able to induce expression of IL-636,37. The fact that IL-6 is also implicated 
in inhibition of IL-1 and TNF-α production38,39, however, indicates that the relation 
between IL-6 and IL-1α and IL-1β is more complex. Looking at the mRNA level, IL-6 
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and IL-1 mRNA production is primarily affected by decreased DC-STAMP expression 
at early time points. The decrease in IL-6 protein level was observed early on after 
LPS stimulation, while translation and release of IL-1α and IL-1β took much longer. 
These data suggest that the cytokine profile in DC-STAMP KO DC may be explained 
by differences in the kinetics in the transcription, translation and release of IL-6 
and IL-1 cytokines, and could possibly occur through the involvement of caspase-1/
calpain in IL-1β /IL-1α release40,41. 
Many factors influence the differentiation process of CD4+ T cells into Th1, 
Th2 or Th17 effector cells, including antigen dose, the signal strength through the 
T cell receptor, and costimulation42. Especially cytokines were shown to be key 
determinants in the outcome of this differentiation2-7. In our MLR assays we observed 
negative effect of DC-STAMP silencing on T cell activation by mature DCs. Decreased 
levels of IFN-γ in these co-cultures, indicate an impaired ability of mature DC-STAMP 
knock-down mBMDCs to prime Th1 responses.  As IL-12 is critically involved in the 
promotion of Th1 development3, we postulate that this decreased ability to support 
the development of Th1 lineage is determined by the reduced production of IL-12 by 
LPS-stimulated DC-STAMP knock-down mBMDCs. This is also supported by the fact 
that expression of costimulatory molecules was not affected by DC-STAMP knock-
down. Impaired stimulation of Th1 responses allows differentiation of Th2 and 
Th17 subsets. Additionally, IL-1α and IL-1β were shown to stimulate Th2 and Th17 
responses6, as well as induce the release of Th2 cytokines43. The observed increase 
in IL-4 and IL-5 levels in co-cultures with mature DC-STAMP knock-down mBMDCs 
could suggest skewing the responses towards Th2 cells, which may be enhanced due 
to the higher levels of IL-1 cytokines in these co-cultures. Lower number of CD8+ 
T cells alone was observed after co-culture with DC-STAMP knock-down mature 
mBMDCs, however cells, which were dividing, went through the same number of 
divisions like the ones in co-culture with control mBMDC (data not shown). We 
postulate that the decrease in the CD8+ T cells proliferation is a result of the reduced 
CD4+ T cells help.  
Sawatani et al. showed that aged DC-STAMP knock-out mice have symptoms 
of autoimmune disease and suggested involvement of increased phagocytosis and 
antigen presentation in onset of autoimmunity30. We did not observe any differences 
in T cell proliferation between control and DC-STAMP knock-down cells when we 
used immature DC. This discrepancy between our and Sawatani et al. data may be 
explained by different design of the proliferation assays. We used allogeneic MLR to 
look at the ability of the DC-STAMP knock-down mBMDCs to stimulate differentiation 
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of naïve T cells while they looked at antigen-specific (OVA) responses. Decreased 
levels of proinflammatory cytokines IL-6, IL-12 and TNF-α do not easily explain 
the symptoms of autoimmune diseases observed in DC-STAMP-deficient mice. On 
the other hand, diminished production of anti-inflammatory cytokine IL-10 could 
be dominant over the reduction in proinflammatory cytokines. As IL-10 is crucially 
involved in preventing excessive immune responses44 and plays an important role 
in development of suppressor T cells45,46 decrease in its production could lead to 
autoimmune disease. 
In conclusion we clearly show the importance of DC-STAMP expression in 
cytokines production by mature mBMDCs. Further studies are necessary to resolve 
the pathway by which this phenomenon occurs. We postulate that the deregulated 
cytokines production in DC-STAMP knock-down mBMDCs upon LPS stimulation is 
responsible for impaired T-cell stimulatory capacity of these cells. 
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Abstract
Dendritic cells (DCs) are professional antigen presenting cells of the immune system 
that play a crucial role in initiating immune responses and maintaining self tolerance. 
Better understanding of the molecular basis of DC immunobiology is required to 
improve DC-based immunotherapies. We previously described the interaction of 
transcription factor LUMAN (also known as CREB3 or LZIP) with the DC-specific 
transmembrane protein DC-STAMP in DCs. Target genes of LUMAN and its role in 
DCs are currently unknown. In this study we set out to identify genes regulated by 
LUMAN in DCs using microarray analysis. Expression of a constitutively active form 
of LUMAN in mouse DC cell line D2SC/1 identified Apolipoprotein A4 (ApoA4) as 
its target gene. Subsequent validation experiments, bioinformatics-based promoter 
analysis, and silencing studies confirmed that ApoA4 is a true target gene of LUMAN 




Dendritic cells (DCs) are key regulators of immunological responses in our 
body. They bridge the innate and adaptive immune systems, and maintain the 
balance between immunity and tolerance1. DCs are particularly abundant in tissues 
forming the interface with the external environment. They constantly monitor the 
extracellular space detecting incoming pathogens. Antigen uptake in the presence 
of inflammation and danger signals results in DC maturation2. The transition from 
immature to a mature state involves physiological, functional and morphological 
changes. Many of them are driven by transcription factors (TFs). To allow fast 
reprogramming, DCs make use of so-called “ready to go” transcription factors which 
are present in immature DCs in an inactive state. Binding of pathogen associated 
molecular patterns (PAMPs) to pattern recognition receptors (PRRs) leads to the 
initiation of signaling cascades and the subsequent activation of TFs such as NFκβ. 
In immature DCs, NFκβ is sequestered in the cytoplasm by binding to an inhibitor. 
Its activation is achieved through stimulus-responsive proteolysis of the inhibitors3. 
All known PAMPs and the resulting inflammatory cytokines are potent activators of 
the NF-κB pathway4.
Recently we described the interaction of DC-STAMP with the transcription factor 
LUMAN (CREB3/LZIP) in DCs5. LUMAN belongs to the bZIP superfamily of TFs and 
is the prototype member of the CREB3 subfamily6. The physiological roles of LUMAN 
were primarily deduced through overexpression studies conducted in cultured 
cells and LUMAN interaction partners7. LUMAN was reported to interact with 
transcriptional coactivator HCF18, hepatitis C virus core protein9 and CC chemokine 
receptor 110. Messenger RNA of LUMAN is ubiquitously expressed while the 
protein was shown to be expressed only in trigeminal ganglional neurons and in 
monocytes10,11. We recently have reported expression of LUMAN at the protein 
level in DCs and have shown that LUMAN is activated upon DC maturation5. The 
inactive form of LUMAN resides in the endoplasmic reticulum (ER) of immature DCs. 
LUMAN is activated in a process called regulated intramembrane proteolysis (RIP), 
which involves translocation to the Golgi compartment and subsequent proteolytic 
cleavage12. Upon RIP, the cleaved active form of LUMAN can translocate to the nucleus 
to regulate gene expression. Currently, target genes of LUMAN in DCs are not known.
To investigate the role of the DC-STAMP/LUMAN pathway in DCs we set out to 
find target genes of LUMAN. For this purpose, we overexpressed the active form of 
LUMAN in the mouse DC cell line (D2SC/1) using retroviral gene delivery. Altered 
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gene expression was studied using microarray-based expression profiling. Amongst 
the surprisingly low number of differentially expressed genes identified, we here 
report ApoA4 as a direct target gene of LUMAN in mouse bone marrow-derived DCs 
(mBMDCs). 
Material and methods
Cell lines and cell culture
The human embryonic kidney cell line HEK293 was cultured in DMEM (Invitrogen) supple-
mented with 10% heat-inactivated FCS (Greiner Bio-One), 1% of non-essential amino acids 
(NEAA) (Invitrogen) and 0.5% antibiotic-antimycotic (Invitrogen). The mouse embryonic fi-
broblast cell line NIH3T3 was cultured in DMEM supplemented with 5% heat-inactivated FCS, 
and 0.5% antibiotic-antimycotic. HEK293FT cells (Invitrogen) were cultured in DMEM sup-
plemented with 10% heat-inactivated FCS, 1% NEAA, 0.5% antibiotic-antimycotic, 1% ultra-
glutamine (Lonza), and 1 mM sodium pyruvate (Invitrogen). Cells were kept under selection 
with 500 μg/ml of Geneticin (G418) (Invitrogen). Phoenix packaging cells were cultured in 
IMDM (Invitrogen) supplemented with 5% heat-inactivated FCS and 0.5% antibiotic-antimy-
cotic. D2SC/1 cells were cultured in IMDM supplemented with 5% heat-inactivated FCS and 
0.5% antibiotic-antimycotic.
Generation of bone marrow-derived DCs and stimulations
Mouse BMDCs were generated from bone marrow progenitor cells, according to the modified 
protocol of Lutz et al.13. Bone marrow cells were flushed from the femurs and tibias of 6- to 
8-week-old female C57BL/6 mice (Charles River WIGA Gmbh), washed and counted. Cells were 
plated at a concentration of 4 x 106 cells per 10 cm Petri dish in 13 ml of RPMI-1640 medium 
(Invitrogen) supplemented with 10% FCS, 1% ultra-glutamine, 28 μM of β-mercaptoethanol 
(Sigma–Aldrich), 0.5% antibiotic-antimycotic and 20 ng/ml of murine recombinant GM-CSF 
(PeproTech). After 3 days, 4 ml of fresh medium was added containing fresh GM-CSF to final 
concentration of 8.75 ng/ml. For transduction experiments non-adherent and loosely adher-
ent cells at day 6 of culture were used. For activation of endogenous LUMAN non-adherent 
and loosely adherent cells at day 7 of culture were harvested and plated in 12 well culture 
plates (Corning) 106 cells/well in 1.5 ml of mBMDC culture medium. Different concentrations 
of Brefeldin A (BfA), tunicamycin (Tm) and thapsigargin (TG) were tested (all from Sigma) for 
optimal induction of ApoA4 expression without severely influencing the vitality of the cells 
(data not shown).
Retroviral supernatants and transduction of D2SC/1 cells
pLZRS-IRES-ΔNGFR and pLZRS-EGFP-IRES-ΔNGFR vectors were kindly provided by J.H. 
Jansen from Central Hematology Laboratory, RUNMC, Nijmegen, the Netherlands14. Murine 
LUMANdp (aa 1–238) was cloned into pLZRS-IRES-ΔNGFR retroviral expression vector. The 
IRES (internal ribosomal entry site) allows for separate expression of LUMANdp or GFP and 
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a truncated version of the nerve growth factor receptor (ΔNGFR) that lacks intracellular 
domains. Phoenix packaging cells were transfected with expression vectors using polyeth-
ylenimine (PEI) (Polysciences) as a transfection agent. At day 3 after transfection cells were 
harvested, replated for expansion and kept under selection of puromycin (1 μg/ml) for 5 days. 
Next, cells were harvested and replated for virus production in medium without puromycin 
for 24 h. Supernatant was collected, cell debris was removed by centrifugation and superna-
tant containing virus particles was filtered through a 0.45 μm filter. Aliquots were stored at 
–80°C until use.
For transduction, cells were cultured on retronectin (Takara Bio Inc., Japan) coated 35 mm 
Petri dishes together with 2 ml of thawed virus containing supernatant for indicated time and 
then washed with PBS. The percentage of GFP+ and ΔNGFR+ cells after transduction was moni-
tored by FACS analysis (BD FACSCalibur Flow Cytometer). tNGFR expression was detected 
using the supernatant of the 20.4 hybridoma (American Type Culture Collection) producing 
anti-human NGFR antibody. Expression of LUMANdp was confirmed by qPCR. 
RNA isolation for microarray, quality control, and microarray hybridization
Total RNA was isolated from D2SC/1 cells using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s protocol. The quality of RNA was tested using the Agilent2100 Bioanalyzer 
following the manufacturer’s protocol. All samples had a 28S:18S ration >1.5, thus passing 
quality standards for further processing. Two micrograms of total RNA was labeled accord-
ing to the GeneChip Whole Transcript (WT) Sense Target Labeling Assay as provided by the 
manufacturer (Affymetrix, Santa Clara, CA), and hybridized to Mouse Exon 1.0 ST Arrays over-
night before scanning in on Affymetrix GCS 3000 7G scanner. The Mouse Exon 1.0 ST Array 
contains ~1,200,000 probe sets with an average of 4 probes per exon and an average of about 
40 probes per gene. All hybridizations were carried out at the Microarray Facility of the De-
partment of Human Genetics, Nijmegen Centre of Molecular Life Sciences, Radboud Univer-
sity Nijmegen Medical Centre, Nijmegen, the Netherlands.
Analysis of microarrays
The Affymetrix CEL files were imported into Affymetrix Expression Console version 1.1 where 
control probes were extracted using the default RMA algorithm in order to perform quality 
analysis checks. The area under the curve (AUC) of the receiver operator characteristic was 
calculated using the positive and negative control probes. All arrays had an AUC score above 
the empirically defined threshold of 0.85 indicating a good separation of the positive controls 
from the negative control probes. Subsequently, CEL files were imported into Partek (Partek 
Genomic Suite software, version 6.4; Partek Inc., St. Louise, MO) where only core exons were 
extracted and normalized using the RMA algorithm with GC background correction. Core 
transcript intensities were calculated by calculating the mean log2 intensities of the corre-
sponding probe sets. 
Lentiviral supernatants and transduction of mBMDCs
Two SureSilencing shRNA plasmids encoding the shRNA sequence targeting murine LUMAN: 
shLUMANred (5’-GGAGATGTCTAGGCTGATACT-3’), shLUMANgreen (5’-GCGGAGGAAGATTCG-
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TAACAA-3’) and negative control Scrambled shRNA (shScr) (5’-GGAATCTCATTCGATGCAT-
AC-3’) plasmid were obtained from SuperArray Bioscience. Using Gateway technology, DNA 
encoding sequences for short-hairpin BLOCK-iT-U6-RNAi Entry vector were introduced into 
the pLenti6/BLOCK-iT-DEST vector (Invitrogen), following the manufacturer’s protocol. 
cDNA encoding for murine full length LUMAN (LUMANfl), murine dominant positive form of 
LUMAN (LUMANdp) (aa 1–238) and GFP were introduced to the pLenti6/V5-DEST Gateway 
Vector (Invitrogen) using pENTR-1A vector (Invitrogen).  
The individual vectors were co-transfected with packaging vectors into the HEK293FT cells 
according to the manufacturer’s instructions. Virus was produced in HEK293FT culture 
medium supplemented with 82.5 μg/ml of water-soluble cholesterol (Sigma–Aldrich) and 
collected from tissue culture supernatant 24 and 48 hours after transfection. Cell debris was 
removed by centrifugation and supernatant containing virus particles was filtered through a 
0.45 μm filter. Aliquots were stored at –80°C until use.
Viral titers were determined by transduction of NIH3T3 cells with serial dilutions of the virus 
stock in the presence of 10 μg/ml of polybrene (Sigma–Aldrich). Two days after transduc-
tion the cells were cultured under selection with 2 μg/ml Blasticidin (Invitrogen) for 12 days. 
Medium was refreshed every third day. To determine the titer, the number of colonies was 
determined after crystal violet staining. The titer ranged between 2 x 105 and 13 x 105 trans-
fection units (TU)/ml
Lentiviral knock-down and overexpression of LUMAN in mBMDCs 
Mouse BMDCs were harvested after 6 days of culture and 1.2 x 106 cells were resuspended in 
700 ml of virus supernatant containing 10 μg/ml of DEAE-dextran (Pharmacia Biotech AB) to 
facilitate viral infection. Cell-virus suspensions were plated on 12-well tissue culture plates 
(700 μl/well) and centrifuged for 90 minutes at 2200 rpm and 37°C.  After centrifugation, 
virus supernatant was replaced by mBMDC culture medium. The infection procedure was re-
peated the following day. As a negative control, mBMDC culture medium with DEAE-dextran 
was used. The multiplicity of infection (MOI) for silencing of LUMAN was matched with the 
MOI of the scrambled shRNA control in each experiment.
RNA isolation and quantitative real-time PCR (qPCR)
Total RNA was isolated from at least 6 x 105 cells using a Quick-RNA MiniPrep kit (Zymo Re-
search). RNA quantity and purity were determined using a NanoDrop spectrophotometer. Two 
micrograms of total RNA were treated with DNase-I (Invitrogen) and cDNA was synthesized 
using random primers and SuperScript Moloney murine leukemia virus reverse transcriptase 
(II-MMLV) (Invitrogen).  Messenger RNA levels for the genes of interest were determined with 
a Bio-rad CFX96  (Bio-rad) using Fast Start SYBR Green kit (Roche) and primers for one of the 
following genes: porphobilinogen deaminase (PBGD) (forward: 5’-CCTACCATACTACCTCCTG-
GCTT TAC-3’; reverse: 5’-TTTGGGTGAAAGACAACAGCAT-3’), LUMAN (forward: 5’-AC AAC-
TACTCCCTTCCACAG-3’; reverse: 5’-TTCTCCAAGAGCTTCTTCTC-3’), ApoA4 (forward: 
5’-CCAATGTGGTGTGGGATTACTT-3’; reverse: 5’-CCTCTCAGT TTCCTTGGCTAGA-3’). Data were 
analyzed with Bio-rad CFX manager version 1.6 (Bio-rad) and checked for correct amplifica-
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tion and dissociation of the products. PBGD served as a reference gene. mRNA levels relative 
to PBGD were calculated as: 2–(ΔCt).
Promoter analysis of the apoliprotein cluster
Putative promoter regions extending 2 kb upstream of the transcription start site (TSS) of 
mouse apolipoproteins (apoa5, apoc3, apoa1 and apoa4) were extracted from the Genome 
Browser track of the UCSC July 2007 mouse genome assembly [http://genome.ucsc.edu]15. The 
genomic coordinates of the promoter regions used are as follows: apoa5 (chr9: 46074691–
46076690); apoc3 (chr9: 46043381–46045380); apoa1 (chr9: 46034713–46036712) and 
apoa4 (chr9: 46046927–46048926), all on mouse chromosome 9. From the same genome 
browser track, 2 kb promoter sequences of all reference genes in the mouse genome were 
obtained. Subsequently, the algorithm Clover16 was used to screen for over-represented tran-
scription factor binding sites (TFBSs) in the apolipoprotein promoter sequences using a pre-
compiled library of TFBS motifs. The library contained 521 TFBS motifs (position-specific 
weight matrices) culled from the JASPAR core database (2005)17 and TRANSFAC version 7.0 
database18. Our inputs to the Clover algorithm were the following: promoter sequences of 
the apolipoproteins (2 kb upstream of the TSS of their corresponding genes) as test set of 
sequences; the 521 TFBS motifs for screening; and for statistical calculations, promoter se-
quences (2 kb upstream of the TSS) of all genes in the mouse genome were used as back-
ground. All results obtained were filtered at a TFBS instance threshold score ≥5 for recogniz-
ing a specific TFBS, and a significant p-value ≤0.05 for over-represented motifs in the test set 
of sequences relative to the background. An instance score >0 indicates a better match of a 
test sequence to a TFBS motif than randomly expected. 
Phylogenetic conservation of the same 2 kb promoter region upstream of the TSS of the ref-
erence genes of mouse apoa5, apoc3, apoa1 and apoa4 were downloaded (November 2011) 
from the Phastcons tract, phastCons30wayPlacental, of the July 2007 mouse genome assem-
bly of UCSC genome browser. Phastcons scores range from 0 to 1, the higher the score the 
more conserved a nucleotide base19. The conservation tract for placental mammals was used 
to observe the extent of conservation of predicted TFBS sites in the apolipoprotein promoter 
regions. Depiction of the TFBS sites so-obtained in the promoter sequences of the apolipopro-
teins was further performed using inhouse Python scripts.
Results
Identification of ApoA4 as a potential target gene of LUMAN
 We previously reported on the interaction of DC-STAMP with the 
transcription factor LUMAN expressed in DCs5. To investigate this novel pathway in 
DCs we set out to identify potential target genes of LUMAN. 
A mouse DC cell line (D2SC/1)20,21 was retrovirally transduced to overexpress the 
dominant positive form of LUMAN (LUMANdp). Transduction efficiency was between 
35 and 60% as determined by FACS analysis 18 h post transduction (data not shown). 
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Altered gene expression between D2SC/1 cells transduced with either LUMANdp 
or with a control GFP vector was examined using a mouse exon microarray. Gene 
expression was analyzed at 0, 6 and 18 h after transduction. Pairwise comparisons 
between the LUMANdp samples and the GFP samples for 6 h and 18 h time points 
were made using the following criteria; one of the two expression values (log 2) is 
>5.0 (i.e. the gene is expressed), and the gene shows a 2 or more fold difference in 
expression relative to GFP.
Surprisingly, the number of differentially expressed genes was low at both time 
points (Supplementary Table 1). At 6 h after transduction only 40 differentially 
expressed genes were found of which 25 were upregulated and 15 downregulated 
in LUMANdp samples in comparison to the GFP samples. At 18 h post transduction 
39 genes were upregulated and 24 genes downregulated of which only one gene 
was present at the 6 h time point. Although LUMAN mRNA expression was clearly 
upregulated in cells transduced with LUMANdp retrovirus at 6 and 18 h post-
transduction (Fig. 1A), the 6 h post transduction time point was supposedly too 
early for active LUMANdp protein expression and/or function. 
Herp and EDEM genes that were previously reported as the target genes of 
LUMAN in HeLa and HEK293 cell lines, respectively22,23 were not differentially 
expressed in D2SC/1 cells overexpressing active form of LUMAN (Fig. 1A). One of 
the most strongly upregulated genes at the 18 h time point was Apolipoprotein 
A4 (ApoA4) (Fig. 1A). Since apolipoproteins have been frequently implicated in 
regulation of immune responses24-28 we set out to verify the ApoA4 gene as a LUMAN 
target gene in DCs.
Validation of the microarray was performed by real-time quantitative PCR 
(qPCR) using both the microarray samples (Exp1) and samples from an independent 
experiment (Exp2). Besides the 6 and 18 h time points, which were taken for 
microarray analysis, for qPCR analysis we also took along 24 h samples. In correlation 
with the microarray results, levels of LUMAN mRNA were increased more than 4 
times 6 h after transduction with LUMANdp (Fig. 1B). The strong upregulation of 
ApoA4 mRNA was detected at 18 h and 24 h post-transduction with the active form 
of LUMAN confirming the microarray data (Fig. 1B). Consistent with the microarray 
data, no effect on the EDEM and Herp genes expression was observed (data not 
shown).  These data suggest that ApoA4, but not Herp and EDEM gene expression, is 
regulated by LUMANdp in murine DCs.  
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LUMAN specifically regulates Apolipoprotein A4 expression 
ApoA4 is a member of the apolipoprotein family. It forms a gene cluster together 
with ApoA1, ApoC3 and ApoA5 on chromosome 9 in the mouse29,30 (Fig. 2A). Other 
apolipoprotein family members such as ApoE are similar in structure and function 
to ApoA4 although they are located in a distinct gene cluster31. The microarray data 
from D2SC/1 cells transduced with the dominant positive form of LUMAN were 
therefore analyzed for altered expression of the apolipoprotein family genes. From 
the whole apolipoprotein family, only ApoA4 mRNA expression levels were affected 
by LUMANdp expression (Fig. 2B). These results were confirmed independently 
Figure 1. ApoA4 is upregulated upon overexpression of LUMANdp. D2SC/1 cells were infected 
with retrovirus to overexpress active form of LUMAN (LUMANdp) or GFP as a negative control. A) Data 
represent normalized gene expression of LUMAN, Herp, EDEM and ApoA4 mRNA at 0, 6 and 18 hours 
post transduction on mouse exon microarray. B) Validation of microarray experiment by qPCR, samples 
from experiment used for microarray (Exp1) and independent experiment (Exp2) were tested for mRNA 
expression of LUMAN and ApoA4. Data represent expression of LUMAN and ApoA4 mRNA at 0, 6, 18 and 



















































































































































































































































































































































































































































































































































































































































































































































































































































ApoA4 is a target gene of LUMAN
by qPCR on both the microarray samples and samples from another independent 
experiment (data not shown). 
To determine if ApoA4 is an immediate downstream target of the transcription 
factor LUMAN, the promoter of mouse ApoA4 and its gene cluster was examined for 
the presence of the previously published LUMAN binding sites CREB and C/EBP6,8,9,23 
using bioinformatics approaches. Analysis identified the CREB site, Tax/CREB, in 
the proximity of the start of ApoA4 transcription (Fig. S1). Tax is a transactivator 
protein of the human T-cell lymphotropic virus type I (HTLV-I) whose binding to the 
ubiquitous transcriptional factor, CREB, has been shown to lead to the formation of a 
multiprotein complex with far greater DNA recognition specificity than that of CREB 
alone32. Binding sites for C/EBP, which has been shown to enhance transcription 
from CRE site8, were also present in the promoter region of ApoA4 (Fig. S1). The 
promoters of the other apolipoprotein family genes examined did not contain this 
unique combination of CREB and C/EBP sites (Fig. S1), although individual sites are 
represented in some of the other apolipoprotein promoter sequence(s) (Fig. S1). 
Further bioinformatics analysis of the mouse ApoA4 promoter region indicates that 
the Tax/CREB binding site within 500 bp upstream of the TSS is strongly conserved 
 
chromosome: 9; Locations: 9 A5.2; 9 27.0 cM 
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Figure 2. ApoA4 upregulation upon overexpression of LUMANdp is specific for ApoA4 in 
apolipoprotein family.  A) Representation of apolipoproteins cluster on murine chromosome 9. B) 
Normalized expression of apolipoprotein family genes 18 hours post transduction in microarray samples 
(legend of the Fig. 1A). 
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in placental mammals (Fig. S1). Some phylogenetic conservation of C/EBP and Tax/
CREB binding sites was also discerned. Collectively, our data show that only ApoA4 
and none of the other apolipoprotein family members examined contain conserved 
consensus binding sites to which LUMAN could bind.
Overexpression of the active form of LUMAN results in ApoA4 
expression in mBMDC 
Further investigation into the role of LUMAN in the regulation of ApoA4 
expression was carried out in primary mouse bone marrow-derived dendritic cells 
(mBMDCs). Lentiviral transduction of mBMDCs for the overexpression of LUMAN 
protein was optimized to yield ±30% positive mBMDCs (data not shown). The 
effectiveness of transduction for LUMAN was confirmed by qPCR (Fig. 3A). Murine 
BMDCs were transduced with lentivirus encoding the dominant positive form of 
LUMAN (LUMANdp), the full length LUMAN (LUMANfl) or GFP as negative controls. 
Up to 9 fold increase in LUMAN mRNA levels was observed in cells transduced with 
virus encoding either the full length or the active form of LUMAN compared to 
endogenous LUMAN expression in cells transduced with GFP (Fig. 3A). Subsequently, 
we investigated the expression of ApoA4 mRNA in mBMDCs transduced with 
LUMAN. ApoA4 mRNA was detected only in mBMDCs transduced with the active 
form of LUMAN (Fig. 3B), indicating that ApoA4 is also a target of LUMAN in primary 
mBMDCs. Overexpression of the LUMANfl did not result in ApoA4 expression 
demonstrating that activation of LUMAN is necessary to induce ApoA4 expression. 
Figure 3. ApoA4 is expressed in mBMDC expressing LUMANdp but not LUMANfl. mBMDC were 
infected with lentivirus to overexpress full length LUMAN (LUMANfl), active form of LUMAN (LUMANdp) 
or GFP (control). Expression of LUMAN and ApoA4 transcripts was determined using qPCR. Data represent 
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Brefeldin A (BfA) induced activation of endogenous LUMAN 
protein results in ApoA4 induction
Brefeldin A (BfA) has been persistently shown to promote LUMAN cleavage by 
inducing fusion of ER to the Golgi apparatus12,33,34. Therefore, induction of ApoA4 
expression following BfA exposure of mBMDC endogenously expressing LUMAN 
was investigated in time (Fig. 4A).  Low levels of ApoA4 mRNA were first observed 
at 12 h after treatment with 1mg/ml BfA.  This expression was further elevated in 
later time points up to 20 h (Fig. 4A). Several reports12,23,35,36 indicated that LUMAN, 
in contrast with other bZIP TFs is not activated by ER stress. Indeed, treatment of 
mBMDC with the ER stressors thapsigargin (TG) and tunicamycin (Tm) does not 
result in ApoA4 expression (Fig. 4B). 
To study the contribution of LUMAN in BfA mediated induction of ApoA4 we 
performed LUMAN knock down experiment in mBMDC. mBMDC were transduced 
with lentivirus encoding for LUMAN targeting shRNA or a non-targeting scrambled 
control sequence (shScr). Lentiviral infection did not result in maturation of 
mBMDCs (data not shown). Two different shRNAs targeting different sequences of 
LUMAN were used; shLUMANred and shLUMANgreen, which resulted in LUMAN 
mRNA knock- down of 90% and 60%, respectively (Fig. 5A). Luman knock-down 
mBMDC showed a significant decrease in induction of ApoA4 in response to BfA 
treatment. Moreover, the decrease in ApoA4 expression was correlated with the 
level of LUMAN knock-down efficiency resulting in lower ApoA4 mRNA levels 
(Fig. 5B). Taken together, these data demonstrate that BfA treatment of mBMDCs 
leads to expression of ApoA4 mRNA. By silencing LUMAN we proved that this ApoA4 
expression is driven by the activation of the transcription factor LUMAN. 
Discussion
Herein we investigated the target genes of LUMAN in DCs using overexpression of 
the active form of LUMAN in D2SC/1 cells. The microarray analysis indicated ApoA4 
as a potential target gene of LUMAN. The validation experiments, bioinformatics 
analysis of ApoA4 promoter, as well as overexpression and silencing studies in 
mBMDC confirmed that ApoA4 is a direct target gene of the transcription factor 
LUMAN in DCs. Expression of the other genes of the apolipoprotein family was 
not affected by LUMAN. As ApoA4 is considered an anti-inflammatory agent in the 




Figure 5. Silencing of LUMAN attenuates the BfA driven expression of ApoA4. mBMDC were 
infected with lentivirus  expressing shRNA targeting LUMAN (shLUMANred, shLUMANgreen) or control 
shRNA (shScr). A) Silencing efficiency was confirmed by qPCR. Data represent LUMAN expression in 
cells targeted with LUMAN-specific shRNAs relative to shScr, B) Effect of LUMAN silencing on ApoA4 
expression upon BfA treatment was determined in mBMDCs targeted with shRNA. Levels of ApoA4 mRNA 
are show on the graph in the relation to levels in shScr +BfA sample. Data shown are representative of at 

























































































































































































































































Figure 4. Activation of endogenous Luman in mBMDC with BfA. A) ApoA4 expression in mBMDC 
treated with 1ug/ml of BfA was determined by qPCR. Expression level at 16 hours of BfA treatmant was 
set at one. Data represent mean ±SEM of three independent experiments. B) mBMDC were treated for 
16h with indicated concentrations of BfA, tapsigargin (Tg) or Tunicamycin (Tm). ApoA4 expression was 


































































































































































ApoA4 is a target gene of LUMAN
A surprisingly low number of genes was differentially expressed upon 
overexpression of the active form of LUMAN in D2SC/1 cells. We observed less than 
70 differentially expressed genes. Interestingly, overexpression of another bZIP 
family transcription factor XBP1 in muscle cells resulted in about 500 differentially 
expressed genes37. On the other hand, expression of active form of ATF6 in HeLa cells 
or full length LUMAN protein in HEK 293 cell line were also shown to result in a low 
number of differentially expressed genes22,38. In our study we have used the active 
form of LUMAN in DCs instead of natural stimuli to activate full length LUMAN. This 
may have led to the relatively low number of differentially expressed genes observed. 
Signals that activate LUMAN may be necessary for activation or recruitment of other 
regulatory proteins that co-operate with LUMAN in transcriptional regulation. This 
way we may have selected for those genes that are regulated by LUMAN per se and 
do not require other transcription factors, that may be induced by the natural stimuli 
activating the LUMAN pathway. We have previously shown LUMAN activation upon 
maturation of human DCs5. Unfortunately, no antibodies detecting endogenous 
mouse LUMAN are currently available to confirm this finding in mice. 
Several lines of evidence indicate that ApoA4 is a direct, physiological target of 
LUMAN in murine DCs. First, expression profiling and qPCR analyses of D2SC/1 cells 
and mBMDCs indicated that ApoA4 expression is induced upon overexpression of the 
dominant positive form of LUMAN. Second, we found CREB and C/EBP binding sites 
within the 2 kb promoter region of murine ApoA4 gene. These sites have previously 
been shown to promote LUMAN binding8. The combination of CREB and C/EBP 
binding sites was unique for the ApoA4 promoter in the group of apolipoprotein 
promoters analyzed. The identification of a high-scoring and phylogenetically 
conserved (in mammals) CREB site within 500 bp of the transcription start site of 
ApoA4 is interesting because TFBS at such regions have been found to be highly 
conserved amongst mammals, and are likely to be functional39,40. However, to confirm 
if this predicted site in ApoA4 promoter is indeed bound by LUMAN, chromatin 
immunoprecipitation or luciferase assay based studies will be necessary. Of note 
analysis of the promoter region of human apolipoproteins indicates that, despite its 
conservation in placental mammals, this particular CREB site was not found in the 
promoter region of human APOA4.
Third, we found that ApoA4 expression is induced by Brefeldin A treatment, 
which was shown to activate the cleavage and activation of LUMAN5,12,33,34. Moreover, 
shRNA-mediated silencing of LUMAN dramatically reduced the BfA-induced 
expression of ApoA4. Confirmation of the induction of murine ApoA4 on protein 
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level awaits the development of anti mouse ApoA4 antibodies. 
ApoA4 belongs to apolipoprotein family of lipid binding proteins which play an 
important role in lipid transport and metabolism41-46. Members of this family have 
been implicated in regulation of the immune responses and many autoimmune 
diseases24-28. ApoE was reported to enhance endogenous lipid antigen presentation 
and subsequent NKT cell activation25. ApoA1 was shown to modulate immune cell 
function by regulating cellular cholesterol balance28. ApoA4 is located within the 
same gene cluster on the chromosome 9 with ApoA1, ApoC3 and ApoA547. ApoA4 
expression was also found in peripheral blood mononuclear cells (PBMCs) of 
systemic lupus erythematosus (SLE) patients48. Interestingly, ApoA4 was shown to 
reduce secretion of proinflammatory cytokines from human PBMCs49 suggesting 
that ApoA4 may be part of an anti-inflammatory feedback loop. We have previously 
shown a functional interaction of LUMAN with DC-STAMP in human monocyte-
derived DCs and reported LUMANs activation upon maturation of DCs5. Timing of 
LUMAN activation at late time points (16 h) after TLR ligation is in line with potential 
negative feedback properties. Herein we revealed ApoA4 as a novel target gene 
of LUMAN in DCs. Therefore, it is tempting to speculate that ApoA4 induction by 
the DC-STAMP/LUMAN pathway is part of a negative feedback loop used by DCs to 
resolve inflammation. In line with this anti-inflammatory role of ApoA4, our recent 
results demonstrated that DC-STAMP knock-down mBMDCs secrete less IL-6, IL-12, 
TNF-α and IL-10 and showed impaired T-cell activation potential50. 
LUMAN belongs to the bZIP family of transcription factors many of which 
become activated during ER-stress and participate in the unfolded protein 
response (UPR)51,52. Multiple reports suggested that LUMAN is not activated by the 
ER stress12,23,35,36, although others suggested that LUMAN can take part in UPR by 
regulating expression of EDEM and Herp proteins that are involved in aspects of 
ER-associated degradation (ERAD)22,23. In our experiments LUMANdp did not effect 
expression of EDEM and Herp in DCs. Rather, ApoA4 expression was induced by the 
LUMAN activator BfA but was not detected following ER-stress in mBMDCs. This 
finding is in line with our data in human DC that LUMAN is not activated by ER-
stressors, e.g., thapsigargin or tunicamycin (data not shown). These data suggest 
that activation of LUMAN as well as pool of genes regulated by LUMAN may differ 
between different cell types. 
Recently, the liver-specific homologue of LUMAN, CREB-H was shown to regulate 
ApoA4 gene expression53. Other apolipoprotein genes located on chromosome 9 
were unaffected by overexpression of active form of CREB-H in liver, like we show for 
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LUMAN in DCs. As CREB-H’s DNA-binding domain (b-ZIP region) is most homologous 
to that of LUMAN (84%)54, it is tempting to speculate that CREB-H and LUMAN bind 
to the same region in ApoA4 promoter in liver tissue and DC respectively.
Additionally, CREB-H was also shown to be activated by LPS and proinflammatory 
cytokines52 implicating its involvement in cross-talk between ER-stress and innate 
immune pathways. Further research is necessary to fully understand the role of 
LUMAN in ER-stress and its link to innate immune response pathways. 
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Figure S1. Promoter of mApoA4 contains CREB site. The upper subgraph for each apolipoprotein 
promoter depicts the TFBSs with a motif instance score threshold of at least 5 in the apolipoprotein 
promoter regions. The scale of the y-axis ranges from 0 to 12 for each subgraph, the higher the TFBS 
score, the stronger the motif match for the site. For clarity, only CREB and C/EBP related sites are shown. 
On the lower subgraphs the Phastcones scores are depicted. They range from 0 to 1, the higher the score 
the more conserved a nucleotide base.
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Table S1.  Lists of differentially expressed genes. Genes differentially expressed after retroviral 
overexpression of LUMANdp in D2SC/1 cells in comparison with genes expressed by cells transduced 
with GFP after 6 hours A) and 18 hours B) post transduction.  Results are presented as a fold increase or 
decrease.
TABLE S1  
































































































































The immune system developed to protect us from pathogens, cancer and 
autoimmune diseases. In order to function properly the balance between tolerance 
and immunity must be maintained. Dendritic cells (DCs) are the professional 
antigen presenting cells of the immune system that play a strategic role in keeping 
this balance. They link innate and acquired immune responses as well as induce 
tolerance to self-antigens. During recent years DCs attracted much interest in 
the medical community because of their potential use in moderating immune 
responses. Engineered DC based vaccines could tip the balance between immunity 
and tolerance e.g., in favour of transplant or against growing tumour. DCs were first 
described almost 40 years ago1. However, new DC subsets are still being discovered, 
and novel proteins of unknown function preferentially expressed by DCs have been 
identified. Better understanding of DC immunobiology will help to design and 
improve DC-based immunotherapy. This thesis describes the studies directed to 
reveal the function of DC-STAMP in DCs biology.  
DC-STAMP expression 
DC-STAMP known also as TM7SF4 and FIND was identified as a transmembrane 
protein preferentially expressed by DCs2. Subsequent work showed that macrophages 
and osteoclasts are also positive for DC-STAMP3,4 indicating that DC-STAMP 
expression is restricted to the cells derived from common myeloid precursors. 
Nevertheless, fresh monocytes and some subtypes of DCs, like Langerhans cells, 
are essentially negative for DC-STAMP. Transduction of a GFP transgene under the 
control of the DC-STAMP promoter into hematopoietic stem cells (HSCs) resulted 
in the predominant expression of transgene in DCs among different spleen cell 
populations5. CD8 positive DCs were shown to have higher expression of DC-STAMP 
than the CD8 negative DC subsets5. As CD8 positive DCs are important for cross-
presentation6,7 it would be of interest to investigate possible role of DC-STAMP in 
this process.
DC-STAMP promoter
Expression of DC-STAMP appears to be regulated differently in each cell type. 
While RANKL is a potent inducer of DC-STAMP in osteoclasts, IL-4 induces its 
expression in macrophages3,4. Analysis of the chromatin modifications, including 
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histone H3 trimethylation on lysine 4 (H3K4me3) and 27 (H3K27me3), associated 
with the promoter of DC-STAMP gene has shown an increased histone H3K4 
methylation in macrophages and DCs in comparison with monocytes8. This type 
of histone methylation in gene promoters is correlated with higher transcriptional 
activity8, thus explaining the much higher expression of DC-STAMP in macrophages 
and DCs relative to monocytes. 
During differentiation of DCs from bone marrow cells expression of DC-STAMP 
increases and is synchronized with CD11c expression9. Additionally, mRNA levels of 
both transcripts are downregulated upon maturation of DCs10,11. This suggests that 
DC-STAMP gene may be linked with CD11c gene in regulatory network underlying 
the functional maturation of DCs. This hypothesis is supported by bioinformatics 
based comparison of murine CD11c and DC-STAMP promoters recently performed by 
Edelmann et al., which identified an evolutionarily conserved promoter framework 
shared between these two genes10. 
It was previously shown that DC-STAMP promoter could successfully drive 
transgene expression in DCs5,10. Research of our group investigating the use 
of DC-associated promoters in genetic vaccines demonstrated potential use 
of DC-STAMP promoter in a specific targeting of DCs in vivo11 (V. Moulin et al., 
manuscript submitted for publication). Additionally, DCs expressing OVA antigen 
under the control of DC-STAMP promoter were shown to induce strong CD8+ T cells 
proliferation11. Thus utilization of DC-STAMP promoter as a tool to target tumour 
antigens to DCs should be considered. Targeting DCs in vivo could form the basis 
of novel antitumor treatment strategies aimed at boosting immune responses 
alternative to the time-consuming and expensive immunotherapy strategy with ex 
vivo loaded DCs. 
DC-STAMP family (paralogues and orthologues)
DC-STAMP is highly conserved among different species with 95% of homology 
between the murine and the human DC-STAMP protein. Highly conserved, 
presumably orthologous proteins are present in all mammals for which a sequence 
is available12.
DC-STAMP is the founding member a novel family of proteins, as at its identification 
no homology with other protein families was observed. Subsequently, new members 
were added to the DC-STAMP family. DC-STAMP domain containing protein 1 and 
2 (DC-ST1 and DC-ST2) are now classified as DC-STAMP family members12. This 
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classification is based on the presence of highly conserved domain located between 
242-421 amino acids of human DC-STAMP which covers the last two putative 
transmembrane domains and part of cytoplasmic tail (DC_STAMP (PF07782) http://
pfam.sanger.ac.uk)13. Osteoclast stimulatory transmembrane protein (OC-STAMP), a 
DC-STAMP-like protein also expressed in osteoclasts, was proposed to be another 
novel member of the DC-STAMP family12.
DC-STAMP structure
The structure of DC-STAMP protein remains largely unsolved. Human DC-STAMP 
contains 470 amino acids and based on the presence of the hydrophobic regions it 
is predicted to comprise from 4 to 7 transmembrane domains with a 70 amino acids 
long C-terminus2. DC-STAMP was shown to contain three putative N-glycosylations 
sites2. In Chapter 3 using tunicamycin treatment and western blot analysis we 
showed that DC-STAMP protein is indeed glycosylated. Additionally, our unpublished 
results from studies of DC-STAMP mutants strongly suggest that all three predicted 
sites are occupied by the sugar chains (data not shown). 
Post-translational modifications (PTMs) play an important role in regulation 
of protein function. Protein phosphorylation is the most ubiquitous form of PTM 
employed in most of biological processes that allows dynamic activation of signalling 
pathways. Since DC-STAMP was shown to have potential phosphorylation site for 
PKC2 it would be of interest to investigate whether DC-STAMP is indeed a substrate 
for PKC and what would be the role of this modification.          
Recently, it was proposed that DC-STAMP may form homodimers as well as 
heterodimers with OC-STAMP in osteoclasts14. This dimerization partner may be 
important for the observed fusion process in osteoclasts that has been attributed 
to DC-STAMP (see below). It would be interesting to test if DC-STAMP is present as 
a dimer also in DCs.  More insight into structure of DC-STAMP and its PTMs would 
most likely provide important new insights in its function.
Fusogenic properties of DC-STAMP
DC-STAMP is called the “master fusogen” for osteoclast differentiation. 
Osteoclasts are multinuclear giant cells derived from monocytic precursor, and are 
uniquely designed to resorb bone15,16. An essential event in osteoclasts development 
is multinucleation, induced by cell–cell fusion of mononuclear osteoclasts17. This 
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process is analogous to the fusion events that take place between macrophages to 
form giant cells, and involves the coordinated activity of several adhesion molecules, 
fusion proteins, and signaling proteins. DC-STAMP was shown to be necessary for 
fusion of osteoclasts as well as foreign body giant cells18. Mice lacking DC-STAMP 
have symptoms of osteopetrosis characterized by increased bone mass caused 
by decreased osteoclasts activity and lack of multinucleated osteoclasts19. How 
DC-STAMP exerts its fusogenic function is not yet fully understood.
DC-STAMP is believed to localize to the plasma membrane of osteoclasts. 
However, no clear microscopy picture showing colocalization of DC-STAMP with one 
of the cell membrane markers was ever published. Our overexpression studies of 
tagged DC-STAMP from many different cell lines and DCs doubt the localisation of 
DC-STAMP on the cell surface and strongly suggest its localization within ER-Golgi 
membranes. Additionally the results of our yeast-2-hybrid analysis revealing two 
ER-resident interacting partners (Chapter 2 & 3) strengthen the ER localisation of 
DC-STAMP in DCs. Nevertheless, appropriate colocalization studies in osteoclasts 
need to be performed to put an end to this debate. This putative cell membrane 
localization and presumed 7-transmembrane structure led to hypothesis that 
DC-STAMP might function as a G protein-coupled receptor with unknown ligand.
The DC-STAMP gene is a direct target of the transcription factor NFATc1 in 
osteoclasts20,21 and is highly induced in osteoclasts during differentiation4,18. 
Monocyte chemoattractant protein-1 (MCP1/CCL2) was also shown to regulate 
DC-STAMP expression in osteoclasts22, while treatment of RAW264.7 cells with 
TNFα, LPS and RANKL induces fusion without increasing expression of DC-STAMP23. 
Thus, it is not clear if an increase in DC-STAMP expression is necessary for the fusion 
itself. Recent studies have shown that RANKL stimulation of RAW264.7 cells induced 
two functionally different populations of mononuclear osteoclasts precursor cells 
with distinct DC-STAMP expression levels, DC-STAMP high and DC-STAMP low 
cells14. DC-STAMP high cells are mononuclear donors that cannot form osteoclasts 
by themselves, while DC-STAMP low cells are master fusogens14. It is possible 
that stimuli that induce fusion could induce production of the putative ligand for 
DC-STAMP to initiate pro-fusion signalling24.
Fusogenic properties of DC-STAMP go beyond osteoclasts. As DC-STAMP was 
shown to be involved in fusion of foreign body giant cells as well, it may also be 
involved in the formation of giant cells during chronic inflammatory conditions 
such as tuberculosis. A role for DC-STAMP in fusion of cells during malignancies 
has also been proposed. In multiple myeloma, a hematologic malignancy in which 
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tumor progression may account for uncontrolled osteoclastogenesis, the expression 
of DC-STAMP was shown to be upregulated in peripheral macrophages, while DCs 
and myeloma plasma cells showed high fusogenic susceptibility and under specific 
conditions could trans-differentiate to osteoclasts25. Additionally, DC-STAMP was 
upregulated in papillary thyroid cancer26, also featuring multinucleated giant 
cells27,28.
Taken together, these data suggest that DC-STAMP, predominantly important for 
fusion of osteoclasts, in the pathogenic conditions may play a role in fusion of other 
cells i.e., macrophages. 
DC-STAMP interacting partners
OS9
OS-9 is an ubiquitously expressed protein originally identified in a screen for 
genes upregulated in osteosarcoma29 and myeloid leukemia30. Many interacting 
partners of OS9 have been described31-33. Our data presented in Chapter 2 show 
interaction of DC-STAMP with OS9 and its involvement in the translocation of 
DC-STAMP towards the Golgi compartment. 
Recent studies imply a role for OS9 in ER associated degradation (ERAD), a 
process in which potentially toxic, misfolded proteins are translocated from the 
ER into the cytosol for proteosomal degradation. OS9 was shown to recognize and 
bind misfolded glycoproteins in the ER34-38. As DC-STAMP is a glycosylated protein, 
it is important to answer the question whether OS9 interacts with DC-STAMP 
only when misfolded. Our data mapping the interacting regions between OS9 and 
DC-STAMP (Chapter 2) argue against such a role in case of DC-STAMP. The fact 
that the cytoplasmic tail of DC-STAMP, which is sufficient to interact with OS9, is 
not glycosylated and that the domain of OS9 responsible for binding misfolded 
proteins39 is outside of the region necessary for interaction with DC-STAMP strongly 
suggest that interaction of OS9 with DC-STAMP is not based simply on binding to its 
misfolded form.
Rather, our data suggests that OS9 is necessary for the transport of DC-STAMP 
out of Golgi compartment upon maturation of DCs. The fact that OS9 was previously 
implicated in ER-to-Golgi transport of different proteins in mammalian and yeast 
cells31,33,40 supports these findings. Nevertheless, how OS-9 regulates DC-STAMP 
translocation is not fully understood. One hypothesis is that DC-STAMP exerts its 
function in the ER at the moment of DCs maturation and it is transported towards the 
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Golgi compartment (observation in mature DCs, Chapter 2) to be removed as it is not 
longer required. This is supported by immunofluorescence data presented in Chapter 
2 where levels of DC-STAMP are dramatically decreased after TLR stimulation. As 
OS9 was shown to promote proteosomal degradation of hypoxia inducible factor 
1α (HIF-1α)32 it is possible that it also directs DC-STAMP removal from the ER. 
Additionally, stability of HIF-1α in DCs was recently shown to be influenced by TLR 
ligation41. It is not known if OS9 is involved in this process. Further investigation is 
required to determine whether OS9 besides promoting DC-STAMP relocalization is 
involved in driving degradation of DC-STAMP. Silencing studies of OS9 in DCs would 
definitely broaden our knowledge on this subject.  
Another debate concerns OS9 localization. OS9 is considered as an ER associated 
molecule. As no apparent transmembrane domain is detected in predicted OS9 
structure, suggesting that OS9 does not span the ER membranes. Nevertheless, it is 
still controversial on which site of the ER membrane OS9 localizes. Interaction with 
SEL1L (ER luminal protein), would suggest that OS9 must be present in the lumen of 
the ER36. On the other hand, many reports, including our studies showed interaction 
of OS9 with cytoplasmic proteins31-33. Possible explanations of these contradicting 
reports are that OS9 flips between luminal and cytoplasmic site of the ER or is 
present on both sites of the ER membrane.  
LUMAN
In Chapter 3 we described the interaction of the transcription factor LUMAN with 
DC-STAMP and the activation of LUMAN in mature DCs. As understanding the nature 
of this interaction could help to reveal the function of DC-STAMP, we investigated the 
target genes of LUMAN in DCs in Chapter 5. 
LUMAN is the prototype of the CREB3 subfamily of membrane bound bZIP 
transcription factors. This subfamily comprises LUMAN itself (CREB3/LZIP), OASIS 
(CREB3L1), BBF2H7 (CREB3L2), CREB-H (CREB3L3) and AIbZIP (CREB3L4) 
transcription factors42. A knockout mouse model has been reported for all subfamily 
members beside LUMAN. LUMAN is activated in a process called regulated 
intramembrane proteolysis (RIP). Activation of transcription factors by RIP ensures 
a rapid response to stimuli. However, there are several other regulatory points in 
addition to RIP. For example the N-terminal active form of the CREB3 subfamily 
transcription factors can form distinct dimers with different transcriptional 
activity43. It is not clear whether dimerization of LUMAN protein occurs and if it is 
necessary for its function. 
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Members of the bZIP family have been implicated in regulating gene expression 
in the unfolded protein response (UPR)44,45. LUMAN also has been suggested to 
take part in UPR in non-immune cells by regulating the expression of the ER deg-
radation-enhancing alpha-mannosidase-like 1 (EDEM) and homocysteine-induced 
endoplasmic reticulum (Herp) proteins that are involved in different aspects of 
ER-associated degradation (ERAD)46,47. Our studies described in Chapter 5 did not 
show a clear involvement of LUMAN in these processes in DCs. Thus, we postulate 
that in DCs the role of LUMAN goes beyond ER-stress. Recently, a concept of cross-talk 
between the innate immune system and ER-stress pathways came forward48. TLR 
triggering was shown to be able to activate ER-stress pathways in macrophages49. 
Moreover, an intact UPR is necessary for differentiation of DCs and DC survival upon 
TLR ligation50. We hypothesize that in DCs LUMAN may be involved in cross-talk 
between the innate immune response and the ER-stress pathways.
Several studies pointed to an essential role of the CREB3 subfamily members, 
OASIS and BBF2H7 in protein secretion51-55. Our microarray data (Chapter 5, Table 
S1) revealed enhanced expression of Sec24a, Sec24d and Sec23a, all proteins 
involved in intracellular trafficking and protein secretion56, following expression of 
constitutively active LUMAN. Furthermore golgin autoantigen 4 (Golga4/Golgin-245) 
and Golgi-specific brefeldin A-resistance factor 1 (Gbf1) genes important for 
vesicle-mediated transport57,58 were upreglated in this setting. Although it remains 
to be investigated whether these genes are true targets of LUMAN, their differential 
expression and interaction of LUMAN with OS9 (Chapter 3) is suggesting the 
involvement of LUMAN in regulation of ER-to-Golgi transport. 
LUMAN mRNA is ubiquitously expressed. Its protein was shown to be express only 
in neurons, monocytes and dendritic cells. There is no report showing the protein 
expression of LUMAN in osteoclasts however we cannot exclude the possibility that 
“master fusogen” function of DC-STAMP is mediated by LUMAN. Studies of fusion 
of osteoclasts and macrophages in absence of LUMAN (silencing/knock-out mouse) 
could give the answer to that question. 
DC-STAMP and LUMAN activation in dendritic cells
The role of DC-STAMP in fusion of osteoclasts and foreign body giant cells was 
described but its role in DCs remained greatly undefined. In Chapter 3, based on 
similarities with SREB/SCAP model60 we proposed a model of how DC-STAMP and 
its interacting proteins could function in DCs. In this model DC-STAMP interacts 
with LUMAN and OS9 in the ER of immature DCs. Upon maturation DC-STAMP and 
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LUMAN leave the ER, while OS9 localization is not influenced. Upon arrival in the 
Golgi compartment, LUMAN is cleaved by Golgi-residing proteases and its active 
form translocates to the nucleus to regulate gene expression. 
One of the questions that remain to be answered is the precise function of 
DC-STAMP in the DC-STAMP/LUMAN pathway in DCs. One possibility is that 
DC-STAMP facilitates the translocation of LUMAN to the Golgi compartment needed 
for LUMAN activation and thus fulfils a role as transporter/chaperone for LUMAN. 
For now it is not known if DC-STAMP physically interacts with LUMAN after leaving 
the ER. Protein interaction studies in mature DCs would help to resolve this question. 
If DC-STAMP is a transporter, LUMAN translocation to the Golgi/nucleus in the 
absence of DC-STAMP should be impaired.
Another possibility holds that DC-STAMP keeps LUMAN in the ER and is 
responsible for the release of LUMAN from the ER in response to activating signals. It 
will be interesting to test if the lack of DC-STAMP protein results in the spontaneous 
release of LUMAN from the ER. Our unpublished results from overexpression studies 
of LUMAN protein in cell lines where DC-STAMP is not expressed (HEK293, CHO) 
showed that lack of DC-STAMP does not lead to direct LUMAN activation in these 
non-immune cells. Studies are further hampered by the fact that the exact nature 
of the signals required for LUMAN activation is still largely elusive. DCs deficient in 
DC-STAMP would be valuable tools to answer this question. 
Recent data from our lab show that in human monocyte-derived DCs LUMAN 
becomes activated during the maturation of DCs (Chapter 3 and manuscript in 
preparation). An intriguing question is whether DC-STAMP is responsible for sensing 
directly or indirectly the signals leading to DC activation. 
An immunoreceptor tyrosine-based inhibitory motif (ITIM) was identified by 
Chiu et al in the cytoplasmic tail of DC-STAMP63. Interestingly, same group claims 
that DC-STAMP associates with CD16, the molecule bearing a counteracting 
immunoreceptor tyrosine-based activation motif (ITAM). Taken together this gives 
an indication that DC-STAMP may function as a signaling molecule.
Overexpression of DC-STAMP was shown to block differentiation of granulocytes 
while allowing development of myeloid cells61 suggesting the importance of 
DC-STAMP in development of myeloid precursors towards CD11c+ cells.  On the 
other hand, it was reported that lack of DC-STAMP does not inhibit differentiation or 
proliferation of DCs in DC-STAMP knock-out mice19. Although, total number of DCs 
in DC-STAMP knock-out mice was not investigated/shown. Studies on DC-STAMP 
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deficient DCs suggest that DC-STAMP regulates antigen presentation activity in DCs 
and maintenance of immune self-tolerance19. Our data from DC-STAMP silencing 
studies presented in Chapter 4 showed that DC-STAMP is important for cytokine 
production in LPS matured DCs. To understand how DC-STAMP exerts this function 
additional studies are needed. A potential explanation for DC-STAMP’s role in 
cytokine regulation could be related to  the fact that DC-STAMP is a protein with 
highly fusogenic proprieties. It is possible that in DCs DC-STAMP also exerts its 
fusogenic function. DCs do not readily fuse but phagosome formation was shown 
to occur via fusion of ER and plasmalemma underneath phagocytic cups64. It has 
been shown that for secretion of cytokines like IL-6 and TNFα, a proper function of 
phagosome is important65-67. It is possible that DC-STAMP as an ER residing protein 
with fusogenic properties would play a role in that complex process. In this situation 
DC-STAMP deficiency could have a negative impact on cytokine production. Testing 
intracellular cytokine levels could provide a clue about the potential deregulated 
secretion.
On the other hand, in light of interaction between DC-STAMP and LUMAN it is 
tempting to speculate that LUMAN may be involved in the observed deregulated 
cytokine production by DC-STAMP knock-down DCs. It would be very interesting to 
look at the effect of LUMAN silencing in these cells. Our preliminary data suggest that 
mBMDC with LUMAN knock-down have decreased production of TNFα upon LPS 
stimulation similar to the DC-STAMP knock-down DCs. Moreover, our microarray 
data of D2SC1 cells overexpressing active form of LUMAN indicated increase in 
the IL-1β production (data not shown). This effect on cytokine production may 
be mediated by transcription factor activity of LUMAN. Regulation of cytokine 
production by LUMAN might occur directly by binding CREB sites present in 
promoters of many cytokine genes by LUMAN or by influencing NF-κβ activity. 
Supporting the second possibility is a report showing that LUMAN increased NF-κβ 
dependent luciferase activity in response to Lkn-1 chemokine in HOS/CCR1 cells 
and THP-1 cells62. Cleavage of LUMAN protein, which is a hallmark of its activation, 
in mature DCs and its localization to the nucleus, strongly suggests its importance in 
DC immunobiology. 
Our recent data show that activation of LUMAN in mature DCs is triggered by 
number of stimuli like LPS, INFγ, Poly I:C and PGE2 (D. Eleveld-Trancikova et al., 
manuscript in preparation) suggesting that this is more general event not so much 
dependent on pathway by which immature DCs were triggered for maturation. 
Tolerogenic signals like treatment with IL-10 and dexamethasone does not lead to 
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the activation of LUMAN. Additionally, kinetic of LUMAN activation is not influenced 
by the type of tested stimuli and the cleaved product of LUMAN is observed earliest 
16 hours upon adding the stimuli. The nature of the signal that triggers translocation 
of LUMAN to Golgi for its activation is not known. We believe that signalling pathways 
activated upon TLR stimulation induce the production of the activating signal (Fig. 
1). Time needed for the production of the signal would explain the 16 hours delay 
in the LUMANs activation. In Chapter 5 we described ApoA4 as a target gene of 
LUMAN in murine DCs. ApoA4 was shown to reduce secretion of proinflammatory 
cytokines from human PBMCs, which suggested its anti-inflammatory properties59. 
The cytokine secretion by DCs is the fast outcome of stimulation with TLR ligands 
that is important, among others, for an initiation of the inflammation. The delayed 
activation of LUMAN and subsequent control of the ApoA4 expression suggest that 
LUMAN potentially plays a role in a feedback loop controlling the inflammatory 
responses in DCs (Fig. 1). 
Figure 1. Hypothetical model of DC-STAMP/LUMAN/OS9 interaction and function in DCs. 
Stimulation of DC with different TLR ligands (LPS, Poly I:C) or PGE2 and IFNγ leads to induction of 
signalling pathways resulting in production of the undefined LUMAN’s “activation signal”. This signal 
potentially sensed by DC-STAMP provokes translocation of DC-STAMP/LUMAN complex from the ER to 
the Golgi compartment. OS9 facilitates translocation of DC-STAMP and LUMAN but does not leave the ER. 
Golgi-residing proteases (S1P and perhaps another one) can release N-terminal part of LUMAN. Active 
form of LUMAN can translocate to the nucleus to regulate transcription of ApoA4 and different cytokines. 
Additionally, ApoA4 may influence the release/production of cytokines, forming a feedback loop helping 

































General discussion and future perspectives
Conclusions and future directions
We investigated the role of DC-STAMP and its interacting partners LUMAN and 
OS9 in the immunobiology of DCs. While some pieces of the puzzle start fitting into 
place, a lot of work still has to be done to complete the riddle. Our and others work 
showed that DC-STAMP is a very versatile protein. Its function as a “master fusogen” 
was described in osteoclasts and foreign body giant cells. DC-STAMP knock-out mice 
beside the ostheopetrosis phenotype, at older age show symptoms of autoimmune 
diseases, consistent with the postulated role of DC-STAMP within the immune 
system. We have shown that decrease in DC-STAMP expression in dendritic cells 
alters their cytokine production and function as activators of Th1 responses upon 
LPS stimulation. 
In this thesis we often have looked at DC-STAMP through the prism of the 
transcription factor LUMAN. Nevertheless, it is accountable that the role DC-STAMP 
plays in the LUMAN activation covers only a small part of DC-STAMP’s functions. 
Availability of DC-STAMP knock-out mice, preferably mice in which DC-STAMP has 
been specifically eliminated form DCs, would open a wide window of opportunities. 
Challenging such mice with infectious agents, like bacteria or fungi, or with tumour 
cells will certainly provide further insight into the role of DC-STAMP in the immune 
system. Creation of LUMAN knockout mice and parallel experiments to those 
in DC-STAMP deficient mice would help to extract the essence of the DC-STAMP 
and LUMAN interaction and would facilitate the analysis of the role OS9 herein. 
Insight into these pathways in DCs would help to better understand molecular 
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General discussion and future perspectives

Summary 
Our body is constantly challenged by various bacteria, viruses, fungi and 
parasites. The main role of the immune system is to protect us from the attacks 
of those pathogens. Additionally, the immune system needs to deal with dangers 
coming from the cells of our own body to prevent carcinogenesis and to regulate 
its own actions to protect us from autoimmunity. Dendritic cells (DCs) are the cells 
of the immune system that play a strategic role in keeping the balance between 
immunity and tolerance. This dual function of DCs makes them attractive for use in 
immunotherapies against cancer and autoimmune diseases. Better understanding 
of DC immunobiology is vital for improvement of DC-based immunotherapies. 
DC-STAMP is a protein preferentially expressed by DCs. The research described in 
this thesis focused on resolving the function of DC-STAMP in DC immunobiology. 
Chapter 2 identifies OS9 as a novel binding partner of DC-STAMP. OS9 is an ER 
associated protein implicated in ER-to-Golgi transport. We demonstrate that in 
immature DCs DC-STAMP and OS9 colocalize in the ER and that DC maturation leads 
to translocation of DC-STAMP towards the Golgi compartment while localization 
of OS9 remains unaffected. Using deletion mutants we provided evidence that OS9 
plays a role in the redistribution of DC-STAMP upon TLR stimulation.
In Chapter 3 we present the identification of another interacting partner of 
DC-STAMP, the transcription factor LUMAN. LUMAN belongs to the CREB/ATF 
gene family of ER-resident transcription factors. Their activation is governed by a 
process called regulated intramembrane proteolysis (RIP). To undergo RIP, LUMAN 
must be transported from the ER to the Golgi compartment where its active form 
can be liberated by Golgi-residing proteases. In this study we showed localization 
of LUMAN protein in the ER of immature DCs, its cleavage and translocation to the 
nucleus upon DC maturation. As DC-STAMP was shown to translocate to the Golgi 
compartment upon DCs maturation (Chapter 2) and to influence LUMAN cleavage, 
we postulate a function of DC-STAMP in LUMAN activation. 
In Chapter 4 we characterize the effect of DC-STAMP silencing in mouse bone 
marrow derived DCs (mBMDCs) on their phenotype and function. Using lentiviral 
delivery of shRNA we knocked down the expression of DC-STAMP and showed that 
DC-STAMP is important for proper cytokine production by DC after LPS stimulation. 
Moreover, we observed a decreased ability of DC-STAMP knock-down mature 
mBMDCs to stimulate T cell proliferation and differentiation into Th1 type T cells. 
Our data indicate that DC-STAMP is important for regulation of immune responses 
driven by mature DCs. 
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In Chapter 5 we set out to identify the target genes of LUMAN in DCs. We 
overexpressed the active form of LUMAN and analysed its effect on the gene 
expression profile of DC using microarrays. Our approach revealed Apolipoprotein 
A4 (ApoA4) as a specific target gene of LUMAN in DCs. As ApoA4 is considered to be 
an anti-inflammatory protein we postulate that LUMAN may be part of a feedback 
loop necessary for resolving the ongoing inflammation. 
Finally, in Chapter 6 a general discussion and future perspectives on the topics 
presented in this thesis are given 
146
Samenvatting
Ons lichaam wordt continu belaagd door verschillende bacteriën, virussen, 
schimmels en parasieten. De belangrijkste rol van het immuunsysteem is ons te 
beschermen tegen deze pathogenen. Daarnaast beschermt het immuunsysteem ons 
tegen gevaren vanuit ons eigen lichaam, zoals het ontstaan van kanker. Bovendien 
reguleert het zijn eigen acties om ons te beschermen tegen auto-immuunziekten. 
Dendritische cellen (DC’s) zijn cellen van het immuunsysteem die een strategische rol 
spelen in het bewaren van de balans tussen immuniteit en tolerantie. Deze tweedelige 
functie van DC’s maakt ze interessant om te gebruiken in immunotherapie tegen 
zowel kanker en auto-immuunziekten. Meer inzicht in DC immunobiologi is daarom 
essentieel voor de verbetering van immunotherapieen die op DCs gebaseerd zijn. 
DC-STAMP is een eiwit dat voornamelijk tot expressie komt in DC’s. Het onderzoek 
beschreven in dit proefschrift was gericht op het ontrafelen van de functie van 
DC-STAMP in DC immunobiologie. 
In Hoofdstuk 2 laten we zien dat OS9 een nieuwe bindingspartner is van DC-STAMP. 
OS9 is een ER (endoplasmatisch reticulum) geassocieerd eiwit dat betrokken is bij 
de het transport van eiwitten van het ER naar het Golgi-apparaat. We laten zien dat 
in zogenaamde onrijpe DCs zowel DC-STAMP als OS9 aanwezig is in het ER. Rijping 
van DCs leidt tot verplaatsing van DC-STAMP naar het Golgi-apparaat, terwijl OS9 
in het ER blijft. Door gebruik te maken van deletiemutanten demonstreren we dat 
OS9 een rol speelt in de redistributie van DC-STAMP na TLR (Toll-like Receptor) 
stimulatie.
In Hoofdstuk 3 presenteren we de identificatie van een andere bindingspartner 
van DC-STAMP, de transcriptiefactor LUMAN. LUMAN maakt deel uit van de 
CREB/ATF genfamilie van transcriptiefactoren die aanwezig zijn in het ER. De 
activatie van deze transcriptiefactoren wordt geregeld door het zogenoemde RIP 
(gereguleerde intramembraan proteolyse) proces. Om RIP te ondergaan moet 
LUMAN getransporteerd worden van het ER naar het Golgi–apparaat waar zijn 
actieve vorm bevrijd kan worden door de daar aanwezige proteases. In deze studie 
tonen we aan dat LUMAN aanwezig is in het ER van onrijpe DCs. Ook laten we zien 
dat tijdens de rijping van DCs LUMAN geactiveerd wordt en zich verplaatst naar de 
celkern . Omdat we gedemonstreerd hebben dat DC-STAMP zich kan verplaatsten 
naar het Golgi-apparaat tijdens DC rijping en dat het bovendien een rol speelt bij de 
bevrijding van LUMAN uit het Golgi-apparaat stellen we dat DC-STAMP een functie 
heeft in LUMAN activatie.
In Hoofdstuk 4 karakteriseren we het effect op het fenotype en de functie van 
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DCs uit het beenmerg van muizen na verlaging van de expressie van DC-STAMP 
Gebruikmakend van lentivirale overdracht van shRNA hebben we de expressie van 
DC-STAMP in DC’s onderdrukt en aangetoond dat DC-STAMP belangrijk is voor 
een goede cytokine productie van DC’s na LPS stimulatie. Daarnaast zien we een 
verminderd vermogen van deze DC’s om T cel proliferatie en differentiatie in Th1 
type T cellen te stimuleren. Onze data tonen aan dat DC-STAMP belangrijk is voor de 
regulering van immuunreacties die gedreven worden door rijpe DCs.
In Hoofstuk 5 proberen we de targetgenen van LUMAN in DC’s te identificeren. 
Na overexpressie van de actieve vorm van LUMAN hebben we de effecten hiervan 
geanalyseerd in het genexpressie profiel van DC’s met behulp van microarrays. Onze 
aanpak laat zien dat Apolipoprotein A4 (ApoA4) een specifiek targetgen van LUMAN 
in DCs is. Omdat ApoA4 gezien wordt als een ontstekingsremmend eiwit stellen we 
dat LUMAN deel kan uitmaken van een negative terugkoppeling die nodig is voor het 
weer remmen van bestaande ontstekingen. 
Hoofdstuk 6 sluit af met een algemene discussie en toekomstperspectieven van 




Organizm człowieka jest nieustannie narażony na atak ze strony 
chorobotwórczych organizmów takich jak wirusy, bakterie, grzyby czy pasożyty. 
Główną rolą naszego układu odpornościowego jest walka z tymi patogenami. 
Dodatkowo, układ immunologiczny musi radzić sobie z niebezpieczeństwem, 
którego źródłem są własne komórki, tak jak w przypadku nowotworów oraz chorób 
autoimmunizacyjnych. Utrzymanie dynamicznej równowagi pomiędzy reakcjami 
immunologicznymi a mechanizmami odpowiedzialnymi za jej wyciszenie, jest 
niezbędne do prawidłowego funkcjonowania organizmu. Ważną rolę w utrzymaniu 
tej równowagi odgrywają komórki dendrytyczne. Komórki te mogą zarówno 
inicjować odpowiedź immunologiczną, jak również jej zapobiegać. Ta dwojaka 
funkcja odpowiada za niezwykłe zainteresowanie komórkami dendrytycznymi, 
zarówno wśród naukowców jak i lekarzy. Dzieje się tak, ponieważ komórki 
dendrytyczne można wykorzystywać  z jednej strony w celach terapeutycznych 
– zarówno w leczeniu nowotworów i chorób autoimmunizacyjnych, z drugiej 
strony – w zapobieganiu odrzuceniu przeszczepów. Dogłębna charakterystyka 
mechanizmów rządzących immunobiologią komórki dendrytycznej jest niezbędna 
zarówno do ulepszenia istniejących, jak również do opracowania nowych terapii. 
Wyniki zaprezentowane w niniejszej pracy są efektem projektu badawczego, 
którego celem było scharakteryzowanie funkcji białka DC-STAMP, obecnego 
w komórkach dendrytycznych. DC-STAMP jest transbłonownym białkiem, 
zlokalizowanym w retikulum endoplazmatycznym (ER), a ekspresja tego białka 
ograniczona jest głównie do komórek dendrytycznych, makrofagów i osteoklastów. 
Jednym ze sposobów poznania funkcji białka jest identyfikacja innych białek, które 
z nim oddziałują. Dlatego też postanowiliśmy zidentyfikować i scharakteryzować 
białka oddziaływujące z DC-STAMP. 
Rozdział drugi dotyczy charakterystyki białka OS9, które oddziałuje z DC-STAMP. 
OS9 jest białkiem zlokalizowanym w ER i bierze udział w transporcie białek między 
ER a aparatem Golgiego. W tym rozdziale wykazaliśmy, że w niedojrzałych komórkach 
dendrytycznych białka OS9 i DC-STAMP znajdują się w fizycznym kontakcie i 
lokalizują się w ER. W trakcie dojrzewania komórki dendrytycznej DC-STAMP jest 
transportowane w kierunku aparatu Golgiego, natomiast lokalizacja OS9 pozostaje 
bez zmian. Przy użyciu mutantów delecyjnych wykazaliśmy, że fizyczne połączenie 
OS9 z DC-STAMP warunkuje transport DC-STAMP z ER do aparatu Golgiego. Wyniki 
te sugerują, że OS9 odgrywa rolę w transporcie DC-STAMP do aparatu Golgiego 
w czasie dojrzewania komórek dendrytycznych, które jest wywołane stymulacją 
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poprzez ligandy Toll-podobnych receptorów (TLR).
W Rozdziale trzecim opisane zostało drugie białko oddziaływujące z 
DC-STAMP, będące czynnikiem transkrypcyjnym, o nazwie LUMAN. Białko LUMAN 
należy do rodziny czynników transkrypcyjnych CREB/ATF. W postaci nieaktywnej 
jest ono związane z błoną ER. Aby doszło do jego aktywacji, LUMAN musi być 
przetransportowany do aparatu Golgiego, gdzie zachodzi hydroliza jego nieaktywnej 
postaci. Uwolniona, aktywna N-terminalna domena białka jest transportowana do 
jądra komórkowego, gdzie wiąże się do elementów regulatorowych docelowych 
genów. Na podstawie wyników tej części projektu badawczego dowiedliśmy,  że 
białko LUMAN w niedojrzałych komórkach dendrytycznych jest zlokalizowane w ER. 
W dojrzałych komórkach dendrytycznych jego aktywną formę zaobserwowaliśmy w 
jądrze komórkowym. Dodatkowo wykazaliśmy, że obecność DC-STAMP wpływa na 
hydrolityczną aktywację białka LUMAN. W związku z tym, że DC-STAMP tak samo jak 
LUMAN, podczas dojrzewania komórek dendrytycznych jest transportowany z ER 
do aparatu Golgiego, stwierdziliśmy że DC-STAMP jest odpowiedzialny za regulację 
aktywności  czynnika transkrypcyjnego LUMAN. 
Rozdział czwarty poświęcony jest opisowi identyfikacji funkcji białka 
DC-STAMP w komórkach dendrytycznych poprzez wyciszenie jego ekspresji. W 
wyniku obniżonej ekspresji białka DC-STAMP, stymulowane LPSem mysie komórki 
dendrytyczne charakteryzowały się zaburzoną produkcją cytokin i chemokin. 
Dodatkowo, komórki te miały obniżoną zdolność pobudzania limfocytów T do 
podziału i do różnicowania się w kierunku limfocytów pomocniczych typu Th1. 
Nasze wyniki wskazują, że DC-STAMP pełni ważną funkcję w regulacji odpowiedzi 
immunologicznej indukowanej przez dojrzałe komórki dendrytyczne.  
Rozdział piąty dotyczy identyfikacji genów regulowanych przez czynnik 
transkrypcyjny LUMAN w komórkach dendrytycznych. W celu jego charakterystyki 
wprowadziliśmy do komórek dendrytycznych aktywną wersję czynnika LUMAN i 
przy użyciu mikromacierzy DNA przeprowadziliśmy analizę różnic w ekspresji 
genów. W ten sposób udało nam się wykazać, że genem regulowanym przez czynnik 
LUMAN w komórkach dendrytycznych jest gen Apolipoproteiny A4. Apolipoproteina 
A4 jest, miedzy innymi uważana za czynnik przeciwzapalny, dlatego też aktywacja 
jej ekspresji przez czynnik LUMAN, który jest aktywowany podczas dojrzewania 
komórek dendrytycznych, sugeruje jego udział w wygaszaniu stanu zapalnego. 
Podsumowując, odkrycia zaprezentowane w niniejszej pracy rzucają nowe 
światło na rolę białek DC-STAMP, OS9 i LUMAN w immunobiologii komórek 
dendrytycznych. Do pełnego wyjaśnienia interakcji zachodzących pomiędzy tymi 
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